

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
25 March 2004 (25.03.2004)

PCT

(10) International Publication Number  
**WO 2004/024925 A2**

(51) International Patent Classification<sup>7</sup>: C12N 15/62

RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR,  
TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(21) International Application Number:  
PCT/DK2003/000585

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(22) International Filing Date:  
10 September 2003 (10.09.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
PA 2002 01328 10 September 2002 (10.09.2002) DK

**Declarations under Rule 4.17:**

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

— of inventorship (Rule 4.17(iv)) for US only

(71) Applicant (*for all designated States except US*): NATLM-MUNE A/S [DK/DK]; Fruebjergvej 3, DK-2100 København Ø (DK).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): KONGERSLEV, Lelf [DK/DK]; Biskop Svanes Vej 39, DK-3460 Birkerød (DK). WEILGUNY, Dietmar [DK/DK]; Lindevangen 61, DK-2830 Virum (DK). MATTHIESEN, Finn [DK/DK]; Bækkeskovvej 64, DK-2700 Brønshøj (DK).

(74) Agent: HØIBERG A/S; St. Kongensgade 59A, DK-1264 Copenhagen K (DK).

**Published:**

— without international search report and to be republished upon receipt of that report

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT,

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: COLLECTIN-COMPLEMENT ACTIVATING PROTEIN CHIMERAS

(57) Abstract: The present invention relates to a fusion protein capable of activating the complement system, the fusion protein comprising a first polypeptide sequence derived from a lectin-complement pathway activating protein or a functional homologue thereof; and a second polypeptide sequence derived from a collectin or a functional homologue thereof; wherein said complement activating protein is not a collectin. A preferred fusion protein comprises amino acids of the L-ficolin sequence of figure 1 and amino acids of the MBL sequence shown in figure 2. The fusion protein is suitable for use in treatment consisting of creation, reconstitution, enhancing and/or stimulating the opsonic and/or bactericidal activity of the complement system, i.e. enhancing the ability of the immune defence to recognise and kill microbial pathogens, and accordingly, the invention relates to a medicament comprising the fusion protein, methods for producing said fusion protein and methods for treating diseases, in particular infections.

**BEST AVAILABLE COPY**

WO 2004/024925 A2

**DUPLICATE**

**10/527191**  
DT06 REC'd PCT/PTO 10 MAR 2005

**COURTESY COPY OF THE  
PCT APPLICATION AS  
ORIGINALLY FILED  
WITH ABSTRACT**

**Title**

Collectin-complement activating protein chimeras

**Field of invention**

The present invention relates to a fusion protein capable of activating the complement system, methods for producing said fusion protein as well as pharmaceutical composition comprising said fusion protein and methods for treating diseases, in particular infections, with said fusion protein.

**Background of invention**

Animals have developed different complex strategies to protect themselves against infections. The immune responses can be divided into two main groups, the adaptive immune response, in which an adaptation has taken place and in which cells play a dominant part and the innate immune response, which is available instantly and which primarily is based on molecules present in the body fluids. The innate immune system is operational at time of birth, in contrast to the adaptive immune defence which only during infancy obtains its full power of protecting the body (Janeway *et al.*, 1999).

Bacteria entering the body at mucosal surfaces or through broken skin are immediately recognised by collectins, a family of soluble proteins that recognise distinctive carbohydrate configurations that are present on the surfaces of microbes and absent from the cells of the multicellular organism. Collectins thus belong to the large and diverse group of pattern recognition receptors of the innate immune system. In humans, three collectins are known, although others may exist: cows for example have more. Collectins target the particles to which they bind either for uptake by phagocytes or for activation of the complement cascade, and in these ways can mediate their destruction.

Collectins all exhibit the following architecture: they have an N-terminal cysteine-rich region that appears to form inter-chain disulfide bonds, followed by a collagen-like region, an  $\alpha$ -helical coiled-coil region and finally a C-type lectin domain which is the pattern-recognizing region and is referred to as the carbohydrate recognition domain

(CRD). The name collectin is derived from the presence of both collagen and lectin domains. The  $\alpha$ -helical coiled-coil region initiates trimerisation of the individual polypeptides to form collagen triple coils, thereby generating collectin subunits each consisting of 3 individual polypeptides, whereas the N-terminal region mediates formation of oligomers of subunits. Different collectins exhibit distinctive higher order structures, typically either tetramers of subunits or hexamers of subunits. The grouping of large numbers of binding domains allows collectins to bind with high avidity to microbial cell walls, despite a relatively low intrinsic affinity of each individual CRD for carbohydrates.

C-type CRDs are found in proteins with a widespread occurrence, both in phylogenetic and functional perspective. The different CRDs of the different collectins enable them to recognise a range of distinct microbial surface components exposed on different microorganisms. The terminal CRDs are distributed in such a way that all three domain target surfaces that present binding sites has a spacing of approximately 53 Å (Sheriff *et al.*, 1994; Weis & Drickamer, 1994). This property of 'pattern recognition' may contribute further to the selectively binding of microbial surfaces. The collagenous region or possibly the N-terminal tails of the collectins, are recognised by specific receptors on phagocytes, and is the binding site for associated proteases that are activated to initiate the complement cascade upon binding of the CRD domain to a target.

Mannan-binding lectin (MBL) also termed mannanose-binding lectin or mannanose binding protein is a collectin which has gained great interest as an important part of the innate immune system. MBL binds to specific carbohydrate structures found on the surface of a range of microorganisms including bacteria, yeast, parasitic protozoa and viruses, and has been found to exhibit antibacterial activity through killing mediated by activation of the terminal, lytic complement components or through promotion of phagocytosis. MBL deficiency is associated with susceptibility to frequent infections by a variety of microorganisms in childhood, and possibly also in adults.

The CRD of MBL recognises preferentially hexoses with equatorial 3- and 4-OH groups, such as mannanose, glucose, *N*-acetylmannosamin and *N*-acetyl glucoseamin while carbohydrates which do not fulfil this sterical requirement, such as galactose and D-fucose, are not bound (Weis *et al.*, 1992). The carbohydrate selectivity is ob-

viously an important aspect of the self/non-self discrimination by MBL and is probably mediated by the difference in prevalence of mannose and *N*-acetyl glucoseamin residues on microbial surfaces, one example being the high content of mannose in the cell wall of yeasts such as *Saccharomyces cerevisiae* and *Candida albicans*.

5 Carbohydrate structures in glycosylation of mammalian proteins are usually completed with sialic acid, which prevents binding of MBL to these oligomeric carbohydrates and thus prevents MBL recognition of 'self' surfaces. Also, the trimeric structure of each MBL subunit may be of importance for target recognition.

10 Complement is a group of proteins present in blood plasma and tissue fluid that aids the body's defences following an infection. The complement system is being activated through at least three distinct pathways, designated the classical pathway, the alternative pathway, and the MBLelectin pathway (Janeway *et al.*, 1999). The classical pathway is initiated when complement factor 1 (C1) recognises surface-bound  
15 immunoglobulin. The C1 complex is composed of two proteolytic enzymes, C1r and C1s, and a non-enzymatic part, C1q, which contains immunoglobulin-recognising domains. C1q and MBL shares structural features, both molecules having a bouquet-like appearance when visualised by electron microscopy. Also, like C1q, MBL is found in complex with two proteolytic enzymes, the mannan-binding lectin associated proteases (MASP). The three pathways all generate complement factor 3 (C3)  
20 convertase, which ensures the binding of C3b to the surface of the activating surface, *i.e.* the targeted microbial pathogen. Conversion of C3 into surface bound C3b is pivotal in the process of eliminating the microbial pathogen by phagocytosis or lysis (Janeway *et al.*, 1999).

25 Certain O-antigen specific oligosaccharides of *Salmonella* have been reported to activate complement in C4-deficient guinea-pig serum and *Salmonella* serogroup C was later shown to react with MBL and hence activate complement by the MBLelectin pathway, which is also termed the MBL pathway of complement activation or the  
30 lectin pathway.

It has for some time been speculated that the innate immune system may collaborate with the adaptive immune system in the generation of specific immune responses as exemplified by the antibody response after infection or vaccination.

35 Fearon's group have shown that the attachment of the C3d fragment of complement

factor C3 onto a protein antigen through fusion by gene technology can increase the immunogenicity of the antigen 1000 fold or more. Practical applications of this technique, or any number of modifications, are still awaited.

5 The importance of the complement system for normal immune responses was first suggested by Pepys, who found impaired antibody responses to sheep erythrocytes, a thymus-dependent antigen, in mice that were C3-depleted with cobra venom factor. The idea of a link between innate and adaptive immunity was supported by reports demonstrating reduced primary antibody responses to thymus dependent anti-  
10 gens and impaired IgM to IgG switching in patients and experimental animals with deficiencies of C4, C2 and C3. The mechanism may involve the generation of C3-derived ligands for binding of antigen or antigen-containing complexes to complement receptors on B lymphocytes or antigen-presenting cells. Thus, blocking of CR1 (CD35) and CR2 (CD21) in mice with specific anti CR1 and anti-CR2 antibodies or  
15 with soluble receptor protein reduced antibody responses to immunisation and experiments with CR1 and CR2-deficient knock-out mice show the requirement of these receptors for responses to thymus-dependent antigens. In addition, patients with leucocyte adhesion deficiency, who lack the CD11/CD18 adhesion molecule CR3, demonstrate impaired antibody responses and failure to switch from IgM to  
20 IgG. The C3-derived fragment C3d, a specific CR2 ligand, as mentioned above, show a strong dose-dependent adjuvant effect.

Deficiencies of the classical complement pathway (C1, C2, C4 and C3) are associated with infections by encapsulated bacteria. The main reason for this is probably  
25 the reduced efficiency of opsonic and bactericidal defence mechanisms caused by complement dysfunction. However, impaired immune responses to polysaccharide antigens might also be considered. The influence of complement on responses to thymus-independent antigens has not been extensively studied, and the available information is contradictory. Thus, low antibody responses to thymus-independent  
30 antigens have been clearly documented in C3-depleted mice and C3-deficient dogs. On the other hand, some reports find that C3-deficient patients appear to respond normally to immunisation with polysaccharide vaccines.

Ficolins, like MBL, are lectins that contain a collagen-like domain. Unlike MBL, however, they have a fibrinogen-like domain, which is similar to fibrinogen  $\beta$ - and  $\gamma$ -  
35

chains. Ficolins also forms oligomers of structural subunits, each of which is composed of three identical 35 kDa polypeptides. Each subunit is composed of an amino-terminal, cysteine-rich region; a collagen-like domain that consists of tandem repeats of Gly-Xaa-Yaa triplet sequences (where Xaa and Yaa represent any amino acid); a neck region; and a fibrinogen-like domain. The oligomers of ficolins comprises two or more subunits, especially a tetrameric form of ficolin has been observed.

Some of the ficolins triggers the activation of the complement system substantially in similar way as done by MBL. This triggering of the complement system results in the activation of novel serine proteases (MASPs) as described above.

The fibrinogen-like domain of several lectins has a similar function to the CRD of C-type lectins including MBL, and hereby function as pattern-recognition receptors to discriminate pathogens from self.

Serum ficolins have a common binding specificity for GlcNAc (N-acetylglucosamine), elastin or GalNAc (N-acetyl-galactosamine). The fibrinogen-like domain is responsible for the carbohydrate binding. In human serum, two types of ficolin, known as L-ficolin (P35, ficolin L, ficolin 2 or hucolin) and H-ficolin (Hakata antigen, ficolin 3 or thermolabile b2-macroglycoprotein), have been identified, and both of them have lectin activity. L-ficolin recognises GlcNAc and H-ficolin recognises GalNAc. Another ficolin known as M-ficolin (P35-related protein, Ficolin 1 or Ficolin A) is not considered to be a serum protein and is found in leucocytes and in the lungs. L-ficolin and H-ficolin activate the lectin-complement pathway in association with MASPs. M-Ficolin, L-ficolin and H-ficolin has calcium-independent lectin activity.

MASPs (MBL-associated serine proteases) comprising MASP-1, MASP-2 and MASP-3 are proteolytic enzymes that are responsible for activation of the lectin pathway. The overall structure of MASPs resembles that of the two proteolytic components of the first factor in the classical complement pathway, C1r and C1s. The lectin pathway is initiated when MBL or a ficolin associated with MASP-1, MASP-2, MASP-3 and sMAP binds to a carbohydrate structure of the surfaces of e.g. bacteria, yeast, parasitic protozoa, viruses. MASP-2 is the enzyme component that – like

C1s in the classical pathway – cleaves the complement components C4 and C2 to form the C3 convertase C4bC2a, which is common to both the lectin- and classical-pathway activation routes.

5 MASP-1, MASP-2, MASP-3 and sMAP are encoded by two genes; sMAP is a truncated form of MASP-2, and MASP-3 is produced from the MASP-1 gene by alternative splicing. The MASP-1 gene has an H-chain-encoding region that is common to MASP-1 and MASP-3, which is followed by tandem repeats of protease-domain-encoding regions that are specific to MASP-3 and MASP-1.

10

The MASP family can be divided into two phylogenetic lineages – TCN-type and AGY-type lineages. The TCN-type lineage, which includes MASP-1, has a TCN codon (where N denotes A, G, C or T) that encodes the active-site serine, the presence of a histidine-loop disulphide bridge and split exons. By contrast, the AGY-type  
15 lineage, which includes MASP-2, MASP-3, C1r and C1s, is characterised by an AGY codon (where Y denotes C or T) that encodes the active-site serine, the absence of a histidine-loop and a single exon.

15

20 MASP-1, MASP-2, MASP-3, C1r and C1s consist of six domains: two C1r/C1s/Uegf/bone morphogenetic protein 1 (CUB) domains; an epidermal growth factor (EGF)-like domain; two complement control protein (CCP) domains or short consensus repeats (SCRs), and a serine-protease domain. Histidine (H), aspartic acid (D) and serine (S) residues are essential for the formation of the active centre in the serine-protease domain. Only MASP-1 has two additional cysteine residues in  
25 a light chain, which form a histidine-loop disulphide bridge (S-S), as is found in trypsin and chymotrypsin. On binding of MBL and ficolins to carbohydrate on the surface of a pathogen, the pro-enzyme form of a MASP is cleaved between the second CCP and the protease domain, which results in an active form that consists of two polypeptides – heavy and light chains (also known as A and B chains).

25

30

### Summary of invention

The present invention relates to fusion proteins capable of activating the complement system. Accordingly, the present invention relates to a fusion protein comprising  
35 ing

35



5 a first polypeptide sequence derived from a lectin-complement pathway activating protein (=complement activating protein) or a functional homologue thereof; and a second polypeptide sequence derived from a collectin or a functional homologue thereof;

wherein said complement activating protein is not a collectin.

10 The fusion protein is suitable for use in treatment consisting of creation, reconstitution, enhancing and/or stimulating the opsonic and/or bactericidal activity of the complement system, i.e. enhancing the ability of the immune defence to recognise and kill microbial pathogens, and accordingly, the invention relates to a medicament comprising the fusion protein.

15 Also, in another aspect the invention relates to a method of treatment of a clinical condition in an individual in need thereof comprising administering to said individual the fusion protein as defined above.

20 In another aspect the invention relates to a method of treatment or prophylaxis of a clinical condition, such as infection, in an individual in need thereof comprising administering to said individual a the fusion protein a first polypeptide sequence derived from a protein capable of forming oligomers of structural units; and a second polypeptide sequence derived from a mannose binding lectin (MBL, wherein said first polypeptide sequence and said second peptide sequence is not  
25 derived from the same protein, and said fusion protein is capable of associating with mannose-associated serine protease (MASP). The first polypeptide sequence is preferably derived from a protein capable of forming tetramers, pentamers, and/or hexamers of a structural unit. In a preferred embodiment the first polypeptide sequence and the second polypeptide sequence are as described below.

30 In a further aspect the invention relates to use of the fusion protein as defined above for the preparation of a medicament for the treatment of a clinical condition in an individual in need thereof.

Furthermore the invention relates to a method for producing the fusion protein, as well as an isolated nucleic acid sequence encoding the fusion protein, a vector comprising the sequence and a cell comprising the vector.

## 5 Drawings

Figure 1 shows the sequence of L ficolin

Figure 2 shows the sequence of MBL

Figure 3 shows an example of a fusion protein

10 Figures 4-8 show plasmids as described in Example 1

Figure 9 shows an alignment of fusion proteins described in Example 1

Figure 10 shows two Western blots as discussed in Example 2.

## Definitions

15

Collectins: A family of structurally related, carbohydrate-recognising proteins of innate immunity, including mannan-binding lectin (MBL) and surfactant proteins A and D. The name refers to the presence of a collagen-like region and a C-type lectin domain.

20

Complement: A group of proteins present in blood plasma and tissue fluid that aids the body's defences following an infection. Complement is involved in destroying foreign cells and attracting phagocytes to the area of conflict in the body.

25

Conjugated: An association formed between two compounds for example between an immunogenic determinant and a collectin and/or collectin homologue or between an immunogenic determinant and a saccharide. The association may be a physical association generated e.g. by the formation of a chemical bond, such as e.g. a covalent bond.

30

CRD: Carbohydrate recognition domain, a C-type lectin domain that is found at the C-terminus of collectins.

35

Immunogenic determinant: A molecule, or a part thereof, containing one or more epitopes that will stimulate the immune system of a host organism to make a secre-

tory, humoral and/or cellular antigen-specific response, or a DNA molecule which is capable of producing such an immunogen in a vertebrate.

5 Immune response: Response to a immunogenic composition comprising an immunogenic determinant. An immune response involves the development in the host of a cellular- and/or humoral immune response to the administered composition or vaccine in question. An immune response generally involves the action of one or more of i) the antibodies raised, ii) B cells, iii) helper T cells, iv) suppressor T cells, v) cytotoxic T cells and iv) complement directed specifically or unspecifically to an  
10 immunogenic determinant present in an administered immunogenic composition.

Lectin: Proteins that specifically bind carbohydrates.

15 MASP: Mannose-associated serine protease

MBL: Mannan-binding lectin or mannose-binding lectin.

Subunit complex=structural unit: complex of three individual fusion proteins, like the subunit complex discussed above for MBL and ficolins.

20

### **Detailed description of the invention**

25 An object of the present invention is to provide a fusion protein capable of activating the complement system in order to aid in preventing or treating diseases, in particular infectious diseases.

The fusion protein is composed of

30 a first polypeptide sequence derived from a lectin-complement pathway activating protein (=complement activating protein) or from a functional homologue thereof; and

a second polypeptide sequence derived from a collectin or from a functional homologue thereof;

35

wherein said complement activating protein is not a collectin.

5 By combining a polypeptide sequence derived from a lectin-complement pathway activating protein and a polypeptide sequence derived from a collectin it is possible to design a fusion protein having binding affinity for a variety of carbohydrates, preferably bacterial and viral carbohydrates and at the same time having complement system activating activity.

#### 10 First polypeptide sequence

The first polypeptide sequence may be derived from any lectin-complement pathway activating protein. Said lectin-complement pathway activating protein may be naturally occurring lectin-complement pathway activating protein as well as variants or homologues to said lectin-complement pathway activating proteins, wherein said  
15 variants or homologues have maintained the lectin-complement pathway activating activity.

It is preferred that the fusion protein is capable of forming subunit complexes, each consisting of 3 individual fusion proteins as defined above.

20

Also the first polypeptide sequence is preferably capable of forming oligomeric complexes with the first polypeptide sequence of another fusion protein, wherein said another fusion protein may be identical to the first fusion protein. Thereby an oligomeric complex of two or more fusion proteins or two or more subunit complexes  
25 may be provided, said oligomeric complex having a higher binding avidity for bacterial or viral carbohydrates than the monomeric fusion protein. In a preferred embodiment the oligomeric complex is a dimeric subunit complex, more preferably a trimeric subunit complex, more preferably a tetrameric subunit complex.

30

In a preferred embodiment the lectin-complement pathway activating protein is a ficolin as defined above. Said ficolin may be L-ficolin, H-ficolin or M-ficolin or variants or homologues thereof. In a preferred embodiment the lectin-complement pathway activating protein is L-ficolin.

In another embodiment the first polypeptide sequence comprises the fibrinogen domain of the lectin, and/or the neck region of a lectin, such as a ficolin or a homologue or a variant thereof.

- 5 When the first polypeptide sequence is derived from ficolin or from a variant or a homologue of ficolin, it is preferred that the first polypeptide sequence comprises the collagen-like domain from ficolin or from a variant or homologue of ficolin. In another embodiment it is preferred that the first polypeptide sequence comprises the Cystein rich domain from ficolin or from a variant or homologue of ficolin. It is even more preferred that the first polypeptide sequence comprises the collagen-like domain and the Cystein rich domain from ficolin or from a variant or homologue of ficolin.

- 10 It is more preferred that the first polypeptide sequence comprises the collagen-like domain from L-ficolin or from a variant or homologue of L-ficolin. In another embodiment it is more preferred that the first polypeptide sequence comprises the Cystein rich domain from L-ficolin or from a variant or homologue of L-ficolin. It is even more preferred that the first polypeptide sequence comprises the N-terminal region of L-ficolin including two Cystein amino acid residues.

- 20 It is even more preferred that the first polypeptide sequence comprises the collagen-like domain and the Cystein rich domain from L-ficolin or from a variant or homologue of L-ficolin.

- 25 In a particular preferred embodiment the ficolin has one of the sequences listed below with reference to their database and accession No. For each of the sequences the Cystein rich region and the collagen-like region is described.

- 30 NP\_003656. ficolin 3 precursor; ficolin (collagen/fibrinogen domain-containing) 3 (Hakata antigen) [Homo sapiens] [gi:4504331]

- 90..299 /region\_name="pfam00147, fibrinogen\_C, Fibrinogen beta and gamma chains, C-terminal globular domain"  
35 90..299 /region\_name="smart00186, FBG, Fibrinogen-related domains (FReDs); Domain present at the C-termini of fibrinogen beta and gamma chains, and a variety of fibrinogen-related proteins, including tenascin and Drosophila scabrous"

1 mdllwilpsl wllllgppac lktqehpscp gpreleaskv vllpscpgap gspgekgapg

61 pggpppppgk mgpkgepgdp vnllrcqegp mncrellsqg atlsqwyhlc lpegralpvf  
 121 cdmtdtegggw lvfqrqdgds vdffrswssy ragfgnqese fwlgnenlhq ltlqgnwelr  
 181 veledfngnr tfahyatfrl lgevdhyqla lgkfsegtag dslslhsgrp ftydadhdhs  
 241 snsncavivh gawwyascyr snlmgryavs daaahkygid wasgrgvghp yrrvmmmlr

5

XP\_116792. similar to Ficolin 2 precursor (Collagen/fibrinogen domain-containing protein 2) (Ficolin-B) (Ficolin B) (Serum lectin P35) (EBP-37) (Hucolin) (L-Ficolin) [Homo sapiens] [gi:20477458]

10

91..168 /region\_name="pfam00147, fibrinogen\_C, Fibrinogen beta and gamma chains, C-terminal globular domain"

91..168 /region\_name="smart00186, FBG, Fibrinogen-related domains (FReDs); Domain present at the C-termini of fibrinogen beta and gamma chains, and a variety of fibrinogen-related proteins, including tenascin and Drosophila scabrous"

15

1 mgpallalsf lwtmaltedt cpamleyval nsepgmaskn psrrhglsl lvdqggpgarg  
 61 vrtddqpsga dpgslelhge cpifpseqvi lthhnnypfs tedqdndrda encavhyqga  
 121 wwyaschls ingvylggar dsftnginwk sgkgnnysyk vsemkvrpt

20

O00602. Ficolin 1 precursor (Collagen/fibrinogen domain-containing protein 1) (Ficolin-A) (Ficolin A) (M-Ficolin) [gi:20455484]

1..29 /gene="FCN1" /region\_name="Signal" /note="POTENTIAL."

25

30..326 /gene="FCN1" /region\_name="Mature chain" /note="FICOLIN 1."

55..93 /gene="FCN1" /region\_name="Domain" /note="COLLAGEN-LIKE."

133 /gene="FCN1" /region\_name="Conflict" /note="T -> N (IN REF. 1)."

144..290 /gene="FCN1" /region\_name="Domain" /note="FIBRINOGEN C-TERMINAL."

30

287 /gene="FCN1" /region\_name="Conflict" /note="N -> S (IN REF. 1)."

305 /gene="FCN1" /site\_type="glycosylation" /note="N-LINKED (GLCNAC...) (POTENTIAL)."

35

1 melsgatmar glavllvfl hiknlpaqaa dtcpevkvg legsdkltil rgcpglpgap  
 61 gpkgeagvig ergerlpga pgkagpvpgk gdrgekmgmg ekgdagqsqs catgprnckd  
 121 lldrgyflsg whtiylpdcrl pltlvcdmdt dgggwtvfqr rmdgsdvdyr dwaaykqgfg  
 181 sqlgefwlgn dnihaltaqg sselrvdlvd fegnhqfaky ksfkvadeae kyklvlgafv  
 241 ggsagnsltg hnnnffstk dndvssnc aekfqgawwy adchasnlg lylmgphesy  
 301 anginwsaak gykysykvse mkvrpa //

40

O75636. Ficolin 3 precursor (Collagen/fibrinogen domain-containing protein 3) (Collagen/fibrinogen domain-containing lectin 3 P35) (Hakata antigen) [gi:13124185]

1..21 /gene="FCN3" /region\_name="Signal" /note="POTENTIAL."

45

22..299 /gene="FCN3" /region\_name="Mature chain" /note="FICOLIN 3."

48..80 /gene="FCN3" /region\_name="Domain" /note="COLLAGEN-LIKE."

50 /gene="FCN3" /site\_type="hydroxylation"

53 /gene="FCN3" /site\_type="hydroxylation"

59 /gene="FCN3" /site\_type="hydroxylation"

50

65 /gene="FCN3" /site\_type="hydroxylation"

68 /gene="FCN3" /site\_type="hydroxylation"

77 /gene="FCN3" /site\_type="hydroxylation"

119..265 /gene="FCN3" /region\_name="Domain" /note="FIBRINOGEN C-  
TERMINAL."  
189 /gene="FCN3" /site\_type="glycosylation" /note="N-LINKED (GLCNAC...) (PO-  
TENTIAL)."

1 mdllwilpsl wllllggpac lktqehpscp gpreleaskv vllpscpgap gspgekgap  
61 pqgppgppgk mgpkgepgdp vnllrcqegp rncrellsqg atlsqwyhlc lpegalpvf  
121 cdmdtegggw lvfqrqdgsvdfrswssy ragfgnqese fwlgnenlhq ltlqgnwelr  
181 veledfngnr tfahyatfrl lgevdhyqla lgkfsegtag dslslhsgrp ftydadhdh  
241 ssnscavivh gawwyascyr snlngryavs daaahkygid wasgrgvghp yrrvmmmlr

XP\_130120. similar to Ficolin 2 precursor (Collagen/fibrinogen domain-containing  
protein 2) (Ficolin-B) (Ficolin B) (Serum lectin P35) (EBP-37) (Hucolin) [Mus mus-  
culus] [gi:20823464]

59..95 /region\_name="Collagen triple helix repeat (20 copies)" /note="Collagen"  
/db\_xref="CDD:pfam01391"

59..89 /region\_name="Collagen triple helix repeat (20 copies)" /note="Collagen"  
/db\_xref="CDD:pfam01391"

60..95 /region\_name="Collagen triple helix repeat (20 copies)" /note="Collagen"  
/db\_xref="CDD:pfam01391"

60..95 /region\_name="Collagen triple helix repeat (20 copies)" /note="Collagen"  
/db\_xref="CDD:pfam01391"

60..95 /region\_name="Collagen triple helix repeat (20 copies)" /note="Collagen"  
/db\_xref="CDD:pfam01391"

60..95 /region\_name="Collagen triple helix repeat (20 copies)" /note="Collagen"  
/db\_xref="CDD:pfam01391"

60..95 /region\_name="Collagen triple helix repeat (20 copies)" /note="Collagen"  
/db\_xref="CDD:pfam01391"

61..95 /region\_name="Collagen triple helix repeat (20 copies)" /note="Collagen"  
/db\_xref="CDD:pfam01391"

61..95 /region\_name="Collagen triple helix repeat (20 copies)" /note="Collagen"  
/db\_xref="CDD:pfam01391"

61..95 /region\_name="Collagen triple helix repeat (20 copies)" /note="Collagen"  
/db\_xref="CDD:pfam01391"

103..312 /region\_name="Fibrinogen beta and gamma chains, C-terminal globular  
domain" /note="fibrinogen\_C" /db\_xref="CDD:pfam00147"

103..312 /region\_name="Fibrinogen-related domains (FReDs)" /note="FBG"  
/db\_xref="CDD:smart00186"

1 malgsaalfv lltlvhaagt cpelkvidle gykqltilqg cpglpgaagp kgeagakgdr  
61 gesglpgipg kegptgpkgn qgekgrgek gdsgpsqscs tgprtkell tqghfltgy  
121 tiylpdcrl tvlcmdtdg ggwtvfqrrl dgsdfrdw tsykrfgsq lgefwlgn  
181 ihalttgts elrvldsfde gkhdfakyss fqi qgeaeky klilgnflgg gagdsltphn  
241 nrlfstkdqd ndgstsscam gyhgawwysq chtsnlmgly lrgphksyan gvnwkswrgy  
301 nysckvsemk vrli

NP\_056654. ficolin 2 isoform d precursor; ficolin (collagen/fibrinogen domain-  
containing lectin) 2 (hucolin); ficolin (collagen/fibrinogen domain-containing lectin) 2;  
hucolin [Homo sapiens] [gi:8051590]

39..95 /region\_name="collagen-like domain"

1 meldravglv gaatlslfl gmawalqaad tpevkmgvl egskltilr gcpglpgapg  
61 dkgeagtnk rgerppgpp gkagppgng apgeppclt gd

- 5 NP\_056653. ficolin 2 isoform c precursor; ficolin (collagen/fibrinogen domain-containing lectin) 2 (hucolin); ficolin (collagen/fibrinogen domain-containing lectin) 2; hucolin [Homo sapiens] [gi:8051588]

- 39..95 /region\_name="collagen-like domain"  
10 102..143 /region\_name="Fibrinogen beta and gamma chains, C-terminal globular domain" /note="fibrinogen\_C" /db\_xref="CDD:pfam00147"  
102..143 /region\_name="Fibrinogen-related domains (FReDs)" /note="FBG" /db\_xref="CDD:smart00186"

- 15 1 meldravglv gaatlslfl gmawalqaad tpevkmgvl egskltilr gcpglpgapg  
61 dkgeagtnk rgerppgpp gkagppgng apgeppclt gprtckdld rghflsgwht  
121 iylpdcrlt vlcdmtdgg gwtvsvglr ggqpgspggq aahlvgehtl efsillvgds  
181 qr

- 20 NP\_056652. ficolin 2 isoform b precursor; ficolin (collagen/fibrinogen domain-containing lectin) 2 (hucolin); ficolin (collagen/fibrinogen domain-containing lectin) 2; hucolin [Homo sapiens] [gi:8051586]

- sig\_peptide 1..25  
25 mat\_peptide 26..275  
60..275 /region\_name="FBG domain" /note="fibrinogen beta/gamma homology"  
64..275 /region\_name="Fibrinogen-related domains (FReDs)" /note="FBG" /db\_xref="CDD:smart00186"  
64..274 /region\_name="Fibrinogen beta and gamma chains, C-terminal globular domain" /note="fibrinogen\_C" /db\_xref="CDD:pfam00147"  
30

- 1 meldravglv gaatlslfl gmawalqaad tpevkmgvl egskltilr gcpglpgapg  
61 ltpgtrckdl ldrghflsgw htiylpdcrlt vlcdmtdgg ggtvtfqrr vdgsvdfyrd  
121 watykqgfgs rlgefwnld nihaltaggt selrvldvdf ednyqfakyr sfkvadeaek  
35 181 ynlvlgave gsagdsllth nnqsfstkdg dndlntgnca vmfqqawwyk nchvsnlgr  
241 ylrghgsfa nginwksgkg ynysykvsem kvrrpa

- NP\_001994. ficolin 1 precursor; ficolin (collagen/fibrinogen domain-containing) 1 [Homo sapiens] [gi:8051584]

- 40 sig\_peptide 1..27  
mat\_peptide 28..326  
40..108 /region\_name="collagen-like domain"  
50..105 /region\_name="Collagen triple helix repeat (20 copies)" /note="Collagen" /db\_xref="CDD:pfam01391"  
45 51..107 /region\_name="Collagen triple helix repeat (20 copies)" /note="Collagen" /db\_xref="CDD:pfam01391"  
52..106 /region\_name="Collagen triple helix repeat (20 copies)" /note="Collagen" /db\_xref="CDD:pfam01391"  
50 115..326 /region\_name="FBG domain" /note="fibrinogen beta/gamma homology"  
115..326 /region\_name="Fibrinogen-related domains (FReDs)" /note="FBG" /db\_xref="CDD:smart00186"



115..325 /region\_name="Fibrinogen beta and gamma chains, C-terminal globular domain" /note="fibrinogen\_C" /db\_xref="CDD:pfam00147" variation 315  
 /db\_xref="dbSNP:1128428" variation 316 /db\_xref="dbSNP:1128429" variation 317  
 /db\_xref="dbSNP:1128430"

5

1 melsgatmar glavllvlfl hiknlpaqaa dtcpevkvg legsdktlil rgcpplpgap  
 61 gpkgeagvig ergerglpga pgkagpvpgk gdrgekmgmrgekdgagqsqs catgprnckd  
 121 lldrgyflsg whtiylpdcrlptvlcdmdt dgggwtvfqr rmdgsdvdyr dwaaykqgfg  
 181 sqlgefwn gn dnhaltagq sselrvdlvd fegnhqfaky ksfkvadeae kyklvgafv  
 241 ggsagnsltg hnnnffstkd qdndvssnc aekfggawwy adchasnlg lylmgphesy  
 301 anginwsaak gykysykvse mkvrpa

10

NP\_004099. ficolin 2 isoform a precursor; ficolin (collagen/fibrinogen domain-containing lectin) 2 (hucolin); ficolin (collagen/fibrinogen domain-containing lectin) 2; hucolin [Homo sapiens] [gi:4758348]

15

sig\_peptide 1..25

mat\_peptide 26..313

39..95 /region\_name="collagen-like domain"

20

98..313 /region\_name="FBG domain" /note="fibrinogen beta/gamma homology"

102..313 /region\_name="Fibrinogen-related domains (FReDs)" /note="FBG"

/db\_xref="CDD:smart00186"

102..312 /region\_name="Fibrinogen beta and gamma chains, C-terminal globular domain" /note="fibrinogen\_C" /db\_xref="CDD:pfam00147"

25

1 meldravgyvl gaatlillsfl gmawalqaad tpevkmgvl egskltlil rgcpplpgapg  
 61 dkgeagtgk rgerpppgpp gkagpppgng apgeppclt gprtkdlld rghflsgwht  
 121 iylpdcrlpt vlcdmdtdgg gwtvfqrrvd gsvdyrdwa tykqgfgsrl gefwlgndni  
 181 haltaggtse lrvdlvdfed nyqfakysf kvadeaekyn lvgafvegs agdsltfnh  
 241 qsfstkddn dltngncavm fggawwyknc hvsnlngryl rgthgsfang inwkskggyn  
 301 ysykvsemkv rpa

30

Q9WTS8. Ficolin 1 precursor (Collagen/fibrinogen domain-containing protein 1) (Ficolin-A) (Ficolin A) (M-Ficolin) [gi:13124116]

35

1..22 /gene="FCN1" /region\_name="Signal" /note="POTENTIAL."

23..335 /gene="FCN1" /region\_name="Mature chain" /note="FICOLIN 1."

50..88 /gene="FCN1" /region\_name="Domain" /note="COLLAGEN-LIKE."

152..298 /gene="FCN1" /region\_name="Domain" /note="FIBRINOGEN C-TERMINAL."

40

271 /gene="FCN1" /site\_type="glycosylation" /note="N-LINKED (GLCNAC...) (POTENTIAL)."

1 mwwpmlwafp vlclcssqa lgqesgacpd vkivglgaqd kvaviqscps fpgpppgkge  
 61 pgspagrger glqsgpgkmg ppgskgepgt mgppgvkgek gergtasplg qkelgdalcr  
 121 rgrsrckdll trgiltgwy tiylpdcrlptvlcdmdvdg ggwtvfqrrv dgsinfyrdw  
 181 dsykrfgnl gtefwlgndy lhlrtangnq elrvdlrefq gqtsfakys fqvsgaqeqy  
 241 klitgqfleg tagdsltahn nmafsthddq ndtnggknc alfghawwyh dchqsnlgr  
 301 ylpghesya dginwlsgrg hrysakvaem kiras

45

50

Q15485. Ficolin 2 precursor (Collagen/fibrinogen domain-containing protein 2) (Ficolin-B) (Ficolin B) (Serum lectin P35) (EBP-37) (Hucolin) (L-Ficolin) [gi:13124203]

1..25 /gene="FCN2" /region\_name="Signal" /note="POTENTIAL."  
 26..313 /gene="FCN2" /region\_name="Mature chain" /note="FICOLIN 2."  
 54..92 /gene="FCN2" /region\_name="Domain" /note="COLLAGEN-LIKE."  
 131..277 /gene="FCN2" /region\_name="Domain" /note="FIBRINOGEN C-  
 5 TERMINAL."  
 240 /gene="FCN2" /site\_type="glycosylation" /note="N-LINKED (GLCNAC...) (PO-  
 TENTIAL)."  
 300 /gene="FCN2" /site\_type="glycosylation" /note="N-LINKED (GLCNAC...) (PO-  
 10 TENTIAL)."  
 1 meldravglv gaatlillsf gmawalqaad tpevkmgvl egskltilr gcpglpgapg  
 61 dkgeagtnkg rgerpppgpp gkagpppgng apgeppclt gprckdlld rghflsgwht  
 121 iylpdcrlpt vlcdmtdgg gwtvfqrrvd gsvdfyrdwa tykqgfgsrl gefwlgndni  
 181 haltaqgtse lrvldvdfed nyqfakysf kvadeaekyn lvgafvegs agdsltfhnn  
 15 241 qsfstkddqn dltngncavm fggawwyknc hvsnlngryl rgthgsfang inwksgkgyn  
 301 ysykvsemkv rpa  
 O70497. Ficolin 2 precursor (Collagen/fibrinogen domain-containing protein 2) (Fi-  
 colin-B) (Ficolin B) (Serum lectin P35) (EBP-37) (Hucolin) [gi:13124181]  
 20 <1..15 /gene="FCN2" /region\_name="Signal" /note="POTENTIAL."  
 16..>306 /gene="FCN2" /region\_name="Mature chain" /note="FICOLIN 2."  
 41..79 /gene="FCN2" /region\_name="Domain" /note="COLLAGEN-LIKE."  
 130..276 /gene="FCN2" /region\_name="Domain" /note="FIBRINOGEN C-  
 25 TERMINAL."  
 299 /gene="FCN2" /site\_type="glycosylation" /note="N-LINKED (GLCNAC...) (PO-  
 TENTIAL)."  
 1 lgsaalflvt ltvhaagtcp elkvldegy kqltilqgcp glpgaagpkg eagakgdrge  
 30 61 sglpgipgke gptgpkgnqg ekgirgekdg sgpsqscatg prtckelltq ghfltgwyti  
 121 ylpdcrlpmv lcdmtdggg wtvfqrldg svdfrrdwts ykrfgsqglg efwlgndnih  
 181 alttqgtse lrvldsfegk hdfakysf iqgeaekyl ilgnflggga gdsltphnnr  
 241 lfstkdqnd gstsscamgy hgawwysqch tsnlnglyl rphksyangv nwkswrgyny  
 301 sckvse  
 35 O70165. Ficolin 1 precursor (Collagen/fibrinogen domain-containing protein 1) (Fi-  
 colin-A) (Ficolin A) (M-Ficolin) [gi:13124179]  
 1..22 /gene="FCN1" /region\_name="Signal" /note="POTENTIAL."  
 40 23..334 /gene="FCN1" /region\_name="Mature chain" /note="FICOLIN 1."  
 50..88 /gene="FCN1" /region\_name="Domain" /note="COLLAGEN-LIKE."  
 152..298 /gene="FCN1" /region\_name="Domain" /note="FIBRINOGEN C-  
 TERMINAL."  
 261 /gene="FCN1" /site\_type="glycosylation" /note="N-LINKED (GLCNAC...) (PO-  
 45 TENTIAL)."  
 1 mqwptlwafs gllclpsqa lgqergacpd vkvvglgagd kvvviqscpg fpgppgpkge  
 61 pgspagrger gfgsgpgkmg pagskgepgt mgppgvkgek gdtgaapslg ekelgdtlq  
 121 rgrsckdl trgiltgwy tihlpcrl tvcdmvdg ggwtvfrrv dgsidfrdw  
 50 181 dsykrfgnl gtefwlgndy lhlitangnq elrvldqdfq gkgsyakyss fqvseeqeky  
 241 kitlgqfleg tagdsltahn nmsftthdqd ndansmncaa lfhgawwyhn chqsnlrgy  
 301 lsgshesyad ginwgtgqgh hysykvaemk iras

P57756. Ficolin 2 precursor (Collagen/fibrinogen domain-containing protein 2) (Ficolin-B) (Ficolin B) (Serum lectin P35) (EBP-37) (Hucolin) [gi:13124114]

1..22 /gene="FCN2" /region\_name="Signal" /note="POTENTIAL."  
 23..319 /gene="FCN2" /region\_name="Mature chain" /note="FICOLIN 2."  
 48..86 /gene="FCN2" /region\_name="Domain" /note="COLLAGEN-LIKE."  
 137..283 /gene="FCN2" /region\_name="Domain" /note="FIBRINOGEN C-TERMINAL."  
 306 /gene="FCN2" /site\_type="glycosylation" /note="N-LINKED (GLCNAC...) (POTENTIAL)."

1 mvlgsaalfv lslcvfetti haadtcepvk vidlegsnkl tilqgcpplp galgpkgeag  
 61 akgrgesgl pghpgkagpt gpkgrgekg vrgekgtgp sqscatgprt ckelltrgyf  
 121 ltgwytiylp dcrpltlcd mtdgggwtv frridgtvd ffrdwtsykq gfgsqlgefz  
 181 lgndnihalt tqgtneirvd ladfdgnhdf akysfsiqq eaekykliig nllgggagds  
 241 ltsqnmfss tkdqdndqgs sncavryhga wwysdchsn lnglylrglh ksyangvnmk  
 301 swkgynysyk vsemkvrl

JC5980: ficolin-A precurs - mouse [gi:7513652]

1..21 /region\_name="domain" /note="signal sequence"  
 50..64 /region\_name="domain" /note="collagen-like"  
 68..106 /region\_name="domain" /note="collagen-like"  
 123..334 /region\_name="domain" /note="fibrinogen beta/gamma homology #label FBG"

1 mqwptlwafs gllclpsqa lgqergacpd vkvvlgaqd kvvviqscpg fpgppgpkge  
 61 pgspagrger gfgspgkmg pagskgepgt mgppgvkgek gdtgaapslg ekelgdtlcg  
 121 rgprscdli trgiltgwy tihlpdcrpl tlcdmdvdg ggwtvfrrv dgsidffrdw  
 181 dsykrfgnl gtefwlgndy lhlitangnq elrvldqdfq gkgisyakyss fqvseeqeky  
 241 klitgqfleg tagdstlkh nmsftthdqd ndansmncaa lfhgawwyhn chqsnlrgy  
 301 lsgshesyad ginwgtgqgh hysykvaemk iras

S61517. ficolin-1 precurs- human [gi:2135116]

1..326 /note="36K HLA-cross-reactive plasma protein; hucolin, 35K"  
 1..22 /region\_name="domain" /note="signal sequence"  
 52..108 /region\_name="region" /note="collagen-like"  
 115..326 /region\_name="domain" /note="fibrinogen beta/gamma homology #label FBG"  
 305 /site\_type="binding" /note="carbohydrate (Asn) (covalent)"

1 melsgatmar glavllvfl hiknlpaqaa dtcpevkvg legsdktlil rgcpplpgap  
 61 gpkgeagvig ergerglpga pgkagpvpgk gdrgekmgmrgekdgagqsqs catgprnckd  
 121 lldrgyflsg whnipldcr pltlcdmdt dgggwtvfqr rmdgsvdfyr dwaaykqgfg  
 181 sqlgefvlgn dnihaltagq sselrvldvd fegnhqfaky ksfkvadeae kyklvlgafv  
 241 ggsagnsltg hnnnffstk qdndvssnc aekfggawwy adchasslng lylmgphesy  
 301 anginwsaak gykysykvse mkvrpa

A47172. transforming growth factor-beta 1-binding protein homolog ficolin-alpha - pig [gi:423206]

112..323 /region\_name="domain" /note="fibrinogen beta/gamma homology #label FBG"

1 mdtrgvaaam rplvlvaf ctaapaldtc pevkvvgleg scklsilrgc pglpgaagpk  
 61 geagasgpgk gggppgapge pgppgpgkdr gekgepgpgk esweteqclt gprrckellt  
 121 rghilsgwht iylpdcqplt vlcdmtdgg gwtvfqrrsd gsvdfyrdwa aykrfgsq  
 181 gefwlgndhi haltaqgtne lrvdlvdfeg nhqfakysrf qvadeaekym lvgafvegn  
 5 241 agdsltshnn slfttkdqd nqyasncavl yqgawwynsc hvsnlngryl ggshgsfang  
 301 vnwssgkgyn ysykvsemkf rat

JC4942. ficolin-1 precursor – human [gi:2135117]

10 1..22 /region\_name="domain" /note="signal sequence"  
 45..101 /region\_name="region" /note="collagen-like"  
 108..319 /region\_name="domain" /note="fibrinogen beta/gamma homology #label  
 FBG"  
 111..315 /region\_name="region" /note="fibrinogen-like".  
 15 298 /site\_type="binding" /note="carbohydrate (Asn) (covalent)"

1 marglavillv lflhiknlpa qaadtcepvk vvglegsdki tilrgcpglp gapgpkgeag  
 61 vigergergl pgapgkagpv gpkgdrgek mrgckgdagq sqscatgprn ckdldrgyf  
 121 lsgwhitiylp dcrpltlcd mtdgggwtv fqrmdgsvd fyrdwaaykq gfgsqgfw  
 20 181 lgnndihalt aqgsseirvd lvdfeqnhqf akyksfkvad eaekyklvg afvggsagns  
 241 ltghnnnffs tkdqndvss sncaekfqa wwyadchasn lnglylmgph esyanginws  
 301 aakgykysyk vsemkvrpa

AAF44911. symbol=BG:DS00929...[gi:7287873]

25 1 mkscffvfl wtlfevgqs sphtcpgsp ngihqlmlpe eepfqvtqck ttardwiviq  
 61 rldgsvfn qswfsykdgf gdpngeffig lqklylmre qphelfiqlk hgpgatvyah  
 121 fddfqvds et elyklervgk ysgtagdsir yhinkrfstf drdndesskn caaehgggww  
 181 fhsclsr

30

The first polypeptide preferably comprises at least 10, such as at least 12, for exam-  
 ple at least 15, such as at least 20, for example at least 25, such as at least 30, for  
 example at least 35, such as at least 40, for example at least 50 consecutive amino  
 35 acid residues of the complement activating protein or of a variant or a homologue to  
 said protein. Such a variant or homologue is preferably at least 70%, such as 80%,  
 for example 90%, such as 95% identical to the complement activating protein.

The first polypeptide sequence of the fusion protein is preferably capable of activat-  
 40 ing the lectin-complement pathway when bound directly or indirectly to a target,  
 such as a bacteria or a virus. In a preferred embodiment the first polypeptide se-  
 quence is capable of associating with at least one MASP protein, such as a MASP  
 protein selected from the group consisting of MASP-1, MASP-2 and MASP-3 or  
 functional homologues or variants hereof. In particular the first polypeptide is capa-  
 45 ble of associating with said at least one MASP protein when being part of the fusion

protein. Thereby the first polypeptide sequence is capable of providing the fusion protein with complement system activating activity.

5 In a particular preferred embodiment the first polypeptide sequence comprises at least the amino acid residues corresponding to 1-54 of L-ficolin sequence of Figure 1, such as 1-55 of L-ficolin sequence of Figure 1, such as 1-69 of L-ficolin sequence of Figure 1, such as 1-77 of L-ficolin sequence of Figure 1, such as 1-90 of L-ficolin sequence of Figure 1, such as 1-93 of L-ficolin sequence of Figure 1, such as 1-131 of L-ficolin sequence of Figure 1, such as 1-207 of L-ficolin sequence of Figure 1. In particular the first polypeptide sequence comprises the amino acid residues selected from: 1-55 of L-ficolin sequence of Figure 1, 1-54 of L-ficolin sequence of Figure 1, 1-50, or 1-77 of L-ficolin sequence of Figure 1. In a more preferred embodiment the first polypeptide sequence has the amino acid residues selected from: 1-55 of L-ficolin sequence of Figure 1, 1-54 of L-ficolin sequence of Figure 1, 1-50, or 1-77 of L-ficolin sequence of Figure 1. In another embodiment the first polypeptide sequence comprises at least the amino acid residues corresponding to 60-90 of L-ficolin sequence of Figure 1, such as 55-90 of L-ficolin sequence of Figure 1, such as 54-92 of L-ficolin sequence of Figure 1.

20 It is preferred the first polypeptide sequence and the second polypeptide sequence are selected to include the motif X-X-G-X-X-G at least 5 times, such as at least 7 times, preferably in a consecutive sequence. It is more preferred to select the first polypeptide sequence and the second polypeptide sequence so that the aforementioned motif is substituted once with the motif X-X-G-X-G. In the motifs X means any amino acid different from Glycine, and G means Glycine.

### **Second polypeptide sequence**

30 The second polypeptide sequence is preferably capable of associating with one or more carbohydrates. This may be accomplished by incorporating at least the carbohydrate recognizing domain of the collectin in question. Accordingly, the second polypeptide sequence preferably comprises the CRD domain of a collectin or a homologue or a variant thereof.

Preferably the collectin is selected from the group consisting of MBL (mannose-binding lectin), SP-A (lung surfactant protein A), SP-D (lung surfactant protein D), BK (or BC, bovine conglutinin) and CL-43 (collectin-43). Most preferably the collectin is MBL.

In a particular preferred embodiment the collectin has one of the sequences listed below with reference to their database and accession No.

### Collectins

SEQ ID NO: 42

Q9NPY3 Complement component C1q receptor precursor (Complement component 1, q subcomponent, receptor 1) (C1qRp) (C1qR(p)) (C1q/MBL/SPA receptor) (CD93 antigen) (CDw93) gi|21759074|sp|Q9NPY3|CD93\_HUMAN[21759074]

FEATURES Location/Qualifiers source 1..652 /organism="Homo sapiens" /db\_xref="taxon:9606"

gene 1..652 /gene="C1QR1" /note="CD93"

Protein 1..652 /gene="C1QR1" /product="Complement component C1q receptor precursor"

Region 1..21 /gene="C1QR1" /region\_name="Signal"

Region 22..652 /gene="C1QR1" /region\_name="Mature chain" /note="COMPLEMENT COMPONENT C1Q RECEPTOR."

Region 22 /gene="C1QR1" /region\_name="Conflict" /note="T -> V (IN AA SEQUENCE)."

Region 24..580 /gene="C1QR1" /region\_name="Domain" /note="EXTRACELLULAR (POTENTIAL)."

Region 32..174 /gene="C1QR1" /region\_name="Domain" /note="C-TYPE LECTIN."

Region 36 /gene="C1QR1" /region\_name="Conflict" /note="C -> T (IN AA SEQUENCE)."

Region 38..39 /gene="C1QR1" /region\_name="Conflict" /note="TA -> RI (IN AA SEQUENCE)."

Region 155 /gene="C1QR1" /region\_name="Conflict" /note="S -> N (IN REF. 1)."

Region 186 /gene="C1QR1" /region\_name="Conflict" /note="G -> A (IN AA SEQUENCE)."

Region 260..301 /gene="C1QR1" /region\_name="Domain" /note="EGF-LIKE 1."

Bond bond(264,275) /gene="C1QR1" /bond\_type="disulfide" /note="BY SIMILARITY."

Bond bond(271,285) /gene="C1QR1" /bond\_type="disulfide" /note="BY SIMILARITY."

Bond bond(287,300) /gene="C1QR1" /bond\_type="disulfide" /note="BY SIMILARITY."

Region 302..344 /gene="C1QR1" /region\_name="Domain" /note="EGF-LIKE 2."

Bond bond(306,317) /gene="C1QR1" /bond\_type="disulfide" /note="BY SIMILARITY."

Bond bond(311,328) /gene="C1QR1" /bond\_type="disulfide" /note="BY SIMILARITY."

Region 318 /gene="C1QR1" /region\_name="Variant" /note="V -> A.  
/FTId=VAR\_013573."  
Site 325 /gene="C1QR1" /site\_type="glycosylation" /note="N-LINKED (GLCNAC...)  
(POTENTIAL)."  
5 Bond bond(330,343) /gene="C1QR1" /bond\_type="disulfide" /note="BY SIMILAR-  
ITY."  
Region 345..384 /gene="C1QR1" /region\_name="Domain" /note="EGF-LIKE 3,  
CALCIUM-BINDING (POTENTIAL)."  
10 Bond bond(349,358) /gene="C1QR1" /bond\_type="disulfide" /note="BY SIMILAR-  
ITY."  
Bond bond(354,367) /gene="C1QR1" /bond\_type="disulfide" /note="BY SIMILAR-  
ITY."  
Bond bond(369,383) /gene="C1QR1" /bond\_type="disulfide" /note="BY SIMILAR-  
ITY."  
15 Region 385..426 /gene="C1QR1" /region\_name="Domain" /note="EGF-LIKE 4,  
CALCIUM-BINDING (POTENTIAL)."  
Bond bond(389,400) /gene="C1QR1" /bond\_type="disulfide" /note="BY SIMILAR-  
ITY."  
Bond bond(396,409) /gene="C1QR1" /bond\_type="disulfide" /note="BY SIMILAR-  
20 ITY."  
Bond bond(411,425) /gene="C1QR1" /bond\_type="disulfide" /note="BY SIMILAR-  
ITY."  
Region 427..468 /gene="C1QR1" /region\_name="Domain" /note="EGF-LIKE 5,  
CALCIUM-BINDING (POTENTIAL)."  
25 Bond bond(431,443) /gene="C1QR1" /bond\_type="disulfide" /note="BY SIMILAR-  
ITY."  
Bond bond(439,452) /gene="C1QR1" /bond\_type="disulfide" /note="BY SIMILAR-  
ITY."  
Bond bond(454,467) /gene="C1QR1" /bond\_type="disulfide" /note="BY SIMILAR-  
30 ITY."  
Region 492 /gene="C1QR1" /region\_name="Conflict" /note="S -> A (IN AA SE-  
QUENCE)."  
Region 496 /gene="C1QR1" /region\_name="Conflict" /note="R -> Q (IN AA SE-  
QUENCE)."  
35 Region 504 /gene="C1QR1" /region\_name="Conflict" /note="R -> G (IN AA SE-  
QUENCE)."  
Region 541 /gene="C1QR1" /region\_name="Conflict" /note="P -> S (IN REF. 1)."  
Region 581..601 /gene="C1QR1" /region\_name="Transmembrane region"  
/note="POTENTIAL."  
40 Region 594..601 /gene="C1QR1" /region\_name="Domain" /note="POLY-LEU."  
Region 602..652 /gene="C1QR1" /region\_name="Domain" /note="CYTOPLASMIC  
(POTENTIAL)."  
ORIGIN 1 matsmgllll lllltqpga gtgadteavv cvgtacytah sgklsaaeq nhcnqnggnl  
61 atvkskeeq hvqrvlaql rreaaltarm skfwiglqre kgkclpslp lkgfswvggg  
45 121 edtpysnwhk elrnsciskr cvslldlsq pilpsrlpkw segpcgspgs pgsniegfv  
181 kfsfkgmcrp lalggpgqvt ytpfqtss sleavpfasa anvacgegdk detqshyflc  
241 kekadvfdw gssgplcvsp kygcfnngg chqdcfeggd gsflcgrpg frliddlvtc  
301 asrnpccssp crggatcvlg phgknytrc pqgyqldssq ldcvdvdecq dspcaqecvn  
361 tpggfrcecw vgyepggpge gacqdvdeca lgrspcaqgc tntdgsfhcs ceegyvlage  
50 421 dgtqcqdvde cvgpggplcd slcfnqtqsf hcgcipgwvl apngvsctmg pvsigppsgp  
481 pdeedkgeke gstvptraata sprtgrpegtp katptsrps lssdapitsa plkmlapsgs  
541 pgwrepsih hataasgpqe paggdssvat qnndgtgqk lllyilgtv vailllala  
601 lgllyrkr akreekkekk pqnaadsysw vperaesram enqysptpgt dc

SEQ ID NO: 43  
 BAC05523 collectin placenta 1 [Mus musculus]  
 gi|21901969|dbj|BAC05523.1|[21901969]  
 5 FEATURES Location/Qualifiers source 1..742 /organism="Mus musculus"  
 /db\_xref="taxon:10090" /tissue\_lib="Liver"  
 Protein 1..742 /product="collectin placenta 1"  
 CDS 1..742 /gene="CL-P1" /coded\_by="AB078434.1:92..2320"  
 ORIGIN 1 mkddfaeeee vqsfgykrfg iqegtqctkc knnwalkfsi vlyilcall titvailgyk  
 10 61 vvekmdnvt d gmetshqtyd nklavesdl kklgdqagkk alstnselst frsdildlrq  
 121 qlqeteks knkdtlek lq angdsvdrq sqlketlqnn sflittvnkt lqayngyvt n  
 181 lqqdtsvlqg nlqsqmysqs vvmmnnln ln ltqvqqrnli snlqqsvddt slaiqriknd  
 241 fqnlqqvflq akkddtwike kvqslqtlaa nnsalakann dtledmnsq l ssftgqmdni  
 301 ttisqaneqs lkdldlhkd tenrtavkfs qleerfqvfe tdvniisni sytahhlrt l  
 15 361 tsnldvrrt cdtlttrht dltslntlv nirdsislr mqqdmmsrskl dtevanlsv  
 421 meemklvds k hgqliknfti lqpppgprgp kgdrsgqgpp gptgnkgqkg ekgepgppgp  
 481 agertigpv gppgergskg skgsqgpkgs rgspgkpgpq gpsgdpgppg  
 ppgkdglpgp  
 541 qgppgfqglq gtvgepgvpg prglpglpgv pgmpgpkgpp gppgpgsgame  
 20 plalqnept  
 601 asevgcp ph wknftdkcyy fslekeifed aklfcedkss hlvfinsree qqwikkhtvg  
 661 reshwiglt d seqesewkw l dgspvdyknw kagqpdnwgs ghgpgedcag li-  
 yagqwndf  
 721 qcdeinnfic ekereavpss il

SEQ ID NO: 45  
 AAM34742 46-kDa collectin precursor [Bos taurus]  
 gi|21105685|gb|AAM34742.1|AF509589\_1[21105685]  
 30 sig\_peptide 1..20  
 Region 67..245 /region\_name="collagen-like region"  
 Region 245..371 /region\_name="carbohydrate recognition domain"  
 CDS 1..371 /gene="CL-46" /coded\_by="join(AF509589.1:1454..1652,  
 AF509589.1:5950..6066,AF509589.1:6402..6509,  
 35 AF509589.1:6823..6930,AF509589.1:7289..7405,  
 AF509589.1:8021..8104,AF509589.1:10318..10700)"  
 ORIGIN 1 mlliplsvll lltqpwrslg aemkiysqkt langctlvvc rpeggplpgr dgqdgregpq  
 61 gekgdpgspg pagragrpgp agpigpkgn dsagepgpkg dtgppgppgm pgpagregps  
 121 gkqgsmgppg tpgpkgdtpg kggmgapgm q gspgpaglk g ergapgelga pgsagvagpa  
 40 181 gaigpqgpgs argppglkgd rgdpgergak gesgladvna lkqrvtileg qlqrlqnafs  
 241 rykkavlfpd gqavgk kfk tagavksysd aqqlcreakg qlasprsaee neavaqlvra  
 301 knndaflsmn distegkfty ptgeslvysn wasgepn nnn agqpencvqi yregkwndvp  
 361 csepllvce f

SEQ ID NO: 47  
 XP\_139613 similar to collectin sub-family member 10; collectin liver 1; collectin 34  
 [Mus musculus]  
 gi|20903807|ref|XP\_139613.1|[20903807]  
 50 FEATURES Location/Qualifiers source 1..420 /organism="Mus musculus"  
 /strain="C57BL/6J" /db\_xref="taxon:10090" /chromosome="15"  
 Protein 1..420 /product="similar to collectin sub-family member 10; collectin liver 1;  
 collectin 34"



Region 152..269 /region\_name="C-type lectin (CTL) or carbohydrate-recognition domain (CRD)" /note="CLECT" /db\_xref="CDD:smart00034"

Region 165..269 /region\_name="Lectin C-type domain" /note="lectin\_c" /db\_xref="CDD:pfam00059"

5 Region 362..419 /region\_name="Ubiquitin-conjugating enzyme E2, catalytic domain homologues" /note="UBCc" /db\_xref="CDD:smart00212"

Region 363..419 /region\_name="Ubiquitin-conjugating enzyme" /note="UQ\_con" /db\_xref="CDD:pfam00179" CDS 1..420 /gene="LOC239447"

/coded\_by="XM\_139613.1:1..1263" /db\_xref="InterimID:239447"

10 ORIGIN 1 mngfrvllrs nlsmlillal lhfqslgldv dsrsaaevca thtispgpkg ddgergdgtge

61 egkdgkvgrq gpkgvkgelg dmgaqgnigk sgpigkkgdk gekglgipg ekgkagticd

121 cgryrkvvvg ldisvarlkt smkfiknvia gireteekfy yivqeeknyr eslthcrirg

181 gmlampkdev vntliadyva ksgffrvfig vndleregqy vftdntplqn ysnwkeeps

241 dpsghedcve mlssgrwndt echltmyfvs slqedliedc lreagllvqv tpanqellfg

15 301 idtflgpmssc vyqrtgkqk lysqclwdg lakkqtneta niatfckgae pnrgsrpcgq

361 kqemmtlmms gnkgittfpe sdnlfkwwgt mlgaagtide dlkyklslns pvvtilihpg

SEQ ID NO: 48

XP\_123211 similar to collectin sub-family member 12 [Mus musculus]

20 gi|20876566|ref|XP\_123211.1|[[20876566]

FEATURES Location/Qualifiers source 1..742 /organism="Mus musculus"

/strain="C57BL/6J" /db\_xref="taxon:10090" /chromosome="18"

Protein 1..742 /product="similar to collectin sub-family member 12"

Region 79..320 /region\_name="V-type ATPase 116kDa subunit family"

25 /note="V\_ATPase\_sub\_a" /db\_xref="CDD:pfam01496"

Region 92..337 /region\_name="Intermediate filament protein" /note="filament"

/db\_xref="CDD:pfam00038" Region 607..731 /region\_name="C-type lectin (CTL) or carbohydrate-recognition domain (CRD)" /note="CLECT"

/db\_xref="CDD:smart00034"

30 Region 624..732 /region\_name="Lectin C-type domain" /note="lectin\_c"

/db\_xref="CDD:pfam00059"

CDS 1..742 /gene="LOC225157" /coded\_by="XM\_123211.1:77..2305"

/db\_xref="InterimID:225157"

ORIGIN 1 mkddfaeaaa vqsfgykrfg iqegtqctkc knnwalkfsi vlyilcall titvailgk

35 61 vvekmdnvtg dmetshqtyd nklavesdl kklgdqagkk alstnselst frsdildlrq

121 qlqektks knkdtlekq angdsvdrq sqlketlqnn sflittvnkt lqayngyvt

181 lqqdtsvlqg nlqsqmysqs vvimnlnln ltqvqqnli snlqqsvddt slaiqriknd

241 fqnqqvflq akkdt dwike kvqslqlta nnsalakann dtledmnsq ssftgqmdni

301 ttisqaneqs lkdldlhkd tenrtavkfs qleerqvfe tdivniisni sytahhlrt

40 361 tsnlndvrtt ctdltlrhtd dltslnntlv nrlidsislr mqqdmmrskl dtevanlsvv

421 meemklvdsd hgqliknfti lqgppgprgp kgdrsgqgpp gptgnkgqkg ekgepgppgp

481 agerdtigpv gppgergskg skgsqgpkgs rgspgkpgpq gpsgdpgppg

ppgkdglpgp

541 qgppgfqglq gtvgepgvpg prglpglpgv pgmpgpkgpp gppgpgame plalqneptp

45 601 asevgcpvh wknftdkcyy fslekeifed aklfcedkss hlvfinsree qqwikkhvtg

661 reshwigltd seqesewkw dgsppvdyknw kagqpdnwgs ghgpgedcag li-

yagqwndf

721 qcdeinnfic ekereavpss il

50 SEQ ID NO: 49

NP\_571645 mannose binding-like lectin [Danio rerio]

gi|18858997|ref|NP\_571645.1|[[18858997]

sig\_peptide 1..23

mat\_peptide 24..251 /product="mannose binding-like lectin"  
 Region 24..36 /region\_name="N-terminal segment"  
 Region 33..70 /region\_name="Collagen triple helix repeat (20 copies)"  
 /note="Collagen" /db\_xref="CDD:pfam01391"  
 5 Region 33..70 /region\_name="Collagen triple helix repeat (20 copies)"  
 /note="Collagen" /db\_xref="CDD:pfam01391"  
 Region 37..101 /region\_name="collagen-like structure"  
 Region 37..70 /region\_name="Collagen triple helix repeat (20 copies)"  
 /note="Collagen" /db\_xref="CDD:pfam01391"  
 10 Region 71..74 /region\_name="break in collagen structure"  
 Region 102..132 /region\_name="neck region"  
 Region 133..251 /region\_name="carbohydrate recognition domain" /note="CRD"  
 Region 134..247 /region\_name="C-type lectin (CTL) or carbohydrate-recognition  
 domain (CRD)" /note="CLECT" /db\_xref="CDD:smart00034"  
 15 Region 146..247 /region\_name="Lectin C-type domain" /note="lectin\_c"  
 /db\_xref="CDD:pfam00059"  
 CDS 1..251 /gene="mbi" /coded\_by="NM\_131570.1:68..823" /note="collectin with  
 structural homology to mannose-binding lectin but with a predicted carbohydrate  
 specificity for galactose;mannose binding-like lectin" /db\_xref="LocusID:58091"  
 20 ORIGIN 1 mallklflga lllqlvlql magaadpql ncpayagvpg tpghnglpgr dgrvgrdgan  
 61 gpkgekgepg vnvqgppgka gppgpagakg ergpsglpgq dcmsdskse lqlsdskial  
 121 iekvvnfkft kkvqgkyyvt ddveetfdkg mqycssngga lvprtlelen allkvfvssa  
 181 fklrfirtd rekegefvdtd drkklftnw gpnqpdnykg aqdcgaiads glwddvscds  
 241 lypiiceiei k  
 25

SEQ ID NO: 50

NP\_569057 collectin sub-family member 12, isoform I; scavenger receptor with C-type lectin; collectin placenta 1 [Homo sapiens]  
gi|18641360|ref|NP\_569057.1||18641360]

5 FEATURES Location/Qualifiers source 1..742 /organism="Homo sapiens"  
/db\_xref="taxon:9606" /chromosome="18" /map="18pter-p11.3"  
Protein 1..742 /product="collectin sub-family member 12, isoform I" /note="isoform I  
is encoded by transcript variant I; scavenger receptor with C-type lectin; collectin  
10 placenta 1"  
Region 79..328 /region\_name="V-type ATPase 116kDa subunit family"  
/note="V\_ATPase\_sub\_a" /db\_xref="CDD:pfam01496" Region 443..589  
/region\_name="collagen-like domain"  
Region 607..731 /region\_name="C-type lectin (CTL) or carbohydrate-recognition  
15 domain (CRD)" /note="CLECT" /db\_xref="CDD:smart00034"  
Region 624..732 /region\_name="Lectin C-type domain" /note="lectin\_c"  
/db\_xref="CDD:pfam00059"  
Region 668..719 /region\_name="Beta-lactamase" /note="beta-lactamase"  
/db\_xref="CDD:pfam00144"  
20 CDS 1..742 /gene="COLEC12" /coded\_by="NM\_130386.1:172..2400"  
/db\_xref="LocusID:81035"  
ORIGIN 1 mkddfaeeee vqsfgykrfg iqegtqctkc knnwalkfsi illyilcall titvailgyk  
61 vvekmdnvtg gmetsrqtyd dklavesdl kklgdqtkk aistnselst frsdildlrq  
121 qlreitekts knkdtleklq asgdalvdrq sqlketlenn sflittvnkt lqayngyvtn  
25 181 lqqdtsvlqg nlqnqmyshn vvimnlnln ltqvqqnli tnlqrsvddt sqaiqriknd  
241 fqnlqqvflq akkddtwlke kvqslqltaa nnsalakann dtledmnsq nsftgqmeni  
301 ttisqaneqn lkdlqdlhkd aenrtalkfn qleerqlfe tdivniisni sytahhlrtl  
361 tsnlnevrtt cdtltkhhd dltslnntla nirdsvslr mqqdlmrsrl dtevanlsvi  
421 meemklvdsk hgqliknfti lqgppgprgp rgdrsgqgpp gptgnkgqkg ekgepgppgp  
30 481 agergpigpa gppgerggkg skgsqgpkgs rgspgkpgpq gpsgdpgppg  
ppgkeglpgp  
541 qgppgfqglq gtvgepgvpg prglpglpgv pgmpgpkgpp gppgpgsavv plalqneptp  
601 apedngcpvh wknftdkcyy fsvekeifed akfcedkss hlvfintree qqwikkmvg  
661 reshwigltd serenewkw dgtspdyknw kagqpdnwgh ghgpgedcag liyagqwndf  
35 721 qcedvnnfic ekdretvlss al

SEQ ID NO: 51

NP\_110408 collectin sub-family member 12, isoform II; scavenger receptor with C-type lectin; collectin placenta 1 [Homo sapiens]  
gi|18641358|ref|NP\_110408.2||18641358]

40 FEATURES Location/Qualifiers source 1..622 /organism="Homo sapiens"  
/db\_xref="taxon:9606" /chromosome="18" /map="18pter-p11.3"  
Protein 1..622 /product="collectin sub-family member 12, isoform II" /note="isoform  
II is encoded by transcript variant II; scavenger receptor with C-type lectin; collectin  
45 placenta 1"  
Region 79..328 /region\_name="V-type ATPase 116kDa subunit family"  
/note="V\_ATPase\_sub\_a" /db\_xref="CDD:pfam01496"  
Region 443..589 /region\_name="collagen-like domain"  
CDS 1..622 /gene="COLEC12" /coded\_by="NM\_030781.2:172..2040"  
50 /db\_xref="LocusID:81035"  
ORIGIN 1 mkddfaeeee vqsfgykrfg iqegtqctkc knnwalkfsi illyilcall titvailgyk  
61 vvekmdnvtg gmetsrqtyd dklavesdl kklgdqtkk aistnselst frsdildlrq  
121 qlreitekts knkdtleklq asgdalvdrq sqlketlenn sflittvnkt lqayngyvtn

181 lqqdtsvlqg nlqnqmyshn vvimnlnln ltqvqqnli tnlqrsvddt sqaiqriknd  
 241 fqnqqvflq akkdtldwike kvqslqtlaa nnsalakann dtledmnsqf nsftgqmeni  
 301 ttisqaneqn lkdldlhkd aenrtakfn qleerfqlfe tdivniisni sytahhlrtf  
 361 tsnlnevrtt ctdlttkhtd dltslnntla nirdsvslr mqqdlmrsrl dtevanlsvi  
 5 421 meemklvdsk hgqliknfti lqgppgprgp rgdrsgqgpp gptgnkgqkg ekgepgppgp  
 481 agergpiga gppgerggkg skgsqgpkgs rgspgkpgpq gpsgdpgppg  
 ppgkeglpgp  
 541 qgppgfqglq gtvgepgvpg prglpglpgv pgmpgpkgpp gppgpgsavv plalqneptp  
 601 apednsksk slqpggggsa ca

10

SEQ ID NO: 52

NP\_569716 collectin sub-family member 12 [Mus musculus]

gi|18485494|ref|NP\_569716.1|[18485494]

FEATURES Location/Qualifiers source 1..742 /organism="Mus musculus"

15

/db\_xref="taxon:10090"

Protein 1..742 /product="collectin sub-family member 12"

Region 79..320 /region\_name="V-type ATPase 116kDa subunit family"

/note="V\_ATPase\_sub\_a" /db\_xref="CDD:pfam01496"

20

Region 607..731 /region\_name="C-type lectin (CTL) or carbohydrate-recognition

domain (CRD)" /note="CLECT" /db\_xref="CDD:smart00034"

Region 629..732 /region\_name="Lectin C-type domain" /note="lectin\_c"

/db\_xref="CDD:pfam00059"

CDS 1..742 /gene="Colec12" /coded\_by="NM\_130449.1:77..2305"

/db\_xref="LocusID:140792" /db\_xref="MGD:2152907"

25

ORIGIN 1 mkddfaeese vqsfgyrfg ihegtqctkc innwalkfsi vlyilcall titvailyk

61 vvekmdnvsd gmetshqtyd nklavesdl kklgdqagkk alstnselst frsdildlrq

121 qlqetkts knkdtlekfq angdsvdrq sqlketlqnn sflittvnkt lqayngyvt

181 lqqdtnvlqg nlqsmysqs vvimnlnln ltqvqqnli snlqqsavddt slaiqriknd

241 fqnqqvflq akkdtldwike kvqslqtlaa nnsalakann dtledmnsqf ssftgqmdni

30

301 ttisqaneqs lkdldlhkd tenrtavkfs qleerfqvfe tdivniisni sytahhlrtf

361 tsnlndvwt ctdlttrhtd dltslnntlv nirdsvslr mqqdmmrskl dtevanlsv

421 meemklvdsk hgqliknfti lqgppgprgp kgdrsgqgpp gptgnkgqkg ekgepgppgp

481 agergtigpv gppgergskg skgsqgpkgs rgspgkpgpq gpsgdpgppg

ppgkdglpgp

35

541 qgppgfqglq gtvgepgvpg prglpglpgv pgmpgpkgpp gppgpgsavv plalqneptp

601 asevnecpph wknftdkcyf fslekeiled akfcedkss hlvfinsree qqwikkhv

661 reshwiglt seqesewkw dgspvdyknw kagqpdnwgs ghgpgedcag li-

yagqwdf

721 qcdeinifc ekereavpss il

40

SEQ ID NO: 53

AAL61856 43kDa collectin precursor [Bos taurus]

gi|18252111|gb|AAL61856.1|[18252111]

45

FEATURES Location/Qualifiers source 1..321 /organism="Bos taurus"

/db\_xref="taxon:9913"

Protein 1..321 /product="43kDa collectin precursor" /name="CL-43; conglutinin; SP-

D"

Region 1..166 /region\_name="collagen-like"

50

Region 167..193 /region\_name="alpha-helical neck"

Region 195..321 /region\_name="carbohydrate-recognition domain"

5

15

20

30

35

50

Region 126..236 /region\_name="C-type lectin (CTL) or carbohydrate-recognition domain (CRD)" /note="CLECT" /db\_xref="CDD:smart00034"

Region 135..237 /region\_name="Lectin C-type domain" /note="lectin\_c" /db\_xref="CDD:pfam00059"

5 CDS 1..239 /gene="Mbl1" /coded\_by="NM\_010775.1:121..840"

/db\_xref="LocusID:17194" /db\_xref="MGD:96923"

ORIGIN 1 mlllpilpvl lcvsvsssg sqtcedtlkt csviacgrdg rdgpkgekge pgqglrglqg

61 ppgklgppgs vgsppgspgk gqkgdhgdnr aieeklanme aeirilkskl qltnklhafs

121 mgkksqgklf vtnhekmpfs kvkslctelq gtvaipnae enkaieqvat giaflgitde

10 181 ategqfmyvt ggrltsnwk kdepnnhsg edcvildng lwndiscqas fkavceffa

SEQ ID NO: 55

NP\_034906 mannose binding lectin, serum (C) [Mus musculus]

gi|6754656|ref|NP\_034906.1|[6754656]

15 sig\_peptide 1..18

Region 120..241 /region\_name="C-type lectin (CTL) or carbohydrate-recognition domain (CRD)" /note="CLECT" /db\_xref="CDD:smart00034"

Region 140..242 /region\_name="Lectin C-type domain" /note="lectin\_c" /db\_xref="CDD:pfam00059"

20 CDS 1..244 /gene="Mbl2" /coded\_by="NM\_010776.1:177..911"

/note="polysaccharide-binding component of RaRF; sequence similarity to mannose-binding proteins" /db\_xref="LocusID:17195" /db\_xref="MGD:96924" ORIGIN 1 misiftsfill cvvtvyaet ltegvqnsdp vvtcsspgln gfpkgdgrdg akgekgepgg

61 glrglqgppg kvqptgppgn pglkgavgpk gdrgrdraefd tseidseiaa lrselralrn

25 121 wwlfslsekv gkkyfvssvk kmsldrvkal csefggsvat prnaeensa qkvakdiayl

181 gitdvrvsgs fedltgnrvr ytnwndgepn ntgdgedcvv ilgngkwndv pcsdsflaic

241 efsd

SEQ ID NO: 56

30 NP\_006429 collectin sub-family member 10; collectin liver 1; collectin 34 [Homo sapiens] gi|5453619|ref|NP\_006429.1|[5453619]

FEATURES Location/Qualifiers source 1..277 /organism="Homo sapiens"

/db\_xref="taxon:9606" /chromosome="8" /map="8q23-q24.1"

Protein 1..277 /product="collectin sub-family member 10" /note="collectin liver 1; collectin 34"

35 Region 152..271 /region\_name="C-type lectin (CTL) or carbohydrate-recognition domain (CRD)" /note="CLECT" /db\_xref="CDD:smart00034"

Region 165..272 /region\_name="Lectin C-type domain" /note="lectin\_c" /db\_xref="CDD:pfam00059"

40 CDS 1..277 /gene="COLEC10" /coded\_by="NM\_006438.2:76..909"

/db\_xref="LocusID:10584"

ORIGIN 1 mngfasllrr nqfillvfl lqiqlgldi dsrptaevca thtispgpkg ddgekdpge

61 egkhgkvgrm gpkgikgelg dmgrdnigk tgpigkkgdg gekgllgipg ekgkagtvc

121 cgyrkfvqg ldisiarlkt smkfvknvia gireteekfy yivqeenyr eslthcrirg

45 181 gmlampkdea antliadyva ksgffrvfig vndlereqgy mftdntplqn ysnwnegeps

241 dpyghedcve mlssgrwndt echltmyfvc efikkkk

SEQ ID NO: 57

BAB72147 collectin placenta 1 [Homo sapiens]

50 gi|17026101|dbj|BAB72147.1|[17026101]

FEATURES Location/Qualifiers source 1..742 /organism="Homo sapiens"

/db\_xref="taxon:9606" /sex="female" /tissue\_lib="placenta"

Protein 1..742 /product="collectin placenta 1"

CDS 1..742 /gene="CL-P1" /coded\_by="AB005145.1:71..2299"

ORIGIN 1 mkddfaeeree vqsfgykrfg iqegtqctkc knnwalkfsi illyilcall titvailgk  
 61 vvekmdnvtg gmetsrqtyd dklavesdl kklgdqtgkk aistnselst frsdildlrq  
 5 121 qlreitekts knkdtlekq asgdalvdrq sqlketlenn sflittvnkt lqayngyvt  
 181 lqqdtsvlqg nlqnqmyshn vvimnlnln ltqvqqnli tnlqrsvddt sqaiqriknd  
 241 fnlqqvflq akkdtwlke kvqslqlaa nnsalakann dtiedmnsq nsftgqmeni  
 301 ttisqaneqn lkdldlhkd aenrtakfn qleerqlfe tdvniisni sytahhrt  
 361 tslnnevrtd ctdtltkhtd dltslnntla nirdsvslr mqqdlnrsrl dtevanls  
 10 421 meemklvdsk hgqliknfti lqpppgprgp rgdrsgqgpp gptgnkgqkg ekgepgppgp  
 481 agergpigpa gppgerggkg skgsqgpkgs rgspgkpgpq gspgdpggpg ppgkeglpgp  
 541 qgppgfqglq gtvgepgvpg prglpglpgv pgmpgpkgpp gppgpgsavv plalqnept  
 601 apedngcpvh wknftdkcyy fsvekeifed aklfcedkss hlvfintree qqwikkmvg  
 661 reshwigltd serenewkw dgtspdyknw kagqpdnwh ghgpgedcag liyagqwndf  
 15 721 qcedvnnfic ekdretvlss al

SEQ ID NO: 58

AAF63470 mannanose binding-like lectin precursor [Carassius auratus]  
 gi|7542474|gb|AAF63470.1|AF227739\_1[7542474]  
 20 sig\_peptide <1..13  
 Region 14..25 /region\_name="N-terminal segment"  
 Region 26..93 /region\_name="collagen-like structure"  
 Region 60..63 /region\_name="break in collagen structure"  
 Region 94..124 /region\_name="neck region" Region 125..246  
 25 /region\_name="carbohydrate recognition domain" /note="CRD"  
 CDS 1..246 /gene="MBL" /coded\_by="AF227739.1:<1..742" /note="collectin with  
 structural homology to mannanose-binding lectin but with a predicted carbohydrate  
 specificity for galactose"

ORIGIN 1 lllqlfalql ldgaepqnln cpayggvppt pgnglpgdr grdgkdgaig pkgekgesgv  
 61 svqpppgkag ppptagekge rgspgpggsp gsesvleslk seiqlkaki atfekvssvc  
 121 hfrkvqgkyy itdgvgnfd qglkscmefg gtmvsprtsa enqallklv ssglsgkpy  
 181 igvtdrkteg qfvdteqkl tftnwpggqp ddykglqdcg viedtqlwdd ggcdgdirpim  
 241 ceidik

SEQ ID NO: 59

AAF63469 mannanose binding-like lectin precursor [Danio rerio]  
 gi|7542472|gb|AAF63469.1|AF227738\_1[7542472]  
 sig\_peptide 1..23  
 40 mat\_peptide 24..251 /product="mannanose binding-like lectin"  
 Region 24..36 /region\_name="N-terminal segment"  
 Region 37..101 /region\_name="collagen-like structure"  
 Region 71..74 /region\_name="break in collagen structure"  
 Region 102..132 /region\_name="neck region"  
 45 Region 133..251 /region\_name="carbohydrate recognition domain" /note="CRD"  
 CDS 1..251 /gene="mbi" /coded\_by="AF227738.1:68..823" /note="collectin with  
 structural homology to mannanose-binding lectin but with a predicted carbohydrate  
 specificity for galactose"

ORIGIN 1 mallklflga lllqlvlql magaadpql ncpayagvpg tpghnglpgdr dgrvrgdgan  
 50 61 gpkgekgepg vnvqppgka gppgpagak ergpsglpgq dcmsdskse lqlskdial  
 121 iekvvnfktf kkvqgkyyvt ddveetfdkg mqycssngga lvprtleallkvfssa  
 181 fklrflritd rekegefvd drklftfnw gpnqpdnykg aqdcgaiads glwddvscds  
 241 lypliceiei k

SEQ ID NO: 60

AAF63468 mannose binding-like lectin precursor [Cyprinus carpio]  
gi|7542470|gb|AAF63468.1|AF227737\_1[7542470]

5 sig\_peptide 1..23  
mat\_peptide 24..256 /product="mannose binding-like lectin"  
Region 24..35 /region\_name="N-terminal segment"  
Region 36..103 /region\_name="collagen-like structure"  
10 Region 70..73 /region\_name="break in collagen structure"  
Region 104..134 /region\_name="neck region"  
Region 135..256 /region\_name="carbohydrate recognition domain" /note="CRD"  
CDS 1..256 /gene="MBL" /coded\_by="AF227737.1:67..837" /note="collectin with  
structural homology to mannose-binding lectin but with a predicted carbohydrate  
15 specificity for galactose"  
ORIGIN 1 malfklflgt lllqfalql ldgaepqnl cpayggvpgt pghnglpgrd grdgkdgaig  
61 pkgekgesgv svqpppgkag ppgpagekge rgptgsqgsp gsesvleslk seiqqklaki  
121 atfekvasvg hfrqvgqky itdgvgvgtfd qglkfckdfg gtmvfprtsa enqallklv  
181 ssglsskkpy igvtdreteg rfvntegkql tftnwpggqp ddykglqdcg viedsglwd  
20 241 gscgdirpim ceidnk

SEQ ID NO: 61

AAK97540 surfactant protein A precursor [Gallus gallus]  
gi|15420996|gb|AAK97540.1|AF411083\_1[15420996]

25 sig\_peptide 1..18  
Region 19..34 /region\_name="N-terminal segment"  
Region 35..43 /region\_name="putative collagen structure"  
Region 44..76 /region\_name="putative coil structure"  
Region 77..97 /region\_name="alpha-helical coil-coil structure; neck region"  
30 Region 98..222 /region\_name="carbohydrate recognition domain"  
Site 121..123 /site\_type="glycosylation"  
Site 181..183 /site\_type="glycosylation" /note="conserved"  
CDS 1..222 /gene="SP-A" /coded\_by="AF411083.1:61..729"  
ORIGIN 1 mlsysfcmia aavalltpch aqncagapel psipgvsgll glgalkryfg slwpygeek  
35 61 lpecqwlqrq qdlstssdde lgnvllnrq rilqlegvla ldgkitkvge kifasngkev  
121 nfssalesce etggtlatpm neeenkaimg ivkqynryay lgikesdtag qfkyvnnqpl  
181 nytswqqyep ngkgtekcve mytdgnwkdr kcnlyrltvc ey

SEQ ID NO: 62

40 JN0450 conglutinin precursor – bovine gi|346501|pir|JN0450[346501]

FEATURES Location/Qualifiers source 1..371 /organism="Bos taurus"  
/db\_xref="taxon:9913"  
Protein 1..371 /product="conglutinin precursor" /note="C3b-binding protein"  
45 Region 1..20 /region\_name="domain" /note="signal sequence"  
Region 21..371 /region\_name="product" /note="conglutinin"  
Region 46..214 /region\_name="region" /note="collagen-like"  
Site 63 /site\_type="binding" /note="carbohydrate (Lys) (covalent)"  
Site 63 /site\_type="modified" /note="5-hydroxylysine (Lys)"  
50 Region 75..371 /region\_name="product" /note="conglutinin-N"  
Site 78 /site\_type="modified" /note="4-hydroxyproline (Pro)"  
Site 87 /site\_type="binding" /note="carbohydrate (Lys) (covalent)"  
Site 87 /site\_type="modified" /note="5-hydroxylysine (Lys)"



Site 96 /site\_type="modified" /note="4-hydroxyproline (Pro)"  
 Site 99 /site\_type="binding" /note="carbohydrate (Lys) (covalent)"  
 Site 99 /site\_type="modified" /note="5-hydroxylysine (Lys)"  
 Site 108 /site\_type="modified" /note="4-hydroxyproline (Pro)"  
 5 Site 111 /site\_type="modified" /note="4-hydroxyproline (Pro)"  
 Site 129 /site\_type="modified" /note="4-hydroxyproline (Pro)"  
 Site 132 /site\_type="modified" /note="4-hydroxyproline (Pro)"  
 Site 135 /site\_type="binding" /note="carbohydrate (Lys) (covalent)"  
 Site 135 /site\_type="modified" /note="5-hydroxylysine (Lys)"  
 10 Site 141 /site\_type="binding" /note="carbohydrate (Lys) (covalent)"  
 Site 141 /site\_type="modified" /note="5-hydroxylysine (Lys)"  
 Site 147 /site\_type="modified" /note="4-hydroxyproline (Pro)"  
 Site 153 /site\_type="modified" /note="4-hydroxyproline (Pro)"  
 Site 159 /site\_type="binding" /note="carbohydrate (Lys) (covalent)"  
 15 Site 159 /site\_type="modified" /note="5-hydroxylysine (Lys)"  
 Site 162 /site\_type="binding" /note="carbohydrate (Lys) (covalent)"  
 Site 162 /site\_type="modified" /note="5-hydroxylysine (Lys)"  
 Site 171 /site\_type="modified" /note="4-hydroxyproline (Pro)"  
 Site 195 /site\_type="modified" /note="4-hydroxyproline (Pro)"  
 20 Site 198 /site\_type="binding" /note="carbohydrate (Lys) (covalent)"  
 Site 198 /site\_type="modified" /note="5-hydroxylysine (Lys)"  
 Site 210 /site\_type="binding" /note="carbohydrate (Lys) (covalent)"  
 Site 210 /site\_type="modified" /note="5-hydroxylysine (Lys)"  
 Region 248..369 /region\_name="domain" /note="C-type lectin homology #label  
 25 LCH"  
 Site 337 /site\_type="binding" /note="carbohydrate (Asn) (covalent)"

ORIGIN 1 mllplsvll lltqpwrslg aemttfsqki lanactlvmc splesglpgh dgqdgrecph  
 61 gekgdpgspg pagragrpgw vgpigpkgn gfvgepgpkg dtgprgppgm pgpagregps  
 121 gkqgsmgppg tpgpkgetgp kggvgapgiq gfpgpsglkg ekgapgetga pgragvtgps  
 181 gaigpqgpgs argppglkgd rgdpgetgak gesglavna lkqrvtildg hlrrfqnafs  
 241 qykkavlfpd qgavgekifk tagavksysd aeqlcreakg qlasprssae neavtqmvr  
 301 qeknaylsmn distegrfty ptgeilvysn wadgpnnsd egqpencvei fpdgkwndvp  
 361 cskqllvice f

35 SEQ ID NO: 63  
 A57250 mannan-binding protein - chicken (fragment)  
 gi|1362725|pir|A57250[1362725]

40 FEATURES Location/Qualifiers source 1..30 /organism="Gallus gallus"  
 /db\_xref="taxon:9031"  
 Protein 1..30 /product="mannan-binding protein" /note="collectin"  
 Site 28 /site\_type="modified" /note="4-hydroxyproline (Pro)"  
 ORIGIN 1 lltcdkpeek myscpiiqcs apavnglpqd

45 SEQ ID NO: 64  
 A53570 collectin-43 - bovine gi|1083017|pir|A53570[1083017]

50 FEATURES Location/Qualifiers source 1..301 /organism="Bos taurus"  
 /db\_xref="taxon:9913"  
 Protein 1..301 /product="collectin-43" /note="lectin CL-43"  
 Region 177..299 /region\_name="domain" /note="C-type lectin homology #label  
 LCH"

ORIGIN 1 eemdvysekt ltdpctlvvc appadslrgh dgrdgkegpq gekgdpग्pgpg mpgpagregp  
 61 sgrqsgmgpp gtpgpkgepg peggvgapgm pgspgpaglk gergapggg  
 aigpggpgsa  
 121 mgppglkgdr gdpgekgarg etsvlevdtl qrrmrnlege vqrlqnvitq yrkavlfpg  
 5 181 qavgekifkt agavksysda eqlcreakgq lasprssaen eavtqlvrak nkhaylsmd  
 241 iskegkftyp tggslidysnw apgepnnrak degpencei ysdgnwndie creerlvce  
 301 f

SEQ ID NO: 65

10 AAF28384 lung surfactant protein A [Sus scrofa]  
 gi|6782434|gb|AAF28384.1|AF133668\_1[6782434]

FEATURES Location/Qualifiers source 1..116 /organism="Sus scrofa"  
 /db\_xref="taxon:9823"

15 Protein <1..116 /product="lung surfactant protein A" /function="involved in the innate  
 immune system and lipid homeostasis within the lung" /name="collectin; SPA; SP-A"  
 CDS 1..116 /gene="SFTPA" /coded\_by="AF133668.1:<1..353"

ORIGIN 1 avgekvfstn gqsvafdvir elcaraggri aaprspeene aiasivkkhn tyaylgiveg  
 61 ptagdffylg gtpvnytnwy pgeprgrgke kcvemytdgq wndmccqyr laicef

SEQ ID NO: 66

AAF22145 lung surfactant protein D precursor; SPD; SP-D; CP4 [Sus scrofa]  
 gi|6760482|gb|AAF22145.2|AF132496\_1[6760482]

sig\_peptide 1..20

mat\_peptide 21..378 /product="lung surfactant protein D"

CDS 1..378 /gene="SFTPD" /coded\_by="AF132496.2:44..1180"

ORIGIN 1 mlilplsvli lltqpprslg aemktysqra vanacalvmc spmenglpgr dgrdgregpr

61 gekgdpplpg avragmpgl agpvgpkgn gstgepgakg digpcgpppg

30 pgipgpagke

121 gpsgqqgnig ppgtgpkge tgpkgvgal gmqgstgarg paglkgarga pgergap-  
 gsa

181 gaagpagatg pqgpgsargp pglkgdrpgp gergakgesg lpgitalrqv vetlqqqvqr

241 lqkafsqykk velfpngrgv gekifktggf ektfqdaqv ctqaggqmas prseteneal

35 301 sqlvtaqnka aflsmtdikt egnftyptge plvyanwapg epnnnggssg aencveifpn

361 gkwndkacge lrvicf

SEQ ID NO: 67

40 P41317 MANNANOSE-BINDING PROTEIN C PRECURSOR (MBP-C) (MANNAN-  
 BINDING PROTEIN) (RA-REACTIVE FACTOR P28A SUBUNIT) (RARF/P28A)  
 gi|1346477|sp|P41317|MABC\_MOUSE[1346477]

FEATURES Location/Qualifiers source 1..244 /organism="Mus musculus"  
 /db\_xref="taxon:10090"

45 gene 1..244 /gene="MBL2"

Protein 1..244 /gene="MBL2" /product="MANNANOSE-BINDING PROTEIN C PRE-  
 CURSOR"

Region 1..18 /gene="MBL2" /region\_name="Signal" /note="BY SIMILARITY."

Region 3 /gene="MBL2" /region\_name="Conflict" /note="I -> L (IN REF. 1)."

50 Region 15 /gene="MBL2" /region\_name="Conflict" /note="V -> A (IN REF. 1)."

Region 19..244 /gene="MBL2" /region\_name="Mature chain" /note="MANNANOSE-  
 BINDING PROTEIN C."

Bond bond(29) /gene="MBL2" /bond\_type="disulfide" /note="INTERCHAIN (BY SIMILARITY)."

Bond bond(34) /gene="MBL2" /bond\_type="disulfide" /note="INTERCHAIN (BY SIMILARITY)."

5 Region 38..96 /gene="MBL2" /region\_name="Domain" /note="COLLAGEN-LIKE (G-X-Y)."

Site 43 /gene="MBL2" /site\_type="hydroxylation" /note="(POTENTIAL)."

Site 58 /gene="MBL2" /site\_type="hydroxylation" /note="(POTENTIAL)."

Site 69 /gene="MBL2" /site\_type="hydroxylation" /note="(POTENTIAL)."

10 Site 78 /gene="MBL2" /site\_type="hydroxylation" /note="(POTENTIAL)."

Site 81 /gene="MBL2" /site\_type="hydroxylation" /note="(POTENTIAL)."

Region 149..242 /gene="MBL2" /region\_name="Domain" /note="C-TYPE LECTIN (SHORT FORM)."

Bond bond(151,240) /gene="MBL2" /bond\_type="disulfide" /note="BY SIMILARITY."

15 Bond bond(218,232) /gene="MBL2" /bond\_type="disulfide" /note="BY SIMILARITY."

ORIGIN 1 msiftsflll cwtvvyat ltegvqnsclp vwtcsspgln gfpkgdgrdg akgekgepgg  
61 glrglqgppg kvgtgppgn pglkgavgp kdrdgraefd tseidseiaa lrselralrn  
121 wvflslsekv gkkyfvssvk kmsldrvkal csefqgsvat prnaeensa qkvakdiayl  
20 181 gitdvrvegs fedltgnrvr ytnwndgepn ntgdgedcvv ilgngkwndv pcsdsflaia  
241 efsd

SEQ ID NO: 68

25 P39039 MANNOSE-BINDING PROTEIN A PRECURSOR (MBP-A) (MANNAN-BINDING PROTEIN) (RA-REACTIVE FACTOR POLYSACCHARIDE-BINDING COMPONENT P28B POLYPEPTIDE) (RARF P28B)  
gi|729972|sp|P39039|MABA\_MOUSE[729972]

30 FEATURES Location/Qualifiers source 1..239 /organism="Mus musculus"  
/db\_xref="taxon:10090"

gene 1..239 /gene="MBL1"

Protein 1..239 /gene="MBL1" /product="MANNOSE-BINDING PROTEIN A PRE-CURSOR"

35 Region 1..17 /gene="MBL1" /region\_name="Signal" /note="BY SIMILARITY."

Region 18..239 /gene="MBL1" /region\_name="Mature chain" /note="MANNOSE-BINDING PROTEIN A." Region 37..89 /gene="MBL1" /region\_name="Domain" /note="COLLAGEN-LIKE (G-X-Y)."

40 Region 144..239 /gene="MBL1" /region\_name="Domain" /note="C-TYPE LECTIN (SHORT FORM)."

Bond bond(146,235) /gene="MBL1" /bond\_type="disulfide" /note="BY SIMILARITY."

Bond bond(213,227) /gene="MBL1" /bond\_type="disulfide" /note="BY SIMILARITY."

45 ORIGIN 1 mlllpplpvl lcvsvsyssg sqtcedtlkt csiacgrdg rdgpkgekge pgqglrglqg  
61 ppgklgppgs vsgpspgpk gqkgdhgdnr aieeklanme aeirilkskl qltnklhafs  
121 mgkksqklf vtnhekmfks kvkslctelq gtvaipnae enkaievat giaflgitde  
181 ategqfmyvt ggrltytnwk kdepnnhsg edcvilndg lwndiscqas fkavcefp

SEQ ID NO: 69

50 P42916 COLLECTIN-43 (CL-43) gi|1168967|sp|P42916|CL43\_BOVIN[1168967]

FEATURES Location/Qualifiers source 1..301 /organism="Bos taurus"

/db\_xref="taxon:9913"

Protein 1..301 /product="COLLECTIN-43"

Region 29..142 /region\_name="Domain" /note="COLLAGEN-LIKE (G-X-Y)."  
 Region 202..301 /region\_name="Domain" /note="C-TYPE LECTIN (SHORT  
 FORM)."

Bond bond(204,299) /bond\_type="disulfide" /note="BY SIMILARITY."

5 Bond bond(277,291) /bond\_type="disulfide" /note="BY SIMILARITY."

ORIGIN 1 eemdvysekt ldpctlvvc appadslrgh dgrdgkegpq gekgdpgppg mpgpagregp

61 sgrqgsmgpp gtpgpkgepg peggvgapgm pgspppaglk gergapggg

aigpqgpgsa

121 mgppglkgdr gdpgekgarg etsvlevdtl rqrnrlege vqlqnvitq yrkavlfpdg

10 181 qavgekifkt agavksysda eqlcreakgq lasprssaen eavtqlvrak nkaylsmnd

241 iskegkftyp tggldysnw apgepgnrak degpenclei ysdgnwndie creerlvce

301 f

.SEQ ID NO: 70

15 CAB56155 DMBT1/8kb.2 protein [Homo sapiens]

gi|5912464|emb|CAB56155.1|[5912464]

sig\_peptide 1..26

mat\_peptide 26..2412 /product="DMBT1/8kb.2 protein"

CDS 1..2412 /gene="DMBT1" /coded\_by="AJ243212.1:107..7345"

20 /note="Sequence is an alternative splice form of the DMBT1 gene that is expressed  
 in human adult trachea. Isoforms of DMBT1 are identical to the collectin binding  
 protein gp-340. Full-length cDNA clone contains 1 bp deletions in codons 100 and  
 1751, that were corrected by comparison with the genomic exons"

ORIGIN 1 mgistvilem clwgqvlt ggwiprttdy aslipsevpl dttvaegspf pseltlestv

25 61 aegspisles tlettvaegs lipsestles tvaegsdsgl alrlvngdgr cqgrveilyr

121 gswgavcdds wtdndanvvc rqlgcgwams apgnawfgqg sgpiaddvr csghe-

sylws

181 cphngwlshn cghgedagvi csaaqpqstl rpeswpvris ppvptegses slalrvngg

241 drcrgrvevl yrgswgtvcd dywdtndanv vcrqlgcgwa msapгнаqfg qsggpividd

30 301 vrcsghesyl wscphngwlt hncghsedag vicsapqsrp tpsdwtwpts hastagpass

361 lalrvnggd rcqgrvevly rgswwgtvcd swdtsdanvv crqlgcgwat sapgnarfqq

421 gsgpividdv rcsghesylw scphngwlsh ncqhsedagv icsaahswst pspdtlptit

481 lpastvgsses slalrvngg drcqgrvevl yrgswgtvcd dswdtdanv vcrqlgcgwa

541 mlapgnarfqq qsggpividd vrcsgnesyl wscphngwls hncghsedag vicsgpassl

35 601 alrvnggdrc cqgrvevlyr gswgtvcdds wtdndanvvc rqlgcgwams apgnarfqqg

661 sgpiaddvr csghesylws cpnngwlshn cghhedagvi csaaqsrstp rpdltititl

721 ppstvgsses ltlrvngsd rcqgrvevly rgswwgtvcd swdtdanvv crqlgcgwat

781 sapgnarfqq gsgpividdv rcsghesylw scphngwlsh ncghhedagv icsvsqsrt

841 pspdtwptsh astagpassl alrvnggdrc cqgrvevlyr gswgtvcdds wtdsdanvvc

40 901 rqlgcgwats apgnarfqqg sgpiaddvr csgyesylws cphngwlshn cqhsedagvi

961 csaaahswstp spdtlptitl pastvgsses lalrvnggd rcqgrvevly qsgwtvcdd

1021 swdtdanvv crqlgcgwam sapgnarfqq gsgpividda rcsghesylw scphngwlsh

1081 ncghsedagv icsasqsrt pspdtwptsh astagsssl alrvnggdrc cqgrvevlyr

1141 gswgtvcddy wtdndanvac rqlgcgwams apgnarfqqg sgpiaddvr csghesylws

45 1201 cphngwlshn cghhedagvi csasqsqtp spdtwptsha stagssslalrvnggdrc

1261 qgrvevlyrg swgtvcddyw dtdanvvcr qlgcgwatsa pgnarfqqgs gpividdvrc

1321 sghesylwsc phngwlshnc ghhedagvic sasqsqtps pdtwptshas tagssslal

1381 rlvggdrcq grvevlyrgs wgtvcddywd tndanvvcrq lgcgwatsap gnarfqqsg

1441 pividdvrcs ghesylwscph hngwlshncg hhedagvics afqsqtpsp dtwptsrast

50 1501 agestlalrvnggdrcg rvevlyqgs wgtvcddywd tndanvvcrq gcgwamsap

1561 naqfgqsgp ivddvrcsg hepylwscph ngwlshncgh hedagvicsa aqsqstprpd

1621 twlttnlpal tvgsesslal rlvggdrcr grvevlyrgs wgtvcddswd tndanvvcrq

1681 lgcgwamsap gnarfqqsg pivlgdvrcs gnesylwscph hkgwlthncg hhedagvics

35

1741 atqinstttd wwhptttta rpssncggfl fyasgtfssp sypayypnna kcvweievns  
 1801 gyrinlgfsn lklaahhncs fdyveifdgs insslllgki cndtrqifts synrmtihfr  
 1861 sdisfqtngf lawynsfpsd atrlvnlms syglcagrve iyhggtwgav cddswtiqea  
 1921 evvcrqlgcg ravsalignay fgsgsgpiti ddvecsgtes tlwqcmrgw fshncnhred  
 5 1981 agvicsgnhl stpaplinit rpnnyscggi lsqpsgdfss pfypgnypnn akcvwdievq  
 2041 nnyrvtvifr dvqleggcny dyievfdgpy rsspliarvc dgargsftss snfmsirfis  
 2101 dhsitrgrfr aeeysspsnd stnlclpnh mqasvrsyl qslgfsasdl vistwngyye  
 2161 crpqiitpnlv iftipysgci tfkqadndti dysnlltaav sggiikrrtd lrihvsrml  
 2221 qntwvdtmyi andtihvann tiqveevqyg nfdvnisfyt sssflypvts rpyyvdlndq  
 10 2281 lyvqaeilhs davltilvdt cvaspysndf tslydlirs gcvrddtygp ysspslriar  
 2341 frfrafhfln rfpsvylrck mvvcraydps srcyrgcvlr skrdvgisyqe kvdvvlgpiq  
 2401 lqtpprreee pr

## SEQ ID NO: 71

15 BAA81747 collectin 34 [Homo sapiens] gi|5162875|dbj|BAA81747.1|[5162875]  
 FEATURES Location/Qualifiers source 1..277 /organism="Homo sapiens"  
 /db\_xref="taxon:9606"  
 Protein 1..277 /product="collectin 34"  
 CDS 1..277 /coded\_by="AB002631.1:6..839"  
 20 ORIGIN 1 mngfasllrr nqfillvfl lqiqlgldi dsrptaevca thtispgpkg ddgekdpge  
 61 egkhgkvgrm gpkgikgelg dmgrdnigk tpgigkkgdk gekglgipg ekgkagtvcd  
 121 cgryrkfvqg ldisiarlkt smkfvknvia gireteekfy yivqeenyr eslthcirg  
 181 gmlampkdea antliadyva ksgffrvfig vndlereggy mftdntplqn ysnwnegeps  
 241 dpyghedcve mlssgrwndt echltmyfvc efikkkk

## SEQ ID NO: 72

AAB94071 mannan-binding lectin; collectin [Gallus gallus]  
 gi|2736145|gb|AAB94071.1|[2736145]  
 30 FEATURES Location/Qualifiers source 1..238 /organism="Gallus gallus"  
 /strain="White Leghorn" /db\_xref="taxon:9031" /tissue\_type="liver"  
 Protein 1..>238 /product="mannan-binding lectin" /name="c-type lectin"  
 /note="mannan-binding protein; MBP; mannose-binding protein; MBL; collectin"  
 CDS 1..238 /gene="cMBL" /coded\_by="AF022226.1:1..>714"  
 35 ORIGIN 1 mmatsllttd kpeekmyscp iiqcsapavn glpgrdgrdg pkgekdpge glrglqglpg  
 61 kagpqglkge vgpqgekqgk gergivtdd lhrqitdlea kirvleddls rykkalslkd  
 121 vvnigkkmfv stgkkynek gkslcakags vlasprneae ntalkdlidp ssqayigisd  
 181 aqtegrfmyl sggpitysnw kpgepn nhkn edcaviedsg kwndldcsns nifiicel

## SEQ ID NO: 73

40 AAB36019 mannan-binding protein, MBP=lectin {N-terminal} [chickens, serum,  
 Peptide Partial, 30 aa] [Gallus gallus] gi|1311692|gb|AAB36019.1|[1311692]  
 FEATURES Location/Qualifiers source 1..30 /organism="Gallus gallus"  
 /db\_xref="taxon:9031"  
 Protein 1..30 /partial /product="mannan-binding protein" /name="lectin" /note="MBP"  
 45 ORIGIN 1 lltcdkpeek myscpiiqcs apavnglpdg

## SEQ ID NO: 74

AAB27504 conglutinin (N) {N-terminal} [cattle, Peptide Partial, 60 aa] [Bos taurus]  
 gi|386660|gb|AAB27504.1|[386660]  
 50 FEATURES Location/Qualifiers source 1..60 /organism="Bos taurus"  
 /db\_xref="taxon:9913"  
 Protein 1..60 /partial /product="conglutinin (N)"  
 ORIGIN 1 aemtfsqki lanactlvmc splesglpgh dgqdgrecph gekgdpgpsg pagragrpgw

## SEQ ID NO: 75

CAA53511 collectin-43 [Bos taurus] gi|499385|emb|CAA53511.1|[499385]

FEATURES Location/Qualifiers source 1..301 /organism="Bos taurus"

/db\_xref="taxon:9913" /tissue\_type="liver" /clone\_lib="lambda gt 11"

Protein 1..301 /product="collectin-43"

mat\_peptide 1..301 /product="collectin-43"

CDS 1..301 /coded\_by="X75912.1:&lt;1..906" /db\_xref="SWISS-PROT:P42916"

ORIGIN 1 eemdvyxekt ltdpctlvvc appadslrgh dgrdgkegpq gekgdpqppg mpppagregp

61 sgrqgsmgpp gtpgpkgepg pegvggapgm pgspgpaglk gergapppg

aigppqpsga

121 mgppgkkgdr gdpgekgarg etsvlevdtl rqrnrnlege vqrlqnvitq yrkavifpdg

181 qavgekifkt agavksysda eqlcreakgq lasprssaen eavtqlvrak nkhaylsmnd

241 iskegkftyp tggsldysnw apgepgnrak degpenclei ysdgnwndie creerlvce

301 f

## SEQ ID NO: 76

AAA82010 mannose-binding protein C [Mus musculus]

gi|773288|gb|AAA82010.1|[773288]

FEATURES Location/Qualifiers source 1..244 /organism="Mus musculus"

/strain="BALB/c" /db\_xref="taxon:10090" /clone="Lambda 14 and 52; Cos11A"

/clone\_lib="NIH/3T3 Swiss mouse embryo cell line and BALB/c pWE15 cosmid library"

Protein 1..244 /product="mannose-binding protein C"

Site 1..59 /site\_type="signal-peptide" /note="signal-peptide and collagen-like region"

mat\_peptide &lt;59..&gt;98 /product="mannose-binding protein C" /note="collagen-like domain"

mat\_peptide &lt;98..&gt;121 /product="mannose-binding protein C" /note="linking-peptide domain"

mat\_peptide &lt;121..244 /product="carbohydrate recognition domain"

CDS 1..244 /gene="Mbl2" /coded\_by="join(U09013.1:470..644,U09014.1:43..159, U09015.1:97..165,U09016.1:576..949)"

ORIGIN 1 msiftsflll cvtvvyaet ltegvqnsdp vvtcsspgln gfpkgdgrdg akgekgppgq

61 glrglqgppg kvgtgppgn pglkgavgpk gdrdgraefd tseidseiaa lrselralrn

121 wwlfslsekv gkkyfvssvk kmsldrvkal csefqgsvat prnaeensa qkvakdiayl

181 gitdvrvegs fedltgnrvr ytnwndgepn ntgdgedcvv ilngkwndv pcsdsflaic

241 efsd

## SEQ ID NO: 77

AAA82009 mannose-binding protein A [Mus musculus]

gi|773280|gb|AAA82009.1|[773280]

sig\_peptide 1..18

mat\_peptide 19..239 /product="unnamed"

mat\_peptide 19..&gt;52 /product="mannose-binding protein A" /note="collagen-like region"

mat\_peptide &lt;52..&gt;91 /product="mannose-binding protein A" /note="collagen-like domain"

mat\_peptide &lt;91..&gt;116 /product="mannose-binding protein A" /note="linking-peptide domain"

CDS 1..239 /gene="Mbl1" /coded\_by="join(U09007.1:275..428,U09008.1:287..403, U09009.1:166..240,U09010.1:78..451)"

ORIGIN 1 mlllpllpvl lcvsvsssg sqtcedtlkt csyiacgrdg rdgpkgekg pgqglrglqg

61 ppgklgppgs vsgpgspgpk gqkgdhgdnr aieeklanme aeirilkskl qltnklhafs  
 121 mgkksqkklf vtnhekmfks kvkslctelq gtvaipnae enkaivevat giaflgitde  
 181 ategqfmyvt ggrltywnwk kdepnnhgsg edcvildng lwndiscqas fkavcefp

5

### Lung surfactant protein

SEQ ID NO: 78

10 P35247 Pulmonary surfactant-associated protein D precursor (SP-D) (PSP-D)  
 gi|464486|sp|P35247|PSPD\_HUMAN[464486]

FEATURES Location/Qualifiers source 1..375 /organism="Homo sapiens"  
 /db\_xref="taxon:9606"

15 gene 1..375 /gene="SFTPD" /note="SFTP4; PSPD"

Protein 1..375 /gene="SFTPD" /product="Pulmonary surfactant-associated protein D precursor"

Region 1..20 /gene="SFTPD" /region\_name="Signal" /note="BY SIMILARITY."

20 Region 21..375 /gene="SFTPD" /region\_name="Mature chain"

/note="PULMONARY SURFACTANT-ASSOCIATED PROTEIN D."

Region 31 /gene="SFTPD" /region\_name="Conflict" /note="M -> T (IN REF. 2)."

Region 46..222 /gene="SFTPD" /region\_name="Domain" /note="COLLAGEN-LIKE."

Region 59 /gene="SFTPD" /region\_name="Conflict" /note="P -> F (IN REF. 3)."

25 Site 78 /gene="SFTPD" /site\_type="hydroxylation" /note="(BY SIMILARITY)."

Site 87 /gene="SFTPD" /site\_type="hydroxylation" /note="(BY SIMILARITY)."

Site 90 /gene="SFTPD" /site\_type="glycosylation" /note="N-LINKED (GLCNAC...) (POTENTIAL)."

Site 96 /gene="SFTPD" /site\_type="hydroxylation" /note="(BY SIMILARITY)."

Site 99 /gene="SFTPD" /site\_type="hydroxylation" /note="(BY SIMILARITY)."

30 Region 122 /gene="SFTPD" /region\_name="Conflict" /note="A -> P (IN REF. 2)."

Site 171 /gene="SFTPD" /site\_type="hydroxylation" /note="(BY SIMILARITY)."

Site 177 /gene="SFTPD" /site\_type="hydroxylation" /note="(BY SIMILARITY)."

Region 180 /gene="SFTPD" /region\_name="Conflict" /note="T -> A (IN REF. 2)."

Region 206 /gene="SFTPD" /region\_name="Conflict" /note="D -> P (IN REF. 3)."

35 Region 223..252 /gene="SFTPD" /region\_name="Domain" /note="COILED COIL (POTENTIAL)."

Region 227..253 /gene="SFTPD" /region\_name="Helical region"

Region 254..256 /gene="SFTPD" /region\_name="Hydrogen bonded turn"

Region 257..260 /gene="SFTPD" /region\_name="Beta-strand region"

40 Region 261..262 /gene="SFTPD" /region\_name="Hydrogen bonded turn"

Region 263..272 /gene="SFTPD" /region\_name="Beta-strand region"

Region 274..283 /gene="SFTPD" /region\_name="Helical region"

Region 279..375 /gene="SFTPD" /region\_name="Domain" /note="C-TYPE LECTIN (SHORT FORM)."

45 Bond bond(281,373) /gene="SFTPD" /bond\_type="disulfide"

Region 284..285 /gene="SFTPD" /region\_name="Hydrogen bonded turn"

Region 287..288 /gene="SFTPD" /region\_name="Beta-strand region"

Region 294..307 /gene="SFTPD" /region\_name="Helical region"

Region 308 /gene="SFTPD" /region\_name="Hydrogen bonded turn"

50 Region 311..316 /gene="SFTPD" /region\_name="Beta-strand region"

Region 321..322 /gene="SFTPD" /region\_name="Hydrogen bonded turn"

Region 325 /gene="SFTPD" /region\_name="Beta-strand region"

Region 327..328 /gene="SFTPD" /region\_name="Hydrogen bonded turn"

Region 331 /gene="SFTPD" /region\_name="Beta-strand region"  
 Region 337 /gene="SFTPD" /region\_name="Beta-strand region"  
 Region 339..340 /gene="SFTPD" /region\_name="Hydrogen bonded turn"  
 Region 345..347 /gene="SFTPD" /region\_name="Helical region"  
 5 Bond bond(351,365) /gene="SFTPD" /bond\_type="disulfide"  
 Region 351..354 /gene="SFTPD" /region\_name="Beta-strand region"  
 Region 356..357 /gene="SFTPD" /region\_name="Hydrogen bonded turn"  
 Region 360..363 /gene="SFTPD" /region\_name="Beta-strand region"  
 Region 365..366 /gene="SFTPD" /region\_name="Hydrogen bonded turn"  
 10 Region 369..375 /gene="SFTPD" /region\_name="Beta-strand region"  
 Region 374 /gene="SFTPD" /region\_name="Conflict" /note="E -> EH (IN REF. 3)."  
 ORIGIN 1 mlflfllsalv lltqplgyle aemktyshrt mpsactlvmc ssvesglpgr dgrdgregpr  
 61 gekgdpglpq aagqagmpgq agpvgpkgn gsvgepgpkg dtgpsgppgp  
 pgvpgpagre  
 15 121 galgkqgnig pqgkpgpkge agpkgevgap gmqgsagarg lagpkgergv  
 pgergvpgnt  
 181 gaagsagamg pqgspgargp pglkgdkgip gdkgakgesg lpdvaslrqq vealqgqvqh  
 241 lqaafsqqyk velfpngqsv gekifktagf vkpftaql ctqaggqlas prsaaenaal  
 301 qqlvvaknea aflsmtdskt egkftyptge slvysnwapg epnddggsed cveiftngkw  
 20 361 ndraccgkrl vvcef

SEQ ID NO: 79

NP\_002395 microfibrillar-associated protein 4; microfibril-associated glycoprotein 4  
 [Homo sapiens] gi|23111005|ref|NP\_002395.1|[23111005]

25 FEATURES Location/Qualifiers source 1..255 /organism="Homo sapiens"  
 /db\_xref="taxon:9606" /chromosome="17" /map="17p11.2"  
 Protein 1..255 /product="microfibrillar-associated protein 4" /note="microfibril-  
 associated glycoprotein 4"  
 30 Region 36..255 /region\_name="smart00186, FBG, Fibrinogen-related domains  
 (FReDs); Domain present at the C-termini of fibrinogen beta and gamma chains,  
 and a variety of fibrinogen-related proteins, including tenascin and Drosophila  
 scabrous"  
 Region 38..254 /region\_name="pfam00147, fibrinogen\_C, Fibrinogen beta and  
 35 gamma chains, C-terminal globular domain"  
 CDS 1..255 /gene="MFAP4" /coded\_by="NM\_002404.1:26..793"  
 /db\_xref="LocusID:4239" /db\_xref="MIM:600596"  
 ORIGIN 1 mkallalpll llstppcap qvsgirgdal erfclqpld cddiyaqgyq sdgvlyiyps  
 61 gpsvpvpvfc dmtteggkwt vfqkrfngsv sffrgwndyk lgfgradgey wglqnmhll  
 40 121 tlkqkyelrv dledfennta yakyadfsis pnavsaeedg ytlfvagfed ggagdslyh  
 181 sgqkfstfdr dqdlfvqnc aalssgafwfr schfanlngf ylggshlsya nginwaqwkg  
 241 fyyslkrtem kirra

SEQ ID NO: 80

45 1KMRA Chain A, Solution Nmr Structure Of Surfactant Protein B (11-25) (Sp- B11-  
 25) gi|22219056|pdb|1KMR|A[22219056]

FEATURES Location/Qualifiers source 1..15 /organism="Homo sapiens"  
 /db\_xref="taxon:9606"  
 50 SecStr 3..11 /sec\_str\_type="helix" /note="helix 1"  
 ORIGIN 1 cralikriqa mipkg

SEQ ID NO: 81



P50404 Pulmonary surfactant-associated protein D precursor (SP-D) (PSP-D)  
 gi|1709879|sp|P50404|PSPD\_MOUSE[1709879]  
 FEATURES Location/Qualifiers source 1..374 /organism="Mus musculus"  
 /db\_xref="taxon:10090"  
 5 gene 1..374 /gene="SFTPD" /note="SFTPD"  
 Protein 1..374 /gene="SFTPD" /product="Pulmonary surfactant-associated protein D  
 precursor"  
 Region 1..19 /gene="SFTPD" /region\_name="Signal" /note="BY SIMILARITY."  
 Region 20..374 /gene="SFTPD" /region\_name="Mature chain"  
 10 /note="PULMONARY SURFACTANT-ASSOCIATED PROTEIN D."  
 Region 45..221 /gene="SFTPD" /region\_name="Domain" /note="COLLAGEN-LIKE."  
 Site 89 /gene="SFTPD" /site\_type="glycosylation" /note="N-LINKED (GLCNAC...)  
 (POTENTIAL)."  
 Region 222..253 /gene="SFTPD" /region\_name="Domain" /note="COILED COIL  
 15 (POTENTIAL)."  
 Region 278..374 /gene="SFTPD" /region\_name="Domain" /note="C-TYPE LECTIN  
 (SHORT FORM)."  
 Bond bond(280,372) /gene="SFTPD" /bond\_type="disulfide" /note="BY  
 SIMILARITY."  
 20 Bond bond(350,364) /gene="SFTPD" /bond\_type="disulfide" /note="BY  
 SIMILARITY."  
 ORIGIN 1 mlpfslmvl lvqplgnlga emkslsqrsv pntctlvms ptenglprgd grdgregprg  
 61 ekgdpglpdp mglsglqgpt gpvgpkge sagepgpkge rlgsgppglp gipgpagkeg  
 121 psgkqgnigp qgkpgpkgea gpkgevgapg mqqstgakgs tgpkgergap  
 25 gvqgapgnag  
 181 aagpagpagp qgapgsrgpp glkgdrvgp drgikgesgl pdsaalrqm ealkgklql  
 241 evafshyqka alfpdgrsvg dkifrtadse kpfedaqemc kqaggqlasp rsatenaaiq  
 301 qlitahnkaa flsmtdvgte gkftyptgep lvysnwapge pnnnggaenc veiftnqwn  
 361 dkacgeqlrv icef  
 30  
 SEQ ID NO: 82  
 P06908 Pulmonary surfactant-associated protein A precursor (SP-A) (PSP-A)  
 (PSAP) gi|1172693|sp|P06908|PSPA\_CANFA[1172693]  
 35 FEATURES Location/Qualifiers source 1..248 /organism="Canis familiaris"  
 /db\_xref="taxon:9615"  
 gene 1..248 /gene="SFTPA1" /note="SFTPA; SFTPD"  
 Protein 1..248 /gene="SFTPA1" /product="Pulmonary surfactant-associated protein  
 A precursor"  
 40 Region 1..17 /gene="SFTPA1" /region\_name="Signal"  
 Region 18..248 /gene="SFTPA1" /region\_name="Mature chain"  
 /note="PULMONARY SURFACTANT-ASSOCIATED PROTEIN A."  
 Site 20 /gene="SFTPA1" /site\_type="glycosylation" /note="N-LINKED (GLCNAC...)  
 (POTENTIAL)."  
 45 Region 28..100 /gene="SFTPA1" /region\_name="Domain" /note="COLLAGEN-  
 LIKE."  
 Region 153..248 /gene="SFTPA1" /region\_name="Domain" /note="C-TYPE LECTIN  
 (SHORT FORM)."  
 Bond bond(155,246) /gene="SFTPA1" /bond\_type="disulfide" /note="BY  
 50 SIMILARITY."  
 Site 207 /gene="SFTPA1" /site\_type="glycosylation" /note="N-LINKED (GLCNAC...)  
 (PROBABLE)."

Bond bond(224,238) /gene="SFTPA1" /bond\_type="disulfide" /note="BY  
SIMILARITY."

ORIGIN 1 mwlrcalal tllmvsgien ntkdvcvgnp gipgtpgshg lpgrdgrdgv kgdpgppgpl  
61 gppggmpgph gpngmtgapg vagergekge pgergppglp asldeelqt lhdrlhqlq  
121 tmgvlslhes llvvgrkvfs snaqsinfnd iqelcagagg qiaapmspee neavasivkk  
181 yntyaylgv espdsgdfqy mdgapvnytn wypgeprgrg keqcvemytd gqwnknclq  
241 yrlaicef

SEQ ID NO: 83

P12842 Pulmonary surfactant-associated protein A precursor (SP-A) (PSP-A)  
(PSAP) gi|131413|sp|P12842|PSPA\_RABIT[131413]

FEATURES Location/Qualifiers source 1..247 /organism="Oryctolagus cuniculus"  
/db\_xref="taxon:9986"

gene 1..247 /gene="SFTPA1" /note="SFTPA; SFTP1"

Protein 1..247 /gene="SFTPA1" /product="Pulmonary surfactant-associated protein  
A precursor"

Region 1..15 /gene="SFTPA1" /region\_name="Signal" /note="POTENTIAL."

Region 12 /gene="SFTPA1" /region\_name="Variant" /note="S -> P."

Region 16..247 /gene="SFTPA1" /region\_name="Mature chain"

/note="PULMONARY SURFACTANT-ASSOCIATED PROTEIN A."

Region 27..99 /gene="SFTPA1" /region\_name="Domain" /note="COLLAGEN-LIKE."

Region 57..60 /gene="SFTPA1" /region\_name="Conflict" /note="GPMG -> APWA  
(IN REF. 2)."

Region 152..247 /gene="SFTPA1" /region\_name="Domain" /note="C-TYPE LECTIN  
(SHORT FORM)."

Bond bond(154,245) /gene="SFTPA1" /bond\_type="disulfide" /note="BY  
SIMILARITY."

Site 206 /gene="SFTPA1" /site\_type="glycosylation" /note="N-LINKED (GLCNAC...)  
(PROBABLE)."

Bond bond(223,237) /gene="SFTPA1" /bond\_type="disulfide" /note="BY  
SIMILARITY."

ORIGIN 1 millslatl isapasdtd tkdvcigspg ipgtpgshgl pgrdgrdgvk gdpggppgpmg  
61 ppggmpglpg rdgligapgv pgergdkgep gergppglpa yldeelqatl helrhhalqs  
121 igvlslqgsm kavgekfst ngqsvnfda revcaraggr iavprleen eaiasivker  
181 ntyaylglae gptagdfyyl dgdpvnytnw ypgeprgqgr ekevemytdg kwndknclqy  
241 rlvicef

SEQ ID NO: 84

NP\_033186 surfactant associated protein D [Mus musculus]  
gi|6677921|ref|NP\_033186.1|[6677921]

sig\_peptide 1..19

mat\_peptide 20..374 /product="surfactant associated protein D"

Region 260..373 /region\_name="C-type lectin (CTL) or carbohydrate-recognition  
domain (CRD)" /note="CLECT" /db\_xref="CDD:smart00034"

Region 271..374 /region\_name="Lectin C-type domain" /note="lectin\_c"  
/db\_xref="CDD:pfam00059"

CDS 1..374 /gene="Sftpd" /coded\_by="NM\_009160.1:43..1167"

/db\_xref="LocusID:20390" /db\_xref="MGD:109515"

ORIGIN 1 mlpflsmvl lvqplnlgla emkslsqrsv pntctlvms ptenglprgd grdgregprg

61 ekgdpglpdp mglsglqgpt gpvgpkgeng sagepgpkge rglsppglp gipgpagkeg

121 psgkqgnigp qgkpgpkgea gpkgevgapg mqqgstgakgs tgpkgergap  
 gvqgapgnag  
 181 aagpagpagp qgapgsrgpp glkgdrvgpg drgikgesgl pdsaalrqm ealkgklqrl  
 241 evafshyqka alfpdgrsvg dkifrtadse kpfedaqemc kqaggqlasp rsatenaaiq  
 5 301 qlitahnkaa flsmtdvgtg gkftyptgep lvysnwapge pnnnggaenc veiftngqwn  
 361 dkacgeqrly icef

SEQ ID NO: 85

1B08C Chain C, Lung Surfactant Protein D (Sp-D) (Fragment)  
 10 gi|6573321|pdb|1B08|C[6573321]

FEATURES Location/Qualifiers source 1..158 /organism="Homo sapiens"  
 /db\_xref="taxon:9606"  
 15 SecStr 13..36 /sec\_str\_type="helix" /note="helix 7"  
 Region 38..158 /region\_name="Domain 3" /note="NCBI Domains"  
 SecStr 39..44 /sec\_str\_type="sheet" /note="strand 21"  
 SecStr 45..51 /sec\_str\_type="sheet" /note="strand 22"  
 SecStr 53..56 /sec\_str\_type="sheet" /note="strand 23"  
 20 SecStr 57..67 /sec\_str\_type="helix" /note="helix 8"  
 Bond bond(64,156) /bond\_type="disulfide"  
 SecStr 77..90 /sec\_str\_type="helix" /note="helix 9"  
 SecStr 93..96 /sec\_str\_type="sheet" /note="strand 24"  
 Het join(bond(100),bond(100),bond(100),bond(104),bond(104),  
 bond(104),bond(127),bond(132),bond(133)) /heterogen="( CA, 8 )"  
 25 Het join(bond(104),bond(133),bond(133),bond(133)) /heterogen="( CA, 9 )"  
 SecStr 107..110 /sec\_str\_type="sheet" /note="strand 25"  
 SecStr 112..115 /sec\_str\_type="sheet" /note="strand 26"  
 Het join(bond(124),bond(126),bond(132),bond(144),bond(145),  
 bond(145),bond(145),bond(145),bond(145),bond(145),  
 30 bond(145),bond(145),bond(145),bond(145),bond(145),  
 bond(145),bond(145),bond(145),bond(145),bond(145),  
 bond(145),bond(145),bond(145),bond(145),bond(145), bond(145)) /heterogen="( CA, 7 )"  
 SecStr 133..139 /sec\_str\_type="sheet" /note="strand 27"  
 35 Bond bond(134,148) /bond\_type="disulfide"  
 SecStr 141..147 /sec\_str\_type="sheet" /note="strand 28"  
 SecStr 150..158 /sec\_str\_type="sheet" /note="strand 29"  
 ORIGIN 1 eaeagsvasl rqqvealqqg vqhlqaafsq ykkvelfpng qsvgekifkt agfvkpftea  
 61 qlletqaggq lasprsaaen aalqqlvvak neaafismtd sktegkftyp tgeslvysnw  
 40 121 apgepnddgg sedcveiftn gkwndracge krlvcefc

SEQ ID NO: 86

1B08B Chain B, Lung Surfactant Protein D (Sp-D) (Fragment)  
 45 gi|6573320|pdb|1B08|B[6573320]

FEATURES Location/Qualifiers source 1..158 /organism="Homo sapiens"  
 /db\_xref="taxon:9606"  
 SecStr 11..34 /sec\_str\_type="helix" /note="helix 4"  
 Region 37..158 /region\_name="Domain 2" /note="NCBI Domains"  
 50 SecStr 39..44 /sec\_str\_type="sheet" /note="strand 11"  
 SecStr 45..51 /sec\_str\_type="sheet" /note="strand 12"  
 SecStr 53..56 /sec\_str\_type="sheet" /note="strand 13"  
 SecStr 57..67 /sec\_str\_type="helix" /note="helix 5"

Bond bond(64,156) /bond\_type="disulfide"  
 SecStr 77..90 /sec\_str\_type="helix" /note="helix 6"  
 SecStr 93..96 /sec\_str\_type="sheet" /note="strand 14"  
 SecStr 97..100 /sec\_str\_type="sheet" /note="strand 15"  
 5 Het join(bond(100),bond(100),bond(100),bond(104),bond(104),  
 bond(104),bond(127),bond(132),bond(133)) /heterogen="( CA, 5 )"  
 Het join(bond(104),bond(133),bond(133),bond(133)) /heterogen="( CA, 6 )"  
 SecStr 107..110 /sec\_str\_type="sheet" /note="strand 16"  
 Het join(bond(124),bond(126),bond(132),bond(144),bond(145), bond(145))  
 10 /heterogen="( CA, 4 )"  
 SecStr 133..139 /sec\_str\_type="sheet" /note="strand 17"  
 Bond bond(134,148) /bond\_type="disulfide"  
 SecStr 141..147 /sec\_str\_type="sheet" /note="strand 18"  
 SecStr 150..153 /sec\_str\_type="sheet" /note="strand 19"  
 15 SecStr 154..158 /sec\_str\_type="sheet" /note="strand 20"  
 ORIGIN 1 eaeagsvasl rqqvealqgg vqhlqaafs ykkvelfpng qsvgekifkt agfvkpfta  
 61 qltctqaggq lasprsaen aalqqlvvak neaafismtd sktegfktyp tgeslvysnw  
 121 apgepnddgg sedcveiftn gkwndracge krlvvcef  
  
 20 SEQ ID NO: 87  
 1B08A Chain A, Lung Surfactant Protein D (Sp-D) (Fragment)  
 gi|6573319|pdb|1B08|A[6573319]  
  
 FEATURES Location/Qualifiers source 1..158 /organism="Homo sapiens"  
 25 /db\_xref="taxon:9606"  
 SecStr 10..36 /sec\_str\_type="helix" /note="helix 1"  
 Region 38..158 /region\_name="Domain 1" /note="NCBI Domains"  
 SecStr 39..44 /sec\_str\_type="sheet" /note="strand 1"  
 SecStr 45..51 /sec\_str\_type="sheet" /note="strand 2"  
 30 SecStr 53..56 /sec\_str\_type="sheet" /note="strand 3"  
 SecStr 57..67 /sec\_str\_type="helix" /note="helix 2"  
 Bond bond(64,156) /bond\_type="disulfide"  
 SecStr 77..90 /sec\_str\_type="helix" /note="helix 3"  
 SecStr 93..96 /sec\_str\_type="sheet" /note="strand 4"  
 35 SecStr 97..100 /sec\_str\_type="sheet" /note="strand 5"  
 Het join(bond(100),bond(100),bond(100),bond(104),bond(104),  
 bond(104),bond(127),bond(132),bond(133)) /heterogen="( CA, 2 )"  
 Het join(bond(104),bond(133),bond(133),bond(133)) /heterogen="( CA, 3 )"  
 SecStr 107..110 /sec\_str\_type="sheet" /note="strand 6"  
 40 Het join(bond(124),bond(126),bond(132),bond(144),bond(145), bond(145))  
 /heterogen="( CA, 1 )"  
 SecStr 133..139 /sec\_str\_type="sheet" /note="strand 7"  
 Bond bond(134,148) /bond\_type="disulfide"  
 SecStr 141..147 /sec\_str\_type="sheet" /note="strand 8"  
 45 SecStr 150..153 /sec\_str\_type="sheet" /note="strand 9"  
 SecStr 154..158 /sec\_str\_type="sheet" /note="strand 10"  
 ORIGIN 1 eaeagsvasl rqqvealqgg vqhlqaafs ykkvelfpng qsvgekifkt agfvkpfta  
 61 qltctqaggq lasprsaen aalqqlvvak neaafismtd sktegfktyp tgeslvysnw  
 121 apgepnddgg sedcveiftn gkwndracge krlvvcef  
  
 50 SEQ ID NO: 88  
 NP\_060049 deleted in malignant brain tumors 1 isoform c precursor [Homo sapiens]  
 gi|8923740|ref|NP\_060049.1|[8923740]

sig\_peptide 1..25  
mat\_peptide 26..2403 /product="deleted in malignant brain tumors 1 isoform c"  
Region 102..202 /region\_name="Scavenger receptor Cys-rich" /note="SR"  
5 /db\_xref="CDD:SR"  
Region 105..202 /region\_name="Scavenger receptor cysteine-rich domain"  
/note="SRCR" /db\_xref="CDD:pfam00530"  
Region 234..334 /region\_name="Scavenger receptor Cys-rich" /note="SR"  
/db\_xref="CDD:SR"  
10 Region 237..334 /region\_name="Scavenger receptor cysteine-rich domain"  
/note="SRCR" /db\_xref="CDD:pfam00530"  
Region 363..463 /region\_name="Scavenger receptor Cys-rich" /note="SR"  
/db\_xref="CDD:SR"  
Region 366..463 /region\_name="Scavenger receptor cysteine-rich domain"  
15 /note="SRCR" /db\_xref="CDD:pfam00530"  
Region 484..584 /region\_name="Scavenger receptor Cys-rich" /note="SR"  
/db\_xref="CDD:SR"  
Region 487..584 /region\_name="Scavenger receptor cysteine-rich domain"  
/note="SRCR" /db\_xref="CDD:pfam00530"  
20 Region 594..692 /region\_name="Scavenger receptor Cys-rich" /note="SR"  
/db\_xref="CDD:SR"  
Region 595..692 /region\_name="Scavenger receptor cysteine-rich domain"  
/note="SRCR" /db\_xref="CDD:pfam00530"  
Region 723..823 /region\_name="Scavenger receptor Cys-rich" /note="SR"  
25 /db\_xref="CDD:SR"  
Region 726..823 /region\_name="Scavenger receptor cysteine-rich domain"  
/note="SRCR" /db\_xref="CDD:pfam00530"  
Region 852..952 /region\_name="Scavenger receptor Cys-rich" /note="SR"  
/db\_xref="CDD:SR"  
30 Region 855..952 /region\_name="Scavenger receptor cysteine-rich domain"  
/note="SRCR" /db\_xref="CDD:pfam00530"  
Region 983..1083 /region\_name="Scavenger receptor Cys-rich" /note="SR"  
/db\_xref="CDD:SR"  
Region 986..1083 /region\_name="Scavenger receptor cysteine-rich domain"  
35 /note="SRCR" /db\_xref="CDD:pfam00530"  
Region 1112..1212 /region\_name="Scavenger receptor Cys-rich" /note="SR"  
/db\_xref="CDD:SR"  
Region 1115..1212 /region\_name="Scavenger receptor cysteine-rich domain"  
/note="SRCR" /db\_xref="CDD:pfam00530"  
40 Region 1241..1341 /region\_name="Scavenger receptor Cys-rich" /note="SR"  
/db\_xref="CDD:SR"  
Region 1244..1341 /region\_name="Scavenger receptor cysteine-rich domain"  
/note="SRCR" /db\_xref="CDD:pfam00530"  
Region 1370..1470 /region\_name="Scavenger receptor Cys-rich" /note="SR"  
45 /db\_xref="CDD:SR"  
Region 1373..1470 /region\_name="Scavenger receptor cysteine-rich domain"  
/note="SRCR" /db\_xref="CDD:pfam00530"  
Region 1499..1599 /region\_name="Scavenger receptor Cys-rich" /note="SR"  
/db\_xref="CDD:SR"  
50 Region 1502..1599 /region\_name="Scavenger receptor cysteine-rich domain"  
/note="SRCR" /db\_xref="CDD:pfam00530"  
Region 1630..1730 /region\_name="Scavenger receptor Cys-rich" /note="SR"  
/db\_xref="CDD:SR"

Region 1633..1730 /region\_name="Scavenger receptor cysteine-rich domain"  
 /note="SRCR" /db\_xref="CDD:pfam00530"  
 Region 1756..1867 /region\_name="Domain first found in C1r, C1s, uEGF, and bone  
 morphogenetic protein." /note="CUB" /db\_xref="CDD:CUB"  
 5 Region 1756..1864 /region\_name="CUB domain" /note="CUB"  
 /db\_xref="CDD:pfam00431"  
 Region 1873..1976 /region\_name="Scavenger receptor Cys-rich" /note="SR"  
 /db\_xref="CDD:SR"  
 Region 1885..1976 /region\_name="Scavenger receptor cysteine-rich domain"  
 10 /note="SRCR" /db\_xref="CDD:pfam00530"  
 Region 1998..2106 /region\_name="Domain first found in C1r, C1s, uEGF, and bone  
 morphogenetic protein." /note="CUB" /db\_xref="CDD:CUB"  
 Region 1998..2104 /region\_name="CUB domain" /note="CUB"  
 /db\_xref="CDD:pfam00431"  
 15 Region 2117..2371 /region\_name="Zona pellucida-like domain"  
 /note="zona\_pellucida" /db\_xref="CDD:pfam00100"  
 Region 2117..2368 /region\_name="Zona pellucida (ZP) domain" /note="ZP"  
 /db\_xref="CDD:ZP"  
 CDS 1..2403 /gene="DMBT1" /coded\_by="NM\_017579.1:107..7318" /note="isoform  
 20 c is encoded by transcript variant 3" /db\_xref="LocusID:1755"  
 /db\_xref="MIM:601969"  
 ORIGIN 1 mgistvilem clwggqvlt ggwiprttdy aslipsevpl dtvaegspf pseltlesta  
 25 61 aegspisles tlestvaegs lipsestles tvaegsdsgl alrlvngdgr cqgrveilyr  
 121 gswgtvcdds wdtnanvvc rqlgcgwams apgnawfgqg sgpiaddvr csghesylws  
 181 cphngwlshn cghgedagvi csaaqpqstl rpeswpvris ppvptegses slalrlvngg  
 241 drcrgrvevl yrgswgtvcd dywdtnanv vcrqlgcgwa msapgnaqfg qsgspivdd  
 301 vrcsghesyl wscphngwlt hncghsedag vicsaplsrp tpsdwtwpts hastagpess  
 361 lalrlvnggd rcqgrvevly rgswwgtvcdd swdtsdanvv crqlgcgwat sapgnarfqq  
 421 gsgpivddv rcsgyesylw scphngwlsh ncqhsedagv icsdtlptit lpastvgses  
 30 481 slalrlvngg drcqgrvevl yrgswgtvcd dswdtnanv vcrqlgcgwa mlapgnarfq  
 541 qsgspivdd vrcsgnesyl wscphngwls hncghsedag vicsgpessl alglvnggdr  
 601 cqgrvevlyr gswgtvcdds wdtnanvvc rqlgcgwats apgnarfqqg sgpiaddvr  
 661 csghesylws cpnngwlshn cghhedagvi csaaqsrstp rpdltititl ppstvgsses  
 721 ltlrlvngsd rcqgrvevly rgswwgtvcdd swdtnanv vcrqlgcgwat sapgnarfqq  
 35 781 gsgpivddv rcsghesylw scphngwlsh ncghhedagv icsvsqsrt pspdwtwptsh  
 841 astagsessl alrlvnggdr cqgrvevlyr gswgtvcdds wdtsdanvvc rrlgcgwats  
 901 apgnarfqqg sgpiaddvr csgyesylws cphngwlshn cqhsedagvi csaaahswstp  
 961 spdtlptitl pastvgsses lalrlvnggd rcqgrvevly qsgwtvcdd swdtnanv  
 1021 crqlgcgwam sapgnarfqq gsgpivddv rcsghesylw scphngwlsh ncghsedagv  
 40 1081 icsasqsrt pspdwtwptsh astagsessl alrlvnggdr cqgrvevlyr gswgtvcddy  
 1141 wdtnanvvc rqlgcgwams apgnarfqqg sgpiaddvr csghesylws cphdglshn  
 1201 cghhedagvi csasqsqtp spdtwptsha stagsessla lrlvnggdrq qgrvevlyrg  
 1261 pwgtvcddyw dtndanvvc rqlgcgwatsa pgnarfqqgs gpivddvrc sghesylwsc  
 1321 phngwlshnc ghhedagvic sasqsqtps pdtwptshas tagsesslal rlvnggdrq  
 45 1381 grvevlyrgs wgtvcddywd tndanvvc rqlgcgwatsa pgnarfqqgs pialddvrcs  
 1441 ghesylwscph hngwlshncg hhedagvics asqsqtpsp dtwptsrast agsestlalr  
 1501 lvnggdrq rvevlyqgs wgtvcddywd tndanvvc rqlgcgwamsap naqfqqgsgp  
 1561 ivddvrcs ghesylwscph ngwlshncg hhedagvics aqsqstprpd twltltpal  
 1621 tvgsesslal rlvnggdrq grvevlyrgs wgtvcddswd tndanvvc rqlgcgwamsap  
 50 1681 gnarfqqgs pivddvrcs gnesylwscph hkgwlthncg hhedagvics atqinstttd  
 1741 wwhtttta rpssncggfl fyasgtfssp sypayypnna kcvweievns gyrinlgfsn  
 1801 lkleahhncs fdyveifdgs inslllgki cndtrqfts synrmtihfr sdisfntgf  
 1861 lawynsfpsd atrlvnlhs syglcagrve iyhggtwgtv cddswtiqea evvcrqlgcg

1921 ravsalgnay fgsgsgpitl ddvecsgtes tlwqcrnrgw fshncnhred agvicsgnhl  
 1981 stpaplfnit rpntdyscgg flsqpsgdfs spfypgnypn nakcvwdiev qnnyrvtvif  
 2041 rdvqleggc n ydyievf dgp yrsspliarv cdgargsfts ssnfmsirfi sdhsitrgrf  
 2101 raeyyspsn dstnlclpn hmqasvsrsy lqslgfsasd lvistwnggy ecrpqitpnl  
 2161 viftipysgc gtfkqadndt idysnfltaa vsggiikrrt dlrihvscrm lqntwvdtmy  
 2221 iandtihvan ntiqveevqy gnfvdnisfy tsssflypvt srpyyvdlnq dlyvqaeilh  
 2281 sdavltifvd tcvaspysnd ftsltydlir sgcvrddtyg pysspslria rfrfrahfl  
 2341 nrfpsvylrc kmvvcraydp ssrccrgcvl rskrdvgsyq ekvdvvlgi qlqtpprree  
 2401 epr

10

SEQ ID NO: 89

NP\_015568 deleted in malignant brain tumors 1 isoform b precursor [Homo sapiens]  
 gi|6633801|ref|NP\_015568.1||6633801]

15

sig\_peptide 1..25

mat\_peptide 26..2413 /product="deleted in malignant brain tumors 1 isoform b"

Region 102..202 /region\_name="Scavenger receptor Cys-rich" /note="SR"  
 /db\_xref="CDD:SR"

20

Region 105..202 /region\_name="Scavenger receptor cysteine-rich domain"  
 /note="SRCR" /db\_xref="CDD:pfam00530"

Region 234..334 /region\_name="Scavenger receptor Cys-rich" /note="SR"  
 /db\_xref="CDD:SR"

25

Region 237..334 /region\_name="Scavenger receptor cysteine-rich domain"  
 /note="SRCR" /db\_xref="CDD:pfam00530"

Region 363..463 /region\_name="Scavenger receptor Cys-rich" /note="SR"  
 /db\_xref="CDD:SR"

Region 366..463 /region\_name="Scavenger receptor cysteine-rich domain"  
 /note="SRCR" /db\_xref="CDD:pfam00530"

30

Region 494..594 /region\_name="Scavenger receptor Cys-rich" /note="SR"  
 /db\_xref="CDD:SR"

Region 497..594 /region\_name="Scavenger receptor cysteine-rich domain"  
 /note="SRCR" /db\_xref="CDD:pfam00530"

Region 602..702 /region\_name="Scavenger receptor Cys-rich" /note="SR"  
 /db\_xref="CDD:SR"

35

Region 605..702 /region\_name="Scavenger receptor cysteine-rich domain"  
 /note="SRCR" /db\_xref="CDD:pfam00530"

Region 733..833 /region\_name="Scavenger receptor Cys-rich" /note="SR"  
 /db\_xref="CDD:SR"

40

Region 736..833 /region\_name="Scavenger receptor cysteine-rich domain"  
 /note="SRCR" /db\_xref="CDD:pfam00530"

Region 862..962 /region\_name="Scavenger receptor Cys-rich" /note="SR"  
 /db\_xref="CDD:SR"

Region 865..962 /region\_name="Scavenger receptor cysteine-rich domain"  
 /note="SRCR" /db\_xref="CDD:pfam00530"

45

Region 993..1093 /region\_name="Scavenger receptor Cys-rich" /note="SR"  
 /db\_xref="CDD:SR"

Region 996..1093 /region\_name="Scavenger receptor cysteine-rich domain"  
 /note="SRCR" /db\_xref="CDD:pfam00530"

50

Region 1122..1222 /region\_name="Scavenger receptor Cys-rich" /note="SR"  
 /db\_xref="CDD:SR"

Region 1125..1222 /region\_name="Scavenger receptor cysteine-rich domain"  
 /note="SRCR" /db\_xref="CDD:pfam00530"

Region 1251..1351 /region\_name="Scavenger receptor Cys-rich" /note="SR"  
 /db\_xref="CDD:SR"  
 Region 1254..1351 /region\_name="Scavenger receptor cysteine-rich domain"  
 /note="SRCR" /db\_xref="CDD:pfam00530"  
 5 Region 1380..1480 /region\_name="Scavenger receptor Cys-rich" /note="SR"  
 /db\_xref="CDD:SR"  
 Region 1383..1480 /region\_name="Scavenger receptor cysteine-rich domain"  
 /note="SRCR" /db\_xref="CDD:pfam00530"  
 10 Region 1509..1609 /region\_name="Scavenger receptor Cys-rich" /note="SR"  
 /db\_xref="CDD:SR"  
 Region 1512..1609 /region\_name="Scavenger receptor cysteine-rich domain"  
 /note="SRCR" /db\_xref="CDD:pfam00530"  
 Region 1640..1740 /region\_name="Scavenger receptor Cys-rich" /note="SR"  
 /db\_xref="CDD:SR"  
 15 Region 1643..1740 /region\_name="Scavenger receptor cysteine-rich domain"  
 /note="SRCR" /db\_xref="CDD:pfam00530"  
 Region 1766..1877 /region\_name="Domain first found in C1r, C1s, uEGF, and bone  
 morphogenetic protein." /note="CUB" /db\_xref="CDD:CUB"  
 Region 1766..1874 /region\_name="CUB domain" /note="CUB"  
 20 /db\_xref="CDD:pfam00431"  
 Region 1883..1986 /region\_name="Scavenger receptor Cys-rich" /note="SR"  
 /db\_xref="CDD:SR"  
 Region 1895..1986 /region\_name="Scavenger receptor cysteine-rich domain"  
 /note="SRCR" /db\_xref="CDD:pfam00530"  
 25 Region 2008..2116 /region\_name="Domain first found in C1r, C1s, uEGF, and bone  
 morphogenetic protein." /note="CUB" /db\_xref="CDD:CUB"  
 Region 2008..2114 /region\_name="CUB domain" /note="CUB"  
 /db\_xref="CDD:pfam00431"  
 Region 2127..2381 /region\_name="Zona pellucida-like domain"  
 30 /note="zona\_pellucida" /db\_xref="CDD:pfam00100"  
 Region 2127..2378 /region\_name="Zona pellucida (ZP) domain" /note="ZP"  
 /db\_xref="CDD:ZP"  
 CDS 1..2413 /gene="DMBT1" /coded\_by="NM\_007329.1:107..7348"  
 /db\_xref="LocusID:1755" /db\_xref="MIM:601969"  
 35 ORIGIN 1 mgistvilem clwgqvlst ggwiprttdy aslipsevpl dqtvaegspf psestlesta  
 61 aegspisles tlestvaegs lipsestles tvaegsdsl alrlvngdgr cqgrveilyr  
 121 gswgtvcdds wdndanvvc rqlgcgwams apgnawfgqg sgpiatddvr csghesylws  
 181 cphngwlshn cghgedagvi csaaqpqstl rpeswpvris ppvptegses slalrlvngg  
 241 drcgrgrevl yrgswgtvcd dywdndanv vcrqlgcgwa msapгнаqfg qsgspivldd  
 40 301 vrcsghesyl wscphngwlt hncghsedag vicsapqsrp tpspdtwpts hastagpess  
 361 lalrlvnggd rcqgrvevly rgswwgtvcdd swdtsdanvv crqlgcgwat sapgnarfqq  
 421 gsgpivlddv rcsghesylw scphngwlsh ncqhsedagv icsaahswst pspdtlptit  
 481 lpastvgses slalrlvngg drcqgrrevl yrgswgtvcd dswdndanv vcrqlgcgwa  
 541 mlapgnarfqq qsgspivldd vrcsgnesyl wscphngwls hncghsedag vicsgpessl  
 45 601 alrlvnggdr cqgrvevlyr gswgtvcdds wdndanvvc rqlgcgwams apgnarfqqg  
 661 sgpiatddvr csghesylws cpnngwlshn cghhedagvi csaaqsrstp rpdltititl  
 721 ppstvgsses ltlrlvngsd rcqgrvevly rgswwgtvcdd swdndanvv crqlgcgwam  
 781 sapgnarfqq gsgpivlddv rcsghesylw scphngwlsh ncghhedagv icsvsqsrt  
 841 pspdtwptsh astagssessl alrlvnggdr cqgrvevlyr gswgtvcdds wdtsdanvvc  
 50 901 rqlgcgwats apgnarfqqg sgpiatddvr csgyesylws cphngwlshn cqhsedagvi  
 961 csaaahswstp spdtlptitl pastvgsess lalrlvnggd rcqgrvevly qsgswgtvcdd  
 1021 swdndanvv crqpgcgwam sapgnarfqq gsgpivlddv rcsghesypw  
 scphngwlsh



1081 ncghsedagv icsasqsprt pspdtwptsh astagsessl alrlvnggdr cqgrvevlyr  
 1141 gswgtvcddy wtdndanvvc rqlgcgwams apgnarfqqg sgpiivddvr csghesylws  
 1201 cphngwlshn cghhedagvi csasqsqptp spdtwptsha stagsessla lrlvnggdrc  
 1261 qgrvevlyrg swgtvcddyw dtdanvvcr qlgcgwatsa pgnarfqqgs gpiivddvrc  
 5 1321 sghesylwsc phngwlshnc ghhedagvic sasqsqptps pdtwptshas tagsesslal  
 1381 rlvnggdrcq grvevlyrgs wgtvcddywd tndanvvcrq lgcgwatsap gnarfqqgsg  
 1441 pivddvrscs ghesylwscph hngwlshncg hhedagvics asqsqptps dtwptsrast  
 1501 agsestlaln lvggdrcrg rvevlyqgs wgtvcddywd ndanvvcrql gcgwamsapg  
 1561 naqfgqgsgp ivddvrscg hesylwscph ngwlshncg hhedagvicsa aqsqstprpd  
 10 1621 twlttnlpal tvgsesslal rlvnggdrcr grvevlyrgs wgtvcddswd tndanvvcrq  
 1681 lgcgwamsap gnarfqqgsg pivddvrscs ghesylwscph hkgwlthncg hhedagvics  
 1741 atqinsttd wwwhptttta rpssncggfl fyasgtfssp sypayypnna kcvweievns  
 1801 gyrinlgfsn kkleahhncs fdyveifdgs lnslllgki cndtrqifts synrmtihfr  
 1861 sdisfntgf lawynsfpsd atrlvnlins syglcagrve iyhggtwgtv cddswtqiea  
 15 1921 evvcrqlcg ravsalignay fgsgsgpiti dvecsgtes tlwqcmrgw fshncnhred  
 1981 agvicsgnhl stpaplinit rptdyscgg flsqpsgdfs spfypgnypn nakcvwdiev  
 2041 qnnrvrtvif rdvqleggc n ydyievfdgp yrsspliarv cdgargsfts ssnfmsirfi  
 2101 sdhsitrgf raeyyspsn dstnlclpn hmqasvsrsy lqslgfsasd livistwngyy  
 2161 ecrpqtprnl viftipysgc gtfkqadndt idysnftaa vsggiikrrt dlrihvscrm  
 20 2221 lqntwvdtmy iandtihvan ntiqveevqy gnfdvnisfy tsssflypvt srpyvdlng  
 2281 dlyvqaeilh sdavltifvd tcvaspysnd ftsltydlir sgcvrddtyg pysspslria  
 2341 rfrfrahfl nrfpsvylrc kmvvcraydp ssrccyrgcvl rskrdvgsyq ekvdvlgpi  
 2401 qlqtpprree epr

25 SEQ ID NO: 90  
 NP\_004397 deleted in malignant brain tumors 1 isoform a precursor [Homo sapiens]  
 gi|4758170|ref|NP\_004397.1|[4758170]

sig\_peptide 1..25  
 30 mat\_peptide 26..1785 /product="deleted in malignant brain tumors 1 isoform a"  
 Region 102..202 /region\_name="Scavenger receptor Cys-rich" /note="SR"  
 /db\_xref="CDD:SR"  
 Region 105..202 /region\_name="Scavenger receptor cysteine-rich domain"  
 /note="SRCR" /db\_xref="CDD:pfam00530"  
 35 Region 234..334 /region\_name="Scavenger receptor Cys-rich" /note="SR"  
 /db\_xref="CDD:SR"  
 Region 237..334 /region\_name="Scavenger receptor cysteine-rich domain"  
 /note="SRCR" /db\_xref="CDD:pfam00530"  
 Region 363..463 /region\_name="Scavenger receptor Cys-rich" /note="SR"  
 40 /db\_xref="CDD:SR"  
 Region 366..463 /region\_name="Scavenger receptor cysteine-rich domain"  
 /note="SRCR" /db\_xref="CDD:pfam00530"  
 Region 494..594 /region\_name="Scavenger receptor Cys-rich" /note="SR"  
 /db\_xref="CDD:SR"  
 45 Region 497..594 /region\_name="Scavenger receptor cysteine-rich domain"  
 /note="SRCR" /db\_xref="CDD:pfam00530"  
 Region 623..723 /region\_name="Scavenger receptor Cys-rich" /note="SR"  
 /db\_xref="CDD:SR"  
 Region 626..723 /region\_name="Scavenger receptor cysteine-rich domain"  
 50 /note="SRCR" /db\_xref="CDD:pfam00530"  
 Region 752..852 /region\_name="Scavenger receptor Cys-rich" /note="SR"  
 /db\_xref="CDD:SR"

Region 755..852 /region\_name="Scavenger receptor cysteine-rich domain"  
 /note="SRCR" /db\_xref="CDD:pfam00530"  
 Region 881..981 /region\_name="Scavenger receptor Cys-rich" /note="SR"  
 /db\_xref="CDD:SR"  
 5 Region 884..981 /region\_name="Scavenger receptor cysteine-rich domain"  
 /note="SRCR" /db\_xref="CDD:pfam00530"  
 Region 1012..1112 /region\_name="Scavenger receptor Cys-rich" /note="SR"  
 /db\_xref="CDD:SR"  
 10 Region 1015..1112 /region\_name="Scavenger receptor cysteine-rich domain"  
 /note="SRCR" /db\_xref="CDD:pfam00530"  
 Region 1138..1249 /region\_name="Domain first found in C1r, C1s, uEGF, and bone  
 morphogenetic protein." /note="CUB" /db\_xref="CDD:CUB"  
 Region 1138..1246 /region\_name="CUB domain" /note="CUB"  
 /db\_xref="CDD:pfam00431"  
 15 Region 1255..1358 /region\_name="Scavenger receptor Cys-rich" /note="SR"  
 /db\_xref="CDD:SR"  
 Region 1267..1358 /region\_name="Scavenger receptor cysteine-rich domain"  
 /note="SRCR" /db\_xref="CDD:pfam00530"  
 20 Region 1380..1488 /region\_name="Domain first found in C1r, C1s, uEGF, and bone  
 morphogenetic protein." /note="CUB" /db\_xref="CDD:CUB"  
 Region 1380..1486 /region\_name="CUB domain" /note="CUB"  
 /db\_xref="CDD:pfam00431"  
 Region 1499..1751 /region\_name="Zona pellucida-like domain"  
 /note="zona\_pellucida" /db\_xref="CDD:pfam00100"  
 25 Region 1499..1750 /region\_name="Zona pellucida (ZP) domain" /note="ZP"  
 /db\_xref="CDD:ZP"  
 CDS 1..1785 /gene="DMBT1" /coded\_by="NM\_004406.1:107..5464"  
 /db\_xref="LocusID:1755" /db\_xref="MIM:601969"  
 ORIGIN 1 mgistvilem clwgqvist ggwiprttdy aslipsevpl dqtvaegspf psestlesta  
 30 61 aegspisles tlestvaegs lipsestles tvaegsdsgl alrlvngdgr cqgrveilyr  
 121 gswgtvcdds wdtnanvvc rqlgcgwams apgnawfgqg sgpiatddvr csghesylws  
 181 cphngwlshn cghgedagvi csaaqpqstl rpeswpvris ppvptegses slalrlvngg  
 241 drcrgrvevl yrgswgtvcd dywdtnanv vcrqlgcgwa msapgnaqfg qsgspivldd  
 301 vrcsghesyl wscphngwlt hncghsedag vicsapqsrp tpspdtwpts hastagpess  
 35 361 lalrlvnggd rcqgrvevly rgswgtvcdd swdtsdanvv crqlgcgwat sapgnarfqq  
 421 gsgpivlddv rcsghesylw scphngwlsh ncqhsedagv icsaahswst pspdtlptit  
 481 lpastvg ses slalrlvngg drcqgrvevl yqgswgtvcd dswdtnanv vcrqpgcgwa  
 541 msapgnarf qsgspivldd vrcsghesyp wscphngwls hncghsedag vicsasqsrp  
 601 tpspdtwpts hastagsses lalrlvnggd rcqgrvevly rgswgtvcdd ywdtnanvv  
 40 661 crqlgcgwam sapgnarfqq gsgpivlddv rcsghesylw scphngwlsh ncghhedagv  
 721 icsasqsqpt pspdtwptsh astagsessl alrlvnggdr cqgrvevlyr gswgtvcddy  
 781 wdtnanvvc rqlgcgwats apgnarfqq sgpiatddvr csghesylws cphngwlshn  
 841 cghhedagvi csasqsqptp spdtwptsra stagestla lrlvnggdrc rgrvevlyqg  
 901 swgtvcddyw dtnanvvc rqlgcgwamsa pgnafgqgs gpivlddvr csghesylwsc  
 45 961 phngwlshnc ghhedagvic saaqsqstpr pdtwlttnlp altvgsssl alrlvnggdr  
 1021 crgrvevlyr gswgtvcdds wdtnanvvc rqlgcgwams apgnarfqq sgpiatddvr  
 1081 csgnesylws cphkgwlshn cghhedagvi csatqinstt tdwwhpttt tarpsncgg  
 1141 flfyasgtfs spsyayypn nakcvweiev nsgrinlglf snkleahhn csfdyveifd  
 1201 glnsslllg kicndtrqif tssynrmtih frsdisfnt glawynsfp sdatlrlvnl  
 50 1261 nssyglcagr veiyhggtwg tvcdswtiq eaevvcrqlg cgravsalgn ayfgsgsgpi  
 1321 tldvecsgt estlwqcrnr gwfnhcnhr edagvicsgn hltpapfln itrntdysc  
 1381 ggflsqpsgd fsspfypgny pnnakcvwdi evqnnryrtv ifrdvqlgg cnydyieafd  
 1441 gpyrssplia rvcdgargsf tssnfmisr fisdhsitr gfraeyysp sndstnlcl

1501 pnhmqasvsr sylqslgfsa sdlvistwng yyecrpqitp nlviftipys gcgtfkqadn  
 1561 dtidysnflt aavsggiikr rtdlrihvsc rmlqntwvdt myiandtihv anntiqveev  
 1621 qygnfdvnis fytsssflyp vtsrpyyvdI nqdlvqaei lhsdavlIf vdtcvaspys  
 1681 ndftsltydl irsgcvrddt ygpysspslr iarfrfrah flnrfsvyl rckmvvcray  
 5 1741 dpssrcyrgc vlrskrdvgs yqekvdvvlq piqlqtpprr eeepr

## SEQ ID NO: 91

LNBOC1 pulmonary surfactant protein C – bovine

gi|7428752|pir||LNBOC1[7428752]

10 FEATURES Location/Qualifiers source 1..34 /organism="Bos taurus"  
 /db\_xref="taxon:9913"

Protein 1..34 /product="pulmonary surfactant protein C" /note="pulmonary surfactant protein PSP-6"

Site 4 /site\_type="binding" /note="palmitate (Cys) (covalent)"

15 Site 5 /site\_type="binding" /note="palmitate (Cys) (covalent)"

ORIGIN 1 lipccpvnik rllivvvvvv llvvvivgal lmgI

## SEQ ID NO: 92

LNDGC1 pulmonary surfactant protein C – dog gi|7428750|pir||LNDGC1[7428750]

20 FEATURES Location/Qualifiers source 1..35 /organism="Canis familiaris"  
 /db\_xref="taxon:9615"

Protein 1..35 /product="pulmonary surfactant protein C"

Site 5 /site\_type="binding" /note="palmitate (Cys) (covalent)"

ORIGIN 1 lgipcfssI krllivvvi vlvvvvivga llmgI //

25

## SEQ ID NO: 93

JN0450 conglutinin precursor – bovine gi|346501|pir||JN0450[346501]

30 FEATURES Location/Qualifiers source 1..371 /organism="Bos taurus"  
 /db\_xref="taxon:9913"

Protein 1..371 /product="conglutinin precursor" /note="C3b-binding protein"

Region 1..20 /region\_name="domain" /note="signal sequence"

Region 21..371 /region\_name="product" /note="conglutinin"

Region 46..214 /region\_name="region" /note="collagen-like"

35 Site 63 /site\_type="binding" /note="carbohydrate (Lys) (covalent)"

Site 63 /site\_type="modified" /note="5-hydroxylysine (Lys)"

Region 75..371 /region\_name="product" /note="conglutinin-N"

Site 78 /site\_type="modified" /note="4-hydroxyproline (Pro)"

Site 87 /site\_type="binding" /note="carbohydrate (Lys) (covalent)"

40 Site 87 /site\_type="modified" /note="5-hydroxylysine (Lys)"

Site 96 /site\_type="modified" /note="4-hydroxyproline (Pro)"

Site 99 /site\_type="binding" /note="carbohydrate (Lys) (covalent)"

Site 99 /site\_type="modified" /note="5-hydroxylysine (Lys)"

Site 108 /site\_type="modified" /note="4-hydroxyproline (Pro)"

45 Site 111 /site\_type="modified" /note="4-hydroxyproline (Pro)"

Site 129 /site\_type="modified" /note="4-hydroxyproline (Pro)"

Site 132 /site\_type="modified" /note="4-hydroxyproline (Pro)"

Site 135 /site\_type="binding" /note="carbohydrate (Lys) (covalent)"

Site 135 /site\_type="modified" /note="5-hydroxylysine (Lys)"

50 Site 141 /site\_type="binding" /note="carbohydrate (Lys) (covalent)"

Site 141 /site\_type="modified" /note="5-hydroxylysine (Lys)"

Site 147 /site\_type="modified" /note="4-hydroxyproline (Pro)"

Site 153 /site\_type="modified" /note="4-hydroxyproline (Pro)"

Site 159 /site\_type="binding" /note="carbohydrate (Lys) (covalent)"  
 Site 159 /site\_type="modified" /note="5-hydroxylysine (Lys)"  
 Site 162 /site\_type="binding" /note="carbohydrate (Lys) (covalent)"  
 Site 162 /site\_type="modified" /note="5-hydroxylysine (Lys)"  
 5 Site 171 /site\_type="modified" /note="4-hydroxyproline (Pro)"  
 Site 195 /site\_type="modified" /note="4-hydroxyproline (Pro)"  
 Site 198 /site\_type="binding" /note="carbohydrate (Lys) (covalent)"  
 Site 198 /site\_type="modified" /note="5-hydroxylysine (Lys)"  
 Site 210 /site\_type="binding" /note="carbohydrate (Lys) (covalent)"  
 10 Site 210 /site\_type="modified" /note="5-hydroxylysine (Lys)"  
 Region 248..369 /region\_name="domain" /note="C-type lectin homology #label  
 LCH"  
 Site 337 /site\_type="binding" /note="carbohydrate (Asn) (covalent)"  
 ORIGIN 1 millplsvll lltqpwrsig aemtfsqki lanactlvmc splesglpgh dgqdgrecph  
 15 61 gekgdpqspg pagragrpgw vgpigpkgdn gfvgepgpkg dtgprpppgm  
 ppgpagregps  
 121 gkqgsmgppg tpgpkgetgp kggvgapgiq gfgpgsglkg ekgapgetga ppragvtgps  
 181 gaigpqgpgs argppglkgd rgdpgetgak gesglaevna lkqrvtildg hlrrfqnafs  
 241 qykkavlfpd gqavgekifk tagavksysd aeqlcreakg qlasprssae neavtqmvr  
 20 301 qeknaylsmn distegrfty ptgeilvysn wadgpepnnsd egqpencvei fpdgkwndvp  
 361 cskqllvice f

SEQ ID NO: 94  
 A45225 pulmonary surfactant protein D precursor – human  
 25 gi|346375|pir||A45225[346375]  
 FEATURES Location/Qualifiers source 1..375 /organism="Homo sapiens"  
 /db\_xref="taxon:9606"  
 Protein 1..375 /product="pulmonary surfactant protein D precursor" /note="SP-D"  
 Region 1..20 /region\_name="domain" /note="signal sequence"  
 30 Region 21..375 /region\_name="product" /note="pulmonary surfactant protein D"  
 Region 21..45 /region\_name="domain" /note="non-collagenous"  
 Region 46..222 /region\_name="domain" /note="collagenous"  
 Site 90 /site\_type="binding" /note="carbohydrate (Asn) (covalent)"  
 Region 223..375 /region\_name="domain" /note="non-collagenous"  
 35 Region 254..373 /region\_name="domain" /note="C-type lectin homology #label  
 LCH"  
 Bond bond(281,373) /bond\_type="disulfide"  
 Bond bond(351,365) /bond\_type="disulfide"  
 ORIGIN 1 mlifllsalv lltqplgyle aemktyshrt mpsactlvmc ssvesglpgr dgrdgregpr  
 40 61 gekgdpqlpg aagqagmpgq agpvpgpkgdn gsvgepgpkg dtgpgpppgp  
 pgvpgpagre  
 121 galgkqgnig pqgkpgpkge agpkgevgap gmqgsagarg lagpkgergv  
 pgergvpgnt  
 181 gaagsagamg pqgspgargp pgikgdkgip gdkgakgesg lpdvaslrqq vealqgqvqh  
 45 241 lqaafsqqyk velfpngqsv gekifktagf vkpftaqll ctqaggqlas prsaaenaal  
 301 qqlvvaknea afismtdskt egkftyptge slvysnwapg epnddggsed cveiftngkw  
 361 ndraccgekrl vvcef

SEQ ID NO: 95  
 50 LNHUC pulmonary surfactant protein C precursor, long splice form – human  
 gi|71983|pir||LNHUC[71983]

FEATURES Location/Qualifiers source 1..197 /organism="Homo sapiens"  
 /db\_xref="taxon:9606"  
 Protein 1..197 /product="pulmonary surfactant protein C precursor, long splice form"  
 /note="3.7 kDa surfactant polypeptide; pulmonary surfactant protein SP5; pulmonary  
 5 surfactant proteolipid SP-C; pulmonary surfactant proteolipid SPL(pVal)"  
 Region 1..197 /region\_name="product" /note="pulmonary surfactant protein C  
 precursor, short splice form"  
 Region 1..145 /region\_name="product" /note="pulmonary surfactant protein C  
 precursor, short splice form"  
 10 Region 1..23 /region\_name="domain" /note="propeptide"  
 Region 24..58 /region\_name="product" /note="pulmonary surfactant protein C"  
 Site 28 /site\_type="binding" /note="palmitate (Cys) (covalent)"  
 Site 29 /site\_type="binding" /note="palmitate (Cys) (covalent)"  
 Region 152..197 /region\_name="product" /note="pulmonary surfactant protein C  
 15 precursor, short splice form" ORIGIN 1 mdvgskevlm espddysaap rgrfgipccp vhlkrlivv  
 vvvvlivvvi vgallmglhm  
 61 sqkhtemvle msigapeaqq rlalsehlvt tatsigstg lvvydyqqll iaykpapgtc  
 121 cyimkiapes ipslealnkr vhnfqcmecl qakpavptsk lgqaegrda g sapsggdpaf  
 181 lgmavntlcg evplyyi  
 20  
 SEQ ID NO: 96  
 LNDGPS pulmonary surfactant protein A precursor – dog  
 gi|71970|pir||LNDGPS[71970]  
 FEATURES Location/Qualifiers source 1..248 /organism="Canis familiaris"  
 25 /db\_xref="taxon:9615"  
 Protein 1..248 /product="pulmonary surfactant protein A precursor"  
 /note="pulmonary surfactant 32K apoprotein; pulmonary surfactant-associated  
 protein PSP-A"  
 Region 1..17 /region\_name="domain" /note="signal sequence"  
 30 Region 18..248 /region\_name="product" /note="pulmonary surfactant protein A"  
 Site 20 /site\_type="binding" /note="carbohydrate (Asn) (covalent)"  
 Region 28..102 /region\_name="region" /note="collagen-like"  
 Site 30 /site\_type="modified" /note="4-hydroxyproline (Pro)"  
 Region 127..246 /region\_name="domain" /note="C-type lectin homology #label  
 35 LCH"  
 Site 207 /site\_type="binding" /note="carbohydrate (Asn) (covalent)"  
 ORIGIN 1 mwlrlclal tllmvsgien ntkdvcvgnp gipgtpgshg lpgrdgrdgv kgdpgppgpl  
 61 gppggmpgph gpngmtgapg vagergekge pgergppgl asldeelqt lhdrlrhqilq  
 121 tmgvlsihes llvgrkvfs sgaqsinfnd iqelcagagg qiaapmspee neavasivkk  
 40 181 yntyaylgiv espdsgdfqy mdgapvnytn wypgeprgrg keqcvemytd gqwnknclq  
 241 yrlaicef  
  
 SEQ ID NO: 97  
 LNHUPS pulmonary surfactant protein A precursor (genomic clone) – human  
 45 gi|71967|pir||LNHUPS[71967]  
 FEATURES Location/Qualifiers source 1..248 /organism="Homo sapiens"  
 /db\_xref="taxon:9606"  
 Protein 1..248 /product="pulmonary surfactant protein A precursor (genomic clone)"  
 /note="alveolar proteinosis protein; pulmonary surfactant 32K apoprotein; pulmonary  
 50 surfactant-associated protein (PSP-A)"  
 Region 1..20 /region\_name="domain" /note="signal sequence"  
 Region 21..248 /region\_name="product" /note="pulmonary surfactant protein A"  
 Bond bond(26) /bond\_type="disulfide" /note="interchain"

Region 28..100 /region\_name="domain" /note="collagenous"  
 Site 30 /site\_type="modified" /note="4-hydroxyproline (Pro)"  
 Site 33 /site\_type="modified" /note="4-hydroxyproline (Pro)"  
 Site 36 /site\_type="modified" /note="4-hydroxyproline (Pro)"  
 5 Site 42 /site\_type="modified" /note="4-hydroxyproline (Pro)"  
 Site 51 /site\_type="modified" /note="5-hydroxylysine (Lys)"  
 Site 57 /site\_type="modified" /note="4-hydroxyproline (Pro)"  
 Site 63 /site\_type="modified" /note="4-hydroxyproline (Pro)"  
 Site 76 /site\_type="modified" /note="4-hydroxyproline (Pro)"  
 10 Site 79 /site\_type="modified" /note="4-hydroxyproline (Pro)"  
 Site 82 /site\_type="modified" /note="4-hydroxyproline (Pro)"  
 Site 88 /site\_type="modified" /note="5-hydroxylysine (Lys)"  
 Site 91 /site\_type="modified" /note="4-hydroxyproline (Pro)"  
 Site 97 /site\_type="modified" /note="4-hydroxyproline (Pro)"  
 15 Region 127..246 /region\_name="domain" /note="C-type lectin homology #label  
 LCH"  
 Bond bond(155,246) /bond\_type="disulfide"  
 Site 207 /site\_type="binding" /note="carbohydrate (Asn) (covalent)"  
 Bond bond(224,238) /bond\_type="disulfide"  
 20 ORIGIN 1 mwlclaln lmaasgavc evkdvcvgs gipgtgshg lpgrhgrdgl kgdlgppgpm  
 61 gppgempcpp gndglpgagp ipgecgckge pgergppglp ahldeelqat lhdfrhqlq  
 121 trgalqlqs imtvgekvfs sngqstfda iqeacaragg riavprnpee neaiasfvkk  
 181 yntyayvglt egpspgdfry sdgtpvnytn wyrgepagrg keqcvemytd gqwndmclcy  
 241 srlticef  
 25  
 SEQ ID NO: 98  
 A53570 collectin-43 – bovine gi|1083017|pir||A53570[1083017]  
 30 FEATURES Location/Qualifiers source 1..301 /organism="Bos taurus"  
 /db\_xref="taxon:9913"  
 Protein 1..301 /product="collectin-43" /note="lectin CL-43"  
 Region 177..299 /region\_name="domain" /note="C-type lectin homology #label  
 LCH"  
 35 ORIGIN 1 eemdvysekt ltpctlvvc appadslrgh dgrdgkegpq gekgdpgppg mpgpagregp  
 61 sgrqsgmgpp gtpgpkgepg pegvgapgm pgspgpaglk gergapppg  
 aigpqgpgsa  
 121 mgppglkgdr gdpgekgarg etsvlevdtl rqrnrnlege vqrlqnivtq yrkavlfpdg  
 181 qavgekifkt agavksysda eqlcreakgq lasprssaen eavtqlvrak nkhaylsmd  
 40 241 iskegkftyp tggslidysnw apgepnrak degpenclei ysdgnwndie creerlvce 301  
 f  
 45 SEQ ID NO: 99  
 S33603 surfactant protein D – bovine gi|423283|pir||S33603[423283]  
 45 FEATURES Location/Qualifiers source 1..369 /organism="Bos taurus"  
 /db\_xref="taxon:9913"  
 Protein 1..369 /product="surfactant protein D"  
 Region 248..367 /region\_name="domain" /note="C-type lectin homology #label  
 50 LCH"  
 ORIGIN 1 mlllplsvll lltqpwrsig aemkiysqkt manactlvmc sppedglpgr dgrdgregpr  
 61 gekgdpgspg pagragmpgp agpiglkgn gsagepgpkg dtgppgppgm  
 pgpagregps

121 gkqgsmgppg tpgpkgdtgp kggvgapgiq gspgpaglk ergapgdpga  
 pgragapgr  
 181 gaigpqgpg argppglkgd rgtppgergak gesglaevna lrqrvgileg qlqlqnafs  
 241 qykkamlfpn grsvgekifk tvgsektfqd aqqictqagg qlpsprsgae nealtqlata  
 5 301 qnkaafilms dtrkegtfiy ptgeplvysn wapqepnndg gsencveifp ngkwndkvcg  
 361 eqlvicesf

SEQ ID NO: 100

10 AAF28384 lung surfactant protein A [Sus scrofa]  
 gi|6782434|gb|AAF28384.1|AF133668\_1[6782434]  
 FEATURES Location/Qualifiers source 1..116 /organism="Sus scrofa"  
 /db\_xref="taxon:9823"  
 Protein <1..116 /product="lung surfactant protein A" /function="involved in the innate  
 immune system and lipid homeostasis within the lung" /name="collectin; SPA; SP-A"  
 15 CDS 1..116 /gene="SFTPA" /coded\_by="AF133668.1:<1..353"  
 ORIGIN 1 avgekvfstn gqsvafdir elcaraggri aaprspeene aiasivkxhn tyaylgiveg  
 61 ptagdffylg gtpvnytnwy pgeprgrgke kcvemytdgq wdnrcqqyr laicesf

SEQ ID NO: 101

20 AAF22145 lung surfactant protein D precursor; SPD; SP-D; CP4 [Sus scrofa]  
 gi|6760482|gb|AAF22145.2|AF132496\_1[6760482]  
 sig\_peptide 1..20  
 mat\_peptide 21..378 /product="lung surfactant protein D"  
 CDS 1..378 /gene="SFTPD" /coded\_by="AF132496.2:44..1180"  
 25 ORIGIN 1 mlllplsvli lltqpprslg aemktysqra vanacalvmc spmenglpgr dgrdgregpr  
 61 gekgdpglpg avragmpgl agpvgpkgn gstgepgakg digpcgppgp  
 pgipgpake  
 121 gpsgqqgnig ppgtpgpkge tgpkgvgal gmqgstgarg paglkgerga pgergapgsa  
 181 gaagpagatg pqgpgargp pglkgdrgpp gergakgesg lpgitalrqq vetlqqqvqr  
 30 241 lqkafsqykk velfpnrgv gekifktggf ektfqdaqqv ctqaggqmas prseteneal  
 301 sqlvtaqnka afismtdikt egnftyptge plvyawapg epnnnggssg aencveifpn  
 361 gkwndkacge lrlvicesf

SEQ ID NO: 102

P15783 PULMONARY SURFACTANT-ASSOCIATED PROTEIN C (SP-C)  
(PULMONARY SURFACTANT-ASSOCIATED PROTEOLIPID SPL(VAL))  
gi|131422|sp|P15783|PSPC\_BOVIN[131422]

5 FEATURES Location/Qualifiers source 1..34 /organism="Bos taurus"  
/db\_xref="taxon:9913"  
gene 1..34 /gene="SFTPC" /note="SFTP2"  
Protein 1..34 /gene="SFTPC" /product="PULMONARY SURFACTANT-  
10 ASSOCIATED PROTEIN C"  
Site 4 /gene="SFTPC" /site\_type="lipid-binding" /note="PALMITATE (BY  
SIMILARITY)."  
Site 5 /gene="SFTPC" /site\_type="lipid-binding" /note="PALMITATE (BY  
SIMILARITY)."  
15 Region 21 /gene="SFTPC" /region\_name="Conflict" /note="L -> V (IN REF. 2)."  
Region 26 /gene="SFTPC" /region\_name="Conflict" /note="I -> V (IN REF. 2)."  
Region 28..34 /gene="SFTPC" /region\_name="Conflict" /note="GALLMGL ->  
IGAMLAM (IN REF. 2)."  
ORIGIN 1 lipccpvnik rllivvvvvv llvvvivgal lmgI

20 SEQ ID NO: 103

P35246 PULMONARY SURFACTANT-ASSOCIATED PROTEIN D PRECURSOR  
(SP-D) (PSP-D)  
gi|464485|sp|P35246|PSPD\_BOVIN[464485]

25 FEATURES Location/Qualifiers source 1..369 /organism="Bos taurus"  
/db\_xref="taxon:9913"  
gene 1..369 /gene="SFTPD" /note="SFTP4"  
Protein 1..369 /gene="SFTPD" /product="PULMONARY SURFACTANT-  
30 ASSOCIATED PROTEIN D PRECURSOR"  
Region 1..20 /gene="SFTPD" /region\_name="Signal" /note="BY SIMILARITY."  
Region 21..369 /gene="SFTPD" /region\_name="Mature chain"  
/note="PULMONARY SURFACTANT-ASSOCIATED PROTEIN D."  
Region 46..216 /gene="SFTPD" /region\_name="Domain" /note="COLLAGEN-LIKE."  
35 Site 78 /gene="SFTPD" /site\_type="hydroxylation" /note="(BY SIMILARITY)."  
Site 87 /gene="SFTPD" /site\_type="hydroxylation" /note="(BY SIMILARITY)."  
Site 90 /gene="SFTPD" /site\_type="glycosylation" /note="POTENTIAL."  
Site 96 /gene="SFTPD" /site\_type="hydroxylation" /note="(BY SIMILARITY)."  
Site 99 /gene="SFTPD" /site\_type="hydroxylation" /note="(BY SIMILARITY)."  
40 Site 165 /gene="SFTPD" /site\_type="hydroxylation" /note="(BY SIMILARITY)."  
Site 171 /gene="SFTPD" /site\_type="hydroxylation" /note="(BY SIMILARITY)."  
Region 217..248 /gene="SFTPD" /region\_name="Domain" /note="COILED COIL  
(POTENTIAL)."  
Region 273..369 /gene="SFTPD" /region\_name="Domain" /note="C-TYPE LECTIN  
45 (SHORT FORM)."  
Bond bond(275,367) /gene="SFTPD" /bond\_type="disulfide" /note="BY  
SIMILARITY."  
Bond bond(345,359) /gene="SFTPD" /bond\_type="disulfide" /note="BY  
SIMILARITY."  
50 ORIGIN 1 mlllplsvll lltqpwrsig aemkiysqkt manactlvmc sppedglpgr dgrdgregpr  
61 gekgdpgspg pagragmpgp agpiglkgdn gsagepgpkg dtgppppgm  
pgpagregps



121 gkqgsmgppg tpgpkgtgtp kggvgapgiq gspgpaglk ergapgepga  
 pgragapga  
 181 gaigpqgpgs argppglkgd rgtppgergak gesglaevna lrqrvgileg qlrlqnafs  
 241 qykkamlfpn grsvgekifk tvgsektfqd aqqictqagg qlpsprsgae nealtqlata  
 5 301 qnkaafisms dtrkegtfiy ptgeplvysn wapqepnndg gsencveifp ngkwndkvvcg  
 361 eqlvicef

SEQ ID NO: 104

P42916 COLLECTIN-43 (CL-43) gi|1168967|sp|P42916|CL43\_BOVIN[1168967]

10 FEATURES Location/Qualifiers source 1..301 /organism="Bos taurus"

/db\_xref="taxon:9913"

Protein 1..301 /product="COLLECTIN-43"

Region 29..142 /region\_name="Domain" /note="COLLAGEN-LIKE (G-X-Y)."

15 Region 202..301 /region\_name="Domain" /note="C-TYPE LECTIN (SHORT FORM)."

Bond bond(204,299) /bond\_type="disulfide" /note="BY SIMILARITY."

Bond bond(277,291) /bond\_type="disulfide" /note="BY SIMILARITY."

ORIGIN 1 eemdvysekt ltpctlvvc appadslrgh dgrdgkegpq gekgdpqpgp mpgpagregp

20 61 sgrqgsmgpp gtpgpkgepg pegvgapgm pgspgpaglk gergapggp

aigpqgpgsa

121 mgppglkgdr gdpgekgarg etsvlevdtl rqrnrnlege vqlqnivtq yrkavlfpgd

181 qavgekifkt agavksysda eqicreakgq lasprsaen eavtqlvrak nkaylsmd

241 iskegkftyp tggslsynw apgepgnrak degpenclei ysdgnwndie creerlice

301 f

25 SEQ ID NO: 105

CAB56155 DMBT1/8kb.2 protein [Homo sapiens]

gi|5912464|emb|CAB56155.1|[5912464]

sig\_peptide 1..26

30 mat\_peptide 26..2412 /product="DMBT1/8kb.2 protein"

CDS 1..2412 /gene="DMBT1" /coded\_by="AJ243212.1:107..7345"

/note="Sequence is an alternative splice form of the DMBT1 gene that is expressed in human adult trachea. Isoforms of DMBT1 are identical to the collectin binding protein gp-340. Full-length cDNA clone contains 1 bp deletions in codons 100 and 1751, that were corrected by comparison with the genomic exons"

35 ORIGIN 1 mgistvilem clwgqvlt ggwipttdy aslipsevpl dtvaegspfs pseltlestv

61 aegspisles tlettvaegs lipsestles tvaegsdsgl alrlvngdgr cqgrveilyr

121 gswgavcdds wdtdanvvc rqlgcgwams apgnawfgqg sgpiatddvr csghesylws

181 cphngwlshn cghgedagvi csaaqpqstl rpeswpvris ppvptegses slalrlvngg

40 241 drcgrvevl yrgswgtvcd dywdtdanv vcrqlgcgwa msapgnafqg qsgpividd

301 vrcsghesyl wscphngwlt hncghsedag vicsapqsrp tpspdtwpts hastagpess

361 lalrlvnggd rcqgrvevly rsgwtvcdd swdtdanv vcrqlgcgwa sapgnarfqg

421 gsgpividdv rcsghesylw scphngwlsh ncqhsedagv icsaahswst pspdtlptit

481 lpastvgsses slalrlvngg drcqgrvevl yrgswgtvcd dswdtdanv vcrqlgcgwa

45 541 mlapgnarfq qsgpividd vrcsgnesyl wscphngwls hncghsedag vicsgpassl

601 alrlvnggdrc cqgrvevlyr gswgtvcdds wdtdanvvc rqlgcgwams apgnarfqgq

661 sgpiatddvr csghesylws cphngwlshn cghhedagvi csaaqsrstp rpdltlptit

721 ppstvgsses ltlrlvngsd rcqgrvevly rsgwtvcdd swdtdanv vcrqlgcgwa

781 sapgnarfqg gsgpividdv rcsghesylw scphngwlsh ncghhedagv icsvsqsrt

50 841 pspdtwptsh astagpessl alrlvnggdrc cqgrvevlyr gswgtvcdds wdtdanvvc

901 rqlgcgwats apgnarfqgq sgpiatddvr csgghesylws cphngwlshn cqhsedagvi

961 csaaahswstp spdtlptitl pastvgsses lalrlvnggd rcqgrvevly qsgwtvcdd

1021 swdtdanv vcrqlgcgwam sapgnarfqg gsgpividda rcsghesylw scphngwlsh

1081 ncghsedagv icsasqsrpt pspdtwptsh astagsessl alrlvnggdr cqgrveilyr  
 1141 gswgtvcddy wdtndanvac rqlgcgwams apgnarfqqg sgpiivddvr csghesylws  
 1201 cphngwlshn cghhedagvi csasqsqtp spdtwptsha stagsessla lrlvnggdr  
 1261 qgrveilyrg swgtvcddyw dtndanvcr qlgcgwatsa pgnarfqqgs gpiivddvr  
 5 1321 sgghesylwsc phngwlshnc ghhedagvic sasqsqtps pdtwptshas tagsessla  
 1381 rlvnggdrcq grveilyrgs wgtvcddywd tndanvcrq lgcgwatsap gnarfqqgs  
 1441 pivddvrscs ghesylwscph hngwlshncg hhedagvics afqsqtpsp dtwptsrast  
 1501 agsestlar lvnggdrcrg rveilyqgs wgtvcddywd tndanvcrq lgcgwamsap  
 1561 naqfgqsgp iivddvrscg hepylwscph ngwlshncg hhedagvicsa aqsqstprpd  
 10 1621 twttnlpal tvgsessla rlvnggdrcr grveilyrgs wgtvcddswd tndanvcrq  
 1681 lgcgwamsap gnarfqqgs pivldvrscs ghesylwscph hkgwlshncg hhedagvics  
 1741 atqinsttd wwhttttta rpsncggf fyasgtfss sypayypna kvweievns  
 1801 gyrinlgfn lkleahhncs fdyveifdgs lnslllgi cndtrqfts synrmtihfr  
 1861 sdisfntgf lawynsfpsd atrlvnlns syglcagrve iyhggtwgav cddswtqea  
 15 1921 evvcrqlgcg ravsalignay fgsggpitl ddvecsgtes tlwqcrnrgw fshncnhd  
 1981 agvicsgnhl stpafnit rpnyscgf lqpsgdfss pfypgnypnn akcwdivd  
 2041 nnyrvtivr dvqleggcny dyievfdgpy rsspilarvc dgargstss snfmsirfis  
 2101 dhsitrgfr aeysspsnd stnlclpnh mqasvsrsl qslgfsasdl vistwngyye  
 2161 crpqtlnlv iftipysgcg tfgqadndti dysnltaav sggiikrrtd lrihvscrml  
 20 2221 qntwvdtmyi andtihvann tiqveevqyg nfdvnisfyt sssflypvts rpyvdlndq  
 2281 lyvqaeilhs davltfvdv cvaspysndf tslydlirs gcvrddtygp ysspslriar  
 2341 frfrahfln rpsvylrck mvvcraydps srcyrgcivr skrdvgsyqe kvdvvlpgiq  
 2401 lqtpprree pr  
  
 25 SEQ ID NO: 106  
 AAD49696 gp-340 variant protein [Homo sapiens]  
 gi|5733598|gb|AAD49696.1|AF159456.1[5733598]  
 FEATURES Location/Qualifiers source 1..2413 /organism="Homo sapiens"  
 /db\_xref="taxon:9606" /chromosome="10" /map="10q25.3-26.1"  
 30 Protein 1..2413 /product="gp-340 variant protein" /name="scavenger receptor  
 cysteine-rich protein SRCR" /note="putative receptor for SP-D"  
 CDS 1..2413 /gene="DMBT1" /coded\_by="AF159456.1:107..7348"  
 ORIGIN 1 mgistvilem clwggqvist ggwipttdy aslipsevpl dqtvaegspf psestlesta  
 61 aegspisles tlestvaegs lipsestles tvaegsdsgl alrlvngdgr cqgrveilyr  
 35 121 gswgtvcdds wdtndanvvc rqlgcgwams apgnawfgqg sgpiavddvr csghesylws  
 181 cphngwlshn cghhedagvi csaaqpqstl rpeswpvris ppvptegses slalrlvngg  
 241 drcrgrveiy yrgswgtvcd dywdtndanv vcrqlgcgwa msapgnaqfg qsgpiivdd  
 301 vrcsghesyl wscphngwlt hncghsedag vicsapqsrp tpsdtwpts hastagpess  
 361 lalrlvnggd rcqgrveily rgswwgtvcdd swdtsdanvv crqlgcgwat sapgnarfqq  
 40 421 gsgpiivddv rcsghesylw scphngwlsh ncghsedagv icsaahswst pspdtlptit  
 481 lpastvgses slalrlvngg drcqgrveiy yrgswgtvcd dswdtndanv vcrqlgcgwa  
 541 mlapgnarfqq qsgpiivdd vrcsgnesyl wscphngwls hncghsedag vicsgpessl  
 601 alrlvnggdr cqgrveilyr gswgtvcdds wdtndanvvc rqlgcgwams apgnarfqqg  
 661 sgpiivddvr csghesylws cpnngwlshn cghhedagvi csaaqsrstp rpdltitit  
 45 721 ppstvgsses lrlrlvngsd rcqgrveily rgswwgtvcdd swdtsdanvv crqlgcgwam  
 781 sapgnarfqq gsgpiivddv rcsghesylw scphngwlsh ncghhedagv icsvsqsrpt  
 841 pspdtwptsh astagsessl alrlvnggdr cqgrveilyr gswgtvcdds wdtndanvvc  
 901 rqlgcgwats apgnarfqqg sgpiivddvr csghesylws cphngwlshn cghsedagvi  
 961 csaaahswstp spdtlptitl pastvgsess lalrlvnggd rcqgrveily qgswwgtvcdd  
 50 1021 swdtsdanvv crqpgcgwam sapgnarfqq gsgpiivddv rcsghesypw scphngwlsh  
 1081 ncghsedagv icsasqsrpt pspdtwptsh astagsessl alrlvnggdr cqgrveilyr  
 1141 gswgtvcddy wdtndanvvc rqlgcgwams apgnarfqqg sgpiivddvr csghesylws  
 1201 cphngwlshn cghhedagvi csasqsqtp spdtwptsha stagsessla lrlvnggdr

1261 qgrvevlyrg swgtvcddyw dtndanvvr qlgcgwatsa pgnarfqqgs gpivlddvrc  
 1321 sghesylwsc phngwlshnc ghhedagvic sasqsqtps pdtwptshas tagsesslal  
 1381 rlvnggdrcc grvevlyrgs wgtvcddywd tndanvvrq lgcgwatsap gnarfqqgs  
 1441 pivlddvrcs ghesylwscph hngwlshncg hhedagvics asqsqtpsp dtwptsrast  
 5 1501 agsestlaln lrvnggdrcr rvevlyqgs wgtvcddywd ndanvvrql gcgwamsap  
 1561 naqfgqgsqg ivlddvrcsg hesylwscph ngwlshncgh hedagvicsa aqsqstprpd  
 1621 twlttnlpal tvgsesslal rlvnggdrcr grvevlyrgs wgtvcddswd tndanvvrq  
 1681 lgcgwamsap gnarfqqgsq pivlddvrcs ghesylwscph hngwlshncg hhedagvics  
 1741 atqinstttt wwhpttttta rpssncggfl fyasgtfssp sypayypnna kcvweievns  
 10 1801 gyrinlgfsn kkleahhncs fdyveifdgs insslllgki cndtrqifts synrmtihfr  
 1861 sdisfqntgf lawynsfpsd atlrlnlns syglcagrve iyhggtwgtv cddswtiqea  
 1921 evvcrqlgcg ravsalignay fgsgsgpitt dvecsgtes tlwqcrnrgw fshncnhred  
 1981 agvicsgnhl stpaplinit rpntdyscgg flsqpsgdfs spfypgnypn nakcvwdiev  
 2041 qnnrvrtvif rdvqleggc n ydyievfdgp yrsspliarv cdgargsfts ssnfmsirfi  
 15 2101 sdhsitrrgf raeyyspsn dstnlclpn hmqsavrsy lqslgfsasd lvistwnggy  
 2161 ecrpqitpnl viftipysgc gtfkqadndt idysnflta vsggiikrrt dlrihvscrm  
 2221 lqntwvdtmy iandtihvan ntiqveevqy gnfdvnisfy tsssflypvt srpyyvdlng  
 2281 dlyvqaeilh sdavltlfdv tcvaspysnd ftsltydlir sgcvrddtyg pysspslria  
 2341 rfrfrahfl nrfpsvylrc kmvvcraydp ssrvcrgcvl rskrdvgsyq ekvdvvlgpi  
 20 2401 qlqtpprree epr  
  
 SEQ ID NO: 107  
 AAD31380 surfactant protein D precursor [Mus musculus]  
 gi|4877556|gb|AAD31380.1|AF047742\_1[4877556]  
 25 sig\_peptide 1..19  
 mat\_peptide 20..374 /product="surfactant protein D"  
 CDS 1..374 /gene="Sftp4"  
 /coded\_by="join(AF047741.1:5705..5900,AF047742.1:312..428,  
 AF047742.1:669..785,AF047742.1:1112..1228,  
 30 AF047742.1:1977..2093,AF047742.1:3162..3245, AF047742.1:5010..5386)"  
 ORIGIN 1 mlplfslmvl lvqplgnlga emkslsqrsv pntctlvmsc ptenglpggd grdgregprg  
 61 ekgdpglpgp mglsglqgpt gpvpgkge ng sagepgpkge rglsgppglp gipgpagkeg  
 121 psgkqgnigp qgkpgpkgea gpkgevgap mqqstgakgs tgpkgergap  
 gvqgapgnag  
 35 181 aagpagpagp qgapgsrgpp glkgdrgvpg drgikgesgl pdsaalrqm ealkgklql  
 241 evafshyqka alfpdgrsvg dkifrtadse kpfedaqemc kqaggqlasp rsatenaaiq  
 301 qlitahnkaa flsmtdvgtg gkftyptgep lvysnwapge pnnngaenc veiftnqqwn  
 361 dkacgeqrlv icef  
  
 40 SEQ ID NO: 108  
 B61249 pulmonary surfactant protein C – dog gi|539712|pir|B61249[539712]  
 FEATURES Location/Qualifiers source 1..35 /organism="Canis familiaris"  
 /db\_xref="taxon:9615"  
 Protein 1..35 /product="pulmonary surfactant protein C"  
 45 ORIGIN 1 lgpcfpssl krliivvvi vlvvvivga llmgf  
  
 SEQ ID NO: 109  
 S00609 pulmonary surfactant protein C – bovine gi|89749|pir|S00609[89749]  
 50 FEATURES Location/Qualifiers source 1..34 /organism="Bos taurus"  
 /db\_xref="taxon:9913"  
 Protein 1..34 /product="pulmonary surfactant protein C" /note="pulmonary surfactant  
 protein PSP-6"

Site 4 /site\_type="binding" /note="palmitate (Cys) (covalent)"  
 Site 5 /site\_type="binding" /note="palmitate (Cys) (covalent)"  
 ORIGIN 1 lipccpvnik rllivvvvvv llvvvivgal lmgf

5 SEQ ID NO: 110  
 A43628 pulmonary surfactant protein A - human (fragments)  
 gi|280854|pir|A43628[280854]  
 FEATURES Location/Qualifiers source 1..35 /organism="Homo sapiens"  
 /db\_xref="taxon:9606"  
 10 Protein 1..35 /product="pulmonary surfactant protein A"  
 ORIGIN 1 gqsitfdagk eqcvemytdg qwndrnclyl ticef

SEQ ID NO: 111  
 AAB48076 Surfactant protein B (SP-B) [Oryctolagus cuniculus]  
 15 gi|1850933|gb|AAB48076.1|[1850933]  
 FEATURES Location/Qualifiers source 1..370 /organism="Oryctolagus cuniculus"  
 /db\_xref="taxon:9986" /tissue\_type="liver"  
 Protein 1..370 /product="Surfactant protein B (SP-B)"  
 CDS 1..370 /gene="SP-B"  
 20 /coded\_by="join(U40853.1:2194..2263,U40853.1:2591..2718,  
 U40853.1:2941..3012,U40853.1:3257..3382,  
 U40853.1:3590..3727,U40853.1:3925..4014,  
 U40853.1:6043..6226,U40853.1:6421..6581,  
 U40853.1:7266..7346,U40853.1:7829..7891)" /note="Surfactant protein B (SP-B) is  
 25 a key component of lung surfactant, a surface active material secreted by type II  
 epithelial cells of lung alveolus; SP-B maintains biophysical properties and  
 physiological function of surfactant; Pulmonary surfactant associated protein"  
 ORIGIN 1 makshppwl llllptlpg pgtavwatsp lacaqgpew cqsleqalc kalgclqev  
 61 wghvgaddlc qecqdivnil tkmtkeaiq dtirkflehe cdvlpkliv pqchhldvy  
 30 121 fplityfls qinakaicqh lglcqpqspe pldplpdkl vptllgalp akpgphtqdl  
 181 saqrpiplp lcwlcrllk riqamipkgv lamavaqvch vvplvvggic qclaerytvi  
 241 llevlghvl pqlvcglvr cssvdsigqv pptlealpg wlpqdpecpl cmsvttqarn  
 301 iseqtrpqav yhaclssqld kqecqfvel htpqlsls rgwdaraicq algacvatls  
 361 plqicqspfh

35 SEQ ID NO: 112  
 1901176A surfactant protein A gi|382753|prf|1901176A[382753]  
 FEATURES Location/Qualifiers source 1..247 /organism="Oryctolagus cuniculus"  
 /db\_xref="taxon:9986"  
 40 ORIGIN 1 mllslatl isapasdtd tkdvcigspg ipgtpgshgl pgrdgrdgvk gdpqpppgpmg  
 61 ppgmpglpg rdgligapgv pgergdkgep gergppglpa yldeelqatl helrhhalqs  
 121 igvlslqgsm kavgekfst ngqsvnfda revcaraggr iaivkevprs leeneaiasr  
 181 ntyaylglae gptagdfyyl dgdpvnytnw ypgeprgqgr ekcvemytdg kwndknclqy  
 241 rlvicef

45 SEQ ID NO: 113  
 CAA53510 lung surfactant protein D [Bos taurus]  
 gi|415939|emb|CAA53510.1|[415939]  
 sig\_peptide 1..20  
 50 mat\_peptide 21..369 /product="lung surfactant protein D"  
 CDS 1..369 /coded\_by="X75911.1:102..1211" /db\_xref="SWISS-PROT:P35246"  
 ORIGIN 1 mlllplsvll lltqpwrsig aemkiysqkt manactlymc sppedglpgr dgrdgregpr

- 61 gekgdpqspg pagragmpgp agpiglkgn gsagepgpkg dtgpppppgm  
pgpagregps  
121 gkqgsmgppg tpgpkgtgp kggvgapgiq gspgpaglk ergapgepga  
pgragapga
- 5 181 gaigpqgspg argppglkgd rgtppergak gesglaevna lrqrvigleg qlqlqnafs  
241 qykkamlfpn grsvgekifk tvgséktfqd aqqictqagg qlpsprsgae nealtqlata  
301 qnkaafisms dtrkegtfiy ptgeplvysn wapqepnndg gsencveifp ngkwndkvcb  
361 eqrlvicef
- 10 SEQ ID NO: 114  
CAA53511 collectin-43 [Bos taurus] gi|499385|emb|CAA53511.1|[499385]
- FEATURES Location/Qualifiers source 1..301 /organism="Bos taurus"  
/db\_xref="taxon:9913" /tissue\_type="liver" /clone\_lib="lambda gt 11"  
15 Protein 1..301 /product="collectin-43"  
mat\_peptide 1..301 /product="collectin-43"  
CDS 1..301 /coded\_by="X75912.1:<1..906" /db\_xref="SWISS-PROT:P42916"  
ORIGIN 1 eemdvyxekt ltdpctlvvc appadslrgh dgrdgkegpq gekgdpqspg mpppagregp  
61 sgrqgsmgpp gtpgpkgepg peggvgapgm pgspgpaglk gergapggg  
20 aigpqgppga  
121 mgppglkgdr gdpgekgarg etsvlevdtl rqrnrlege vqlqnivtq yrkavlfpdg  
181 qavgekifkt agavksysda eqlcreakgq lasprsaen eavtqlvrak nkaylsmd  
241 iskegkftyp tggldysnw apgepgnrak degpenlei ysdgnwndie creerlvce  
301 f
- 25 SEQ ID NO: 115  
CAA46152 lung surfactant protein D [Homo sapiens]  
gi|34767|emb|CAA46152.1|[34767]
- 30 sig\_peptide 1..20  
mat\_peptide 21..375 /product="lung surfactant protein D"  
CDS 1..375 /gene="hsp-D" /coded\_by="X65018.1:172..1299" /db\_xref="SWISS-  
PROT:P35247"  
ORIGIN 1 mlflilsalv lltqplgyle aemktyshrt tpsactlvmc ssvesglpgr dgrdgregpr  
35 61 gekgdpqlpg aagqagmpgq agpvpgkgn gsvgepgpkg dtgspgppg  
pgvppgagre  
121 gplgkqgnig pqgkpgpkge agpkgevgap gmqgsagarg lagpkgergv  
pgergvpgna  
181 gaagsagamg pqgspgarg pglkgdkgip gdkgakgesg lpdvaslrqq vealggqvqh  
40 241 lqaafsqqk velfpngqsv gekifktagf vkpfteaql ctqaggqlas prsaaenaal  
301 qqlvvaknea aflsmtdskt egkftptge slvysnwapg epnddggsed cveiftngkw  
361 ndracgekrl vvcef
- 45 SEQ ID NO: 116  
AAA92788 lung surfactant protein C [Rattus norvegicus]  
gi|595282|gb|AAA92788.1|[595282]  
FEATURES Location/Qualifiers source 1..194 /organism="Rattus norvegicus"  
/db\_xref="taxon:10116" /clone="sp-c" /tissue\_type="liver"  
Protein 1..194 /product="lung surfactant protein C"  
50 CDS 1..194 /gene="sp-c"  
/coded\_by="join(U07796.1:1673..1714,U07796.1:2841..2999,  
U07796.1:3252..3377,U07796.1:3598..3707,U07796.1:4053..4200)"  
ORIGIN 1 mdmgskevlm espdydstgp rsqfripccp vhlkrliiv vvvvlvvvi vgallmgllhm

61 sqkhtemvle msiggapetq krlalsehtd tiatfsigst givlydyqrl ltaykpapgt  
 121 ycyimkmape sipslealar kfkntfqakss tptsklgqee ghsagsdsds sgrdlaflgl  
 181 avstlcvlp lyi

5 SEQ ID NO: 117

AAA31468 surfactant protein A [*Oryctolagus cuniculus*]  
 gi|431446|gb|AAA31468.1|[431446]

10 FEATURES Location/Qualifiers source 1..247 /organism="Oryctolagus cuniculus"  
 /strain="New Zealand White" /db\_xref="taxon:9986" /tissue\_type="liver"  
 /dev\_stage="adult"

Protein 1..247 /product="surfactant protein A"

CDS 1..247 /coded\_by="join(L19387.1:3864..4032,L19387.1:4241..4360,  
 L19387.1:5010..5087,L19387.1:5533..5909)"

15 ORIGIN 1 millslatl isapasdtd tkdvcigspg ipgtpgshgl pgrdgrdvk gdpgrpapwa  
 61 ppggmpglpg rdgligapgv pgergdkgep gergppglpa yldeelqatl helrhhalqs  
 121 igvlsqgsm kavgekfst ngqsvnfai revcaraggr iavprleen eaiasivker  
 181 ntyaylglae gptagdfyyl dgdpvnytnw ypgeprgqgr ekcvemytdg kwndknclqy  
 241 rlvicef

20

### Mannose binding lectin

25 SEQ ID NO: 1

NP\_034897 mannan-binding lectin serine protease 2 [*Mus musculus*]  
 gi|6754642|ref|NP\_034897.1|[6754642]

sig\_peptide 1..15

30 mat\_peptide 16..185 /product="mannan-binding lectin serine protease 2"  
 Region 28..137 /region\_name="Domain first found in C1r, C1s, uEGF, and bone  
 morphogenetic protein" /note="CUB" /db\_xref="CDD:smart00042"

Region 28..134 /region\_name="CUB domain" /note="CUB"

/db\_xref="CDD:pfam00431"

35 Region 138..180 /region\_name="Calcium-binding EGF-like domain"  
 /note="EGF\_CA" /db\_xref="CDD:smart00179"

variation 172 /allele="I" /allele="V" /db\_xref="dbSNP:3167338"

CDS 1..185 /gene="Masp2" /coded\_by="NM\_010767.1:32..589"

/db\_xref="LocusID:17175" /db\_xref="MGD:1330832"

40 ORIGIN 1 mrliflgl wslvatllgs kwpepvfgrl vspgfpekya dhqdrswltt appgyrlrl  
 61 fthfdlelsy rceydfvklsgtkvlatlc gqestdteqa pgndtfyslg psikvtfhsd  
 121 ysnekpftgf eafyaaedyd ecrvslgdsd pcdhychnyl ggyycscrag yvlhqnkhtc  
 181 seqsl

45 SEQ ID NO: 2

AAH10760 Similar to mannose binding lectin, serum (C) [*Mus musculus*]  
 gi|14789670|gb|AAH10760.1|[14789670]

50 source 1..244 /organism="Mus musculus" /strain="FVB/N" /db\_xref="taxon:10090"  
 /clone="MGC:18500 IMAGE:4212216" /tissue\_type="Liver, normal. 5 month old  
 male mouse." /clone\_lib="NCI\_CGAP\_Li9" /lab\_host="DH10B" /note="Vector:  
 pCMV-SPORT6"

Protein 1..244 /product="Similar to mannose binding lectin, serum (C)"

CDS 1..244 /coded\_by="BC010760.1:192..926"

ORIGIN 1 msiftsfill cvvtvvyat ltegvqnsdp vvtcsspgln gfpkgdgrdg akgekgepgg  
61 glrglqgppg kvgtptppgn pglkgavgpk gdrgrdraefd tseidseiaa lrselralrn  
121 wvflslsekv gkkyfvssvk kmsldrvkal csefqgsvat prnaeensa qkvakdiayl  
181 gitdvrvs fedltgnrvr ytnwndgepn ntgdgedcvv ilgngkwndv pcsdsflaic  
241 efsd

SEQ ID NO: 3

AAH21762 mannose binding lectin, liver (A) [Mus musculus]

gi|18256010|gb|AAH21762.1|[18256010]

source 1..239 /organism="Mus musculus" /strain="FVB/N" /db\_xref="taxon:10090"  
/clone="MGC:30242 IMAGE:5132514" /tissue\_type="Liver, normal. 5 month old  
male mouse." /clone\_lib="NCI\_CGAP\_Li9" /lab\_host="DH10B" /note="Vector:  
pCMV-SPORT6"

Protein 1..239 /product="mannose binding lectin, liver (A)"

/db\_xref="LocusID:17194"

CDS 1..239 /coded\_by="BC021762.1:75..794" /db\_xref="LocusID:17194"

ORIGIN 1 mlllpllpvi lcvsvsssg sqtcedtlkt csviacgrdg rdgpkgekge pgqglrglqg  
61 ppgklgppgs vgspspgpk gqkgdhgdnr aieeklanme aeirilkskl qltnklhafs  
121 mgkksqkklf vtnhekmfks kvkslctelq gtvaiprae enkaieqvat giaflgitde  
181 ategqfmyvt ggrltsnwk kdepnnhsg edcviildng lwndiscqas fkavcefp

SEQ ID NO: 4

Q9NPY3 Complement component C1q receptor precursor (Complement component  
1, q subcomponent, receptor 1) (C1qRp) (C1qR(p)) (C1q/MBL/SPA receptor) (CD93  
antigen) (CDw93) gi|21759074|sp|Q9NPY3|CD93\_HUMAN[21759074]

source 1..652 /organism="Homo sapiens" /db\_xref="taxon:9606

gene 1..652 /gene="C1QR1" /note="CD93"

Protein 1..652 /gene="C1QR1" /product="Complement component C1q receptor  
precursor"

Region 1..21 /gene="C1QR1" /region\_name="Signal"

Region 22..652 /gene="C1QR1" /region\_name="Mature chain"

/note="COMPLEMENT COMPONENT C1Q RECEPTOR.

Region 22 /gene="C1QR1" /region\_name="Conflict" /note="T -> V (IN AA  
SEQUENCE)."

Region 24..580 /gene="C1QR1" /region\_name="Domain" /note="EXTRACELLULAR  
(POTENTIAL)."

Region 32..174 /gene="C1QR1" /region\_name="Domain" /note="C-TYPE LECTIN."

Region 36 /gene="C1QR1" /region\_name="Conflict" /note="C -> T (IN AA  
SEQUENCE)."

Region 38..39 /gene="C1QR1" /region\_name="Conflict" /note="TA -> RI (IN AA  
SEQUENCE)."

Region 155 /gene="C1QR1" /region\_name="Conflict" /note="S -> N (IN REF. 1)."

Region 186 /gene="C1QR1" /region\_name="Conflict" /note="G -> A (IN AA  
SEQUENCE)."

Region 260..301 /gene="C1QR1" /region\_name="Domain" /note="EGF-LIKE 1."

Bond bond(264,275) /gene="C1QR1" /bond\_type="disulfide" /note="BY  
SIMILARITY."

Bond bond(271,285) /gene="C1QR1" /bond\_type="disulfide" /note="BY  
SIMILARITY."

Bond bond(287,300) /gene="C1QR1" /bond\_type="disulfide" /note="BY  
 SIMILARITY."  
 Region 302..344 /gene="C1QR1" /region\_name="Domain" /note="EGF-LIKE 2."  
 Bond bond(306,317) /gene="C1QR1" /bond\_type="disulfide" /note="BY  
 5 SIMILARITY."  
 Bond bond(311,328) /gene="C1QR1" /bond\_type="disulfide" /note="BY  
 SIMILARITY."  
 Region 318 /gene="C1QR1" /region\_name="Variant" /note="V -> A.  
 /FTId=VAR\_013573."  
 10 Site 325 /gene="C1QR1" /site\_type="glycosylation" /note="N-LINKED (GLCNAC...)  
 (POTENTIAL)."  
 Bond bond(330,343) /gene="C1QR1" /bond\_type="disulfide" /note="BY  
 SIMILARITY."  
 Region 345..384 /gene="C1QR1" /region\_name="Domain" /note="EGF-LIKE 3,  
 15 CALCIUM-BINDING (POTENTIAL)."  
 Bond bond(349,358) /gene="C1QR1" /bond\_type="disulfide" /note="BY  
 SIMILARITY."  
 Bond bond(354,367) /gene="C1QR1" /bond\_type="disulfide" /note="BY  
 SIMILARITY."  
 20 Bond bond(369,383) /gene="C1QR1" /bond\_type="disulfide" /note="BY  
 SIMILARITY."  
 Region 385..426 /gene="C1QR1" /region\_name="Domain" /note="EGF-LIKE 4,  
 CALCIUM-BINDING (POTENTIAL)."  
 Bond bond(389,400) /gene="C1QR1" /bond\_type="disulfide" /note="BY  
 25 SIMILARITY."  
 Bond bond(396,409) /gene="C1QR1" /bond\_type="disulfide" /note="BY  
 SIMILARITY."  
 Bond bond(411,425) /gene="C1QR1" /bond\_type="disulfide" /note="BY  
 SIMILARITY."  
 30 Region 427..468 /gene="C1QR1" /region\_name="Domain" /note="EGF-LIKE 5,  
 CALCIUM-BINDING (POTENTIAL)."  
 Bond bond(431,443) /gene="C1QR1" /bond\_type="disulfide" /note="BY  
 SIMILARITY."  
 Bond bond(439,452) /gene="C1QR1" /bond\_type="disulfide" /note="BY  
 35 SIMILARITY."  
 Bond bond(454,467) /gene="C1QR1" /bond\_type="disulfide" /note="BY  
 SIMILARITY."  
 Region 492 /gene="C1QR1" /region\_name="Conflict" /note="S -> A (IN AA  
 SEQUENCE)."  
 Region 496 /gene="C1QR1" /region\_name="Conflict" /note="R -> Q (IN AA  
 40 SEQUENCE)."  
 Region 504 /gene="C1QR1" /region\_name="Conflict" /note="R -> G (IN AA  
 SEQUENCE)."  
 Region 541 /gene="C1QR1" /region\_name="Conflict" /note="P -> S (IN REF. 1)."  
 Region 581..601 /gene="C1QR1" /region\_name="Transmembrane region"  
 45 /note="POTENTIAL."  
 Region 594..601 /gene="C1QR1" /region\_name="Domain" /note="POLY-LEU."  
 Region 602..652 /gene="C1QR1" /region\_name="Domain" /note="CYTOPLASMIC  
 (POTENTIAL)."  
 50 ORIGIN 1 matsmgllll lllltqpga gtgadteavv cvgtacytah sgklsaaeeq nhcnqnggnl  
 61 atvkskeeeq hvqrvlaql rreaaltarm skfwiglqre kgkclpdlp lkgfswvggg  
 121 edtpysnwhk elrnsciskr cysllldlsq pllprrlpkw segpcgspgs pgsniegfv  
 181 kfsfkgmcrp lalggpgqvt yttptqtss sleavpfasa anvacgegdk detqshyflc  
 241 kekapdvfdw gssgplcvsp kygcfnfngg chqdcfeggd gsflogcrpg frliddlvtc



301 asrnpccssp crggatcvlg phgknytrcr pggyqidssq ldcvvdvdecq dspcaqecvn  
 361 tpggfrcecw vgyepggpge gacqdvdeca lgrspcaqgc tntdgsfhcs ceegyvlage  
 421 dgtqcqdvde cvgpggplcd slcfntqgsf hcgclpgwvl apngvsctmg pvsigppsgp  
 481 pdeedkgeke gstvpraata sprgpegtp katpttsrps lssdapitsa plkmlapsgs  
 5 541 pgvwrepsih hataasgpqe paggdssvat qnndgtgdgqk llfyllgtv vaillllala  
 601 lgllvyrrr akreekkekk pqnaadsysw vperaesram enqysptpgt dc

SEQ ID NO: 5

10 O89103 Complement component C1q receptor precursor (Complement component  
 1, q subcomponent, receptor 1) (C1qRp) (C1qR(p)) (C1q/MBL/SPA receptor) (CD93  
 antigen) (Cell surface antigen AA4) (Lymphocyte antigen 68)  
 gi|21541998|sp|O89103|CD93\_MOUSE|21541998

15 source 1..644 /organism="Mus musculus" /db\_xref="taxon:10090"  
 gene 1..644 /gene="C1QR1" /note="CD93; C1QRP; LY68; AA4"  
 Protein 1..644 /gene="C1QR1" /product="Complement component C1q receptor  
 precursor"  
 Region 1..22 /gene="C1QR1" /region\_name="Signal" /note="POTENTIAL."  
 Region 23..644 /gene="C1QR1" /region\_name="Mature chain"  
 20 /note="COMPLEMENT COMPONENT C1Q RECEPTOR."  
 Region 23..572 /gene="C1QR1" /region\_name="Domain" /note="EXTRACELLULAR  
 (POTENTIAL)."  
 Region 31..173 /gene="C1QR1" /region\_name="Domain" /note="C-TYPE LECTIN."  
 Site 102 /gene="C1QR1" /site\_type="glycosylation" /note="N-LINKED (GLCNAC...)  
 25 (POTENTIAL)."  
 Region 257..298 /gene="C1QR1" /region\_name="Domain" /note="EGF-LIKE 1."  
 Bond bond(261,272) /gene="C1QR1" /bond\_type="disulfide" /note="BY  
 SIMILARITY."  
 Bond bond(268,282) /gene="C1QR1" /bond\_type="disulfide" /note="BY  
 30 SIMILARITY."  
 Bond bond(284,297) /gene="C1QR1" /bond\_type="disulfide" /note="BY  
 SIMILARITY."  
 Region 299..341 /gene="C1QR1" /region\_name="Domain" /note="EGF-LIKE 2."  
 Bond bond(303,314) /gene="C1QR1" /bond\_type="disulfide" /note="BY  
 35 SIMILARITY."  
 Bond bond(308,325) /gene="C1QR1" /bond\_type="disulfide" /note="BY  
 SIMILARITY."  
 Site 322 /gene="C1QR1" /site\_type="glycosylation" /note="N-LINKED (GLCNAC...)  
 (POTENTIAL)."  
 40 Bond bond(327,340) /gene="C1QR1" /bond\_type="disulfide" /note="BY  
 SIMILARITY."  
 Region 342..381 /gene="C1QR1" /region\_name="Domain" /note="EGF-LIKE 3,  
 CALCIUM-BINDING (POTENTIAL)."  
 Bond bond(346,355) /gene="C1QR1" /bond\_type="disulfide" /note="BY  
 45 SIMILARITY."  
 Bond bond(351,364) /gene="C1QR1" /bond\_type="disulfide" /note="BY  
 SIMILARITY."  
 Bond bond(366,380) /gene="C1QR1" /bond\_type="disulfide" /note="BY  
 SIMILARITY."  
 50 Region 382..423 /gene="C1QR1" /region\_name="Domain" /note="EGF-LIKE 4,  
 CALCIUM-BINDING (POTENTIAL)."  
 Bond bond(386,397) /gene="C1QR1" /bond\_type="disulfide" /note="BY  
 SIMILARITY."

Bond bond(393,406) /gene="C1QR1" /bond\_type="disulfide" /note="BY  
 SIMILARITY."  
 Bond bond(408,422) /gene="C1QR1" /bond\_type="disulfide" /note="BY  
 SIMILARITY."  
 5 Region 424..465 /gene="C1QR1" /region\_name="Domain" /note="EGF-LIKE 5,  
 CALCIUM-BINDING (POTENTIAL)."  
 Bond bond(428,440) /gene="C1QR1" /bond\_type="disulfide" /note="BY  
 SIMILARITY."  
 Bond bond(436,449) /gene="C1QR1" /bond\_type="disulfide" /note="BY  
 10 SIMILARITY."  
 Bond bond(451,464) /gene="C1QR1" /bond\_type="disulfide" /note="BY  
 SIMILARITY."  
 Region 573..593 /gene="C1QR1" /region\_name="Transmembrane region"  
 /note="POTENTIAL."  
 15 Region 594..644 /gene="C1QR1" /region\_name="Domain" /note="CYTOPLASMIC  
 (POTENTIAL)."  
 ORIGIN 1 maistglfill lglgqpwwag aaadsqavvc egtacytahw gklssaeeaqh rcnenggnla  
 61 tvkseearh vqqaltqlk tkapleakmg kfwiglqrek gnctyhdipm rgfswvggge  
 121 dtaysnwyka sksscifkrç vsliidlsit phpshlpkwh espcgtpeap gnsiegflck  
 181 fnfkgmcrpl algppgrvty ttpfqtatss leavpfasva nvacgdeaks ethylfclnek  
 20 241 tpgifhwgss gplcvspkfg csfnnggcqq dcfeggdgsf rcgcrpgfrl lddlvctasr  
 301 npcssnpctg ggmchsvpls enytrcpsg yqldssqvhc vdidcdqdsp caqdcvntlg  
 361 sfhcecwgy qpsgpkeeac edvdecaaan spcaqgcint dgsfycscke gyivsgedst  
 421 qcedidecsd argnpcdslc fntdgsfrcg cppgwelapn gvfcsgrtvf selparppqk  
 25 481 ednddrkest mpptempssp sgskdvsra qttglfvqsd iptasvplei eipsevsdvw  
 541 felgtylptt sghskpthed svahsdtgd qnllfyilg tvvaisllv lalgilyhk  
 601 rrakkeeike kkpqnaadsy swvperaesq apenqysptp gtde  
  
 SEQ ID NO: 6  
 30 P09871 Complement C1s component precursor (C1 esterase)  
 gi|115205|sp|P09871|C1S\_HUMAN[115205]  
  
 source 1..688 /organism="Homo sapiens" /db\_xref="taxon:9606"  
 gene 1..688 /gene="C1S"  
 35 Protein 1..688 /gene="C1S" /product="Complement C1s component precursor"  
 /EC\_number="3.4.21.42"  
 Region 1..15 /gene="C1S" /region\_name="Signal"  
 Region 16..437 /gene="C1S" /region\_name="Mature chain" /note="COMPLEMENT  
 C1S HEAVY CHAIN." Region 16..130 /gene="C1S" /region\_name="Domain"  
 40 /note="CUB 1."  
 Bond bond(65,83) /gene="C1S" /bond\_type="disulfide"  
 Region 131..172 /gene="C1S" /region\_name="Domain" /note="EGF-LIKE,  
 CALCIUM-BINDING (POTENTIAL)."  
 Bond bond(135,147) /gene="C1S" /bond\_type="disulfide"  
 45 Bond bond(143,156) /gene="C1S" /bond\_type="disulfide"  
 Site 149 /gene="C1S" /site\_type="hydroxylation" /note="(PROBABLE)."  
 Bond bond(158,171) /gene="C1S" /bond\_type="disulfide"  
 Site 174 /gene="C1S" /site\_type="glycosylation" /note="N-LINKED (GLCNAC...)."  
 Region 175..290 /gene="C1S" /region\_name="Domain" /note="CUB 2."  
 50 Bond bond(175,202) /gene="C1S" /bond\_type="disulfide" Bond bond(234,251)  
 /gene="C1S" /bond\_type="disulfide" Region 293..355 /gene="C1S"  
 /region\_name="Domain" /note="SUSHI 1."  
 Bond bond(294,341) /gene="C1S" /bond\_type="disulfide"

Region 294 /gene="C1S" /region\_name="Conflict" /note="C -> K (IN REF. 6)."  
 Bond bond(321,354) /gene="C1S" /bond\_type="disulfide"  
 Region 358..422 /gene="C1S" /region\_name="Domain" /note="SUSHI 2."  
 Bond bond(359,403) /gene="C1S" /bond\_type="disulfide"  
 5 Bond bond(386,421) /gene="C1S" /bond\_type="disulfide"  
 Site 406 /gene="C1S" /site\_type="glycosylation" /note="N-LINKED (GLCNAC...)."  
 Bond bond(425,549) /gene="C1S" /bond\_type="disulfide" /note="INTERCHAIN."  
 Region 438..688 /gene="C1S" /region\_name="Mature chain" /note="COMPLEMENT  
 C1S LIGHT CHAIN." Region 438..688 /gene="C1S" /region\_name="Domain"  
 10 /note="SERINE PROTEASE."  
 Site 475 /gene="C1S" /site\_type="active" /note="CHARGE RELAY SYSTEM."  
 Region 513 /gene="C1S" /region\_name="Conflict" /note="G -> GG (IN REF. 5)."  
 Site 529 /gene="C1S" /site\_type="active" /note="CHARGE RELAY SYSTEM."  
 Region 573 /gene="C1S" /region\_name="Conflict" /note="T -> A (IN REF. 7)."  
 15 Bond bond(595,618) /gene="C1S" /bond\_type="disulfide"  
 Bond bond(628,659) /gene="C1S" /bond\_type="disulfide"  
 Site 632 /gene="C1S" /site\_type="active" /note="CHARGE RELAY SYSTEM."  
 Region 645..646 /gene="C1S" /region\_name="Conflict" /note="TK -> GR (IN REF.  
 7)."  
 20 ORIGIN 1 mwcivfsl awvyaeptmy geilspnypq aypseveksw dievpegygi hlyfthldie  
 61 lsencaydsv qisgdtteeg rlcqgrssnn phspiveefq vpynklqvif ksdfsneerf  
 121 tgfaayvat dinectdfvd vpcshfcnnf iggyfcscpp eyflhddmkn cgvnscgdrv  
 181 taligeiasp nykpypens rceyqirlek gfqvvtlrr edfdveaads agncldslvf  
 241 vagdrqfgy cghgfgpgln ietksnaldi ifqtdltgqk kgwklyrhgd pmpcpkedtp  
 25 301 nswwepakak yvfrdvvqit clgdfevveg rgatsfyst cqsngkwsns klkcqpvdcg  
 361 ipesiengk v edpestlfgs vitytceepy yymengggge yhcagngswv nevlgpelpk  
 421 cvpvcgvppe pfeekqriig gsdadiknfp wqvffdnppa ggalineyww ltaahvvegn  
 481 reptmyvgst svqtsrlaks kmllpehvf hpgwkllvpe egrtnfdndi alvrldpvc  
 541 mgptvspicl pgtssdynlm dgdglisgw grtekdrav rikaarlpa plrkckevkv  
 30 601 ekptadaeay vftpnmicag gekgmdsckg dsggafavqd pndktkfyaa glvswgpcg  
 661 tyglytrvkn yvdwimktmq enstpred

## SEQ ID NO: 7

NP\_036204 complement component 1, q subcomponent, receptor 1; complement  
 35 component C1q receptor [Homo sapiens]  
 gi|6912282|ref|NP\_036204.1||6912282]

source 1..652 /organism="Homo sapiens" /db\_xref="taxon:9606" /chromosome="20"  
 /map="20p11.21"  
 40 Protein 1..652 /product="complement component 1, q subcomponent, receptor 1"  
 /note="complement component C1q receptor"  
 Region 32..130 /region\_name="smart00034, CLECT, C-type lectin (CTL) or  
 carbohydrate-recognition domain (CRD); Many of these domains function as  
 calcium-dependent carbohydrate binding modules"  
 45 Region 47..128 /region\_name="pfam00059, lectin\_c, Lectin C-type domain. This  
 family includes both long and short form C-type"  
 Region 385..426 /region\_name="smart00179, EGF\_CA, Calcium-binding EGF-like  
 domain"  
 CDS 1..652 /gene="C1QR1" /coded\_by="NM\_012072.2:149..2107"  
 50 /note="C1q/MBL/SPA receptor" /db\_xref="LocusID:22918" /db\_xref="MIM:120577"  
 ORIGIN 1 matsmgllll lllltqpga gtgadteavv cvgtacytah sgklasaaeq nhcnqnggnl  
 61 atvkskeeq hvqrvlaql rreaaltarm skfwiglqre kgkoldpslp lkgfswvggg  
 121 edtpysnwhk elrnsciskr cvslldlsq pllpnrpkw segpcgspgs pgsniegfv

181 kfsfkgmcrp lalggpggvt yttfqtstss sleavpfasa anvacgegdk detqshyflc  
 241 kekapdvfdw gssgplcvsp kygcfnfngg chqdcfeggd gsflcgcrpg frliddlvtc  
 301 asrnpccssp crggatcvlg phgknytrc pqgyqldssq ldcvvdvdecq dspcaqecvn  
 361 tpggfrcecw vgyepggpge gacqdvdeca lgrspcaqgc tntdgsfhcs ceegyvlage  
 421 dgtqcqdvde cvgpggplcd slcfnqtqgs hcgclpgwvl apngvscmtg pvsigppsgp  
 481 pdeedkgeke gstvpraata sptrgpegt katpttsrps lssdapitsa plkmllapsgs  
 541 sgvwrepsih hataasgpqe paggdssvat qnndgtgqk lllyfylv vaillllala  
 601 lgllvykrk akreekkekk pqnaadsysw vperaesram enqysptpgt dc

SEQ ID NO: 8

NP\_000233 soluble mannose-binding lectin precursor; mannose-binding lectin; mannose binding protein; Mannose-binding lectin 2, soluble (opsonic defect) [Homo sapiens]

gi|4557739|ref|NP\_000233.1|[4557739]

sig\_peptide 1..20

mat\_peptide 21..248 /product="soluble mannose-binding lectin"

variation 54 /allele="D" /allele="G" /db\_xref="dbSNP:1800450"

variation 57 /allele="E" /allele="G" /db\_xref="dbSNP:1800451"

Region 134..245 /region\_name="smart00034, CLECT, C-type lectin (CTL) or carbohydrate-recognition domain (CRD); Many of these domains function as calcium-dependent carbohydrate binding modules"

Region 144..246 /region\_name="pfam00059, lectin\_c, Lectin C-type domain. This family includes both long and short form C-type"

CDS 1..248 /gene="MBL2" /coded\_by="NM\_000242.1:66..812"

/db\_xref="LocusID:4153" /db\_xref="MIM:154545"

ORIGIN 1 mslfslpil lsmvaasys etvtcedaak tcpaviacss pgingfpgkd grdgtkgekg

61 epgqglrlq gppgklgppg nppsgsgpgp kgqkgdpgks pdgdsslaas erkalqtema

121 rikkwltfsl gkqvgnkffl tngeimtfek vkalcvkfqa svatprnaae ngaiqnlike

181 eafglitdek tegqfvdltg nrlytnwne gepnagsde dcvlllknqg wndvpcastsh

241 lavcefp

SEQ ID NO: 9

P11226 Mannose-binding protein C precursor (MBP-C) (MBP1) (Mannan-binding protein) (Mannose-binding lectin) gi|126676|sp|P11226|MABC\_HUMAN[126676]

source 1..248 /organism="Homo sapiens" /db\_xref="taxon:9606"

gene 1..248 /gene="MBL2" /note="MBL"

Protein 1..248 /gene="MBL2" /product="Mannose-binding protein C precursor"

Region 1..20 /gene="MBL2" /region\_name="Signal"

Region 21..248 /gene="MBL2" /region\_name="Mature chain" /note="MANNOSE-BINDING PROTEIN C." Region 21..41 /gene="MBL2" /region\_name="Domain"

/note="CYS-RICH."

Region 24 /gene="MBL2" /region\_name="Variant" /note="T -> A (IN CHINESE).

/FTId=VAR\_013294."

Region 42..99 /gene="MBL2" /region\_name="Domain" /note="COLLAGEN-LIKE."

Site 47 /gene="MBL2" /site\_type="hydroxylation"

Region 52 /gene="MBL2" /region\_name="Variant" /note="R -> C (IN 0.05% OF EUROPEAN AND AFRICAN POPULATIONS). /FTId=VAR\_008543."

Region 54 /gene="MBL2" /region\_name="Variant" /note="G -> D (IN CAUCASIAN AND CHINESE POPULATIONS). /FTId=VAR\_004182."

Region 57 /gene="MBL2" /region\_name="Variant" /note="G -> E (IN WEST AFRICAN POPULATION). /FTId=VAR\_004183."

Site 73 /gene="MBL2" /site\_type="hydroxylation"  
 Site 79 /gene="MBL2" /site\_type="hydroxylation"  
 Site 82 /gene="MBL2" /site\_type="hydroxylation"  
 Site 88 /gene="MBL2" /site\_type="hydroxylation"  
 5 Region 109 /gene="MBL2" /region\_name="Hydrogen bonded turn"  
 Region 110..129 /gene="MBL2" /region\_name="Helical region"  
 Region 130 /gene="MBL2" /region\_name="Hydrogen bonded turn"  
 Region 132..134 /gene="MBL2" /region\_name="Beta-strand region"  
 Region 135..136 /gene="MBL2" /region\_name="Hydrogen bonded turn"  
 10 Region 137..147 /gene="MBL2" /region\_name="Beta-strand region"  
 Region 148..157 /gene="MBL2" /region\_name="Helical region"  
 Region 153..246 /gene="MBL2" /region\_name="Domain" /note="C-TYPE LECTIN (SHORT FORM)."  
 Bond bond(155,244) /gene="MBL2" /bond\_type="disulfide"  
 15 Region 158..159 /gene="MBL2" /region\_name="Hydrogen bonded turn"  
 Region 161..162 /gene="MBL2" /region\_name="Beta-strand region"  
 Region 168..177 /gene="MBL2" /region\_name="Helical region"  
 Region 182..187 /gene="MBL2" /region\_name="Beta-strand region"  
 Region 192..193 /gene="MBL2" /region\_name="Hydrogen bonded turn"  
 20 Region 196..197 /gene="MBL2" /region\_name="Beta-strand region"  
 Region 198..199 /gene="MBL2" /region\_name="Hydrogen bonded turn"  
 Region 202 /gene="MBL2" /region\_name="Beta-strand region"  
 Region 208 /gene="MBL2" /region\_name="Beta-strand region"  
 Region 210..211 /gene="MBL2" /region\_name="Hydrogen bonded turn"  
 25 Region 216..218 /gene="MBL2" /region\_name="Helical region"  
 Bond bond(222,236) /gene="MBL2" /bond\_type="disulfide"  
 Region 222..225 /gene="MBL2" /region\_name="Beta-strand region"  
 Region 227..228 /gene="MBL2" /region\_name="Hydrogen bonded turn"  
 Region 231..234 /gene="MBL2" /region\_name="Beta-strand region"  
 30 Region 236..237 /gene="MBL2" /region\_name="Hydrogen bonded turn"  
 Region 239..248 /gene="MBL2" /region\_name="Beta-strand region"

ORIGIN 1 mslfplppll lsmvaasys etvtcedaqk tcpaviacss pgingfpgkd grdgtkgekg  
 61 epqqglrglq gppgklgppg nppgsgspgp kgqkgdpgks pdgdsslaas erkalqtema  
 35 121 rikkwltfsl gkqvgnkffl tngeimtfek vkalcvkfqa svatprnaae ngaiqnlike  
 181 eafglitdek tegqfvdltg nrlytnwne gepnagsde dcvlilkngq wndvpcastsh  
 241 lavcefpj

SEQ ID NO: 10  
 40 Q9ET61 Complement component C1q receptor precursor (Complement component  
 1, q subcomponent, receptor 1) (C1qRp) (C1qR(p)) (C1q/MBL/SPA receptor) (CD93  
 antigen) (Cell surface antigen AA4) gi|21541989|sp|Q9ET61|CD93\_RAT[21541989]

source 1..643 /organism="Rattus norvegicus" /db\_xref="taxon:10116"  
 45 gene 1..643 /gene="C1QR1" /note="CD93; C1QRP2"  
 Protein 1..643 /gene="C1QR1" /product="Complement component C1q receptor  
 precursor"  
 Region 1..23 /gene="C1QR1" /region\_name="Signal" /note="POTENTIAL."  
 Region 24..643 /gene="C1QR1" /region\_name="Mature chain"  
 50 /note="COMPLEMENT COMPONENT C1Q RECEPTOR."  
 Region 24..571 /gene="C1QR1" /region\_name="Domain" /note="EXTRACELLULAR  
 (POTENTIAL)."  
 Region 31..173 /gene="C1QR1" /region\_name="Domain" /note="C-TYPE LECTIN."

Region 257..298 /gene="C1QR1" /region\_name="Domain" /note="EGF-LIKE 1."  
 Bond bond(261,272) /gene="C1QR1" /bond\_type="disulfide" /note="BY  
 SIMILARITY."  
 Bond bond(268,282) /gene="C1QR1" /bond\_type="disulfide" /note="BY  
 SIMILARITY."  
 Bond bond(284,297) /gene="C1QR1" /bond\_type="disulfide" /note="BY  
 SIMILARITY."  
 Region 299..341 /gene="C1QR1" /region\_name="Domain" /note="EGF-LIKE 2."  
 Bond bond(303,314) /gene="C1QR1" /bond\_type="disulfide" /note="BY  
 SIMILARITY."  
 Bond bond(308,325) /gene="C1QR1" /bond\_type="disulfide" /note="BY  
 SIMILARITY."  
 Site 322 /gene="C1QR1" /site\_type="glycosylation" /note="N-LINKED (GLCNAC...)  
 (POTENTIAL)."  
 Bond bond(327,340) /gene="C1QR1" /bond\_type="disulfide" /note="BY  
 SIMILARITY."  
 Region 342..381 /gene="C1QR1" /region\_name="Domain" /note="EGF-LIKE 3,  
 CALCIUM-BINDING (POTENTIAL)."  
 Bond bond(346,355) /gene="C1QR1" /bond\_type="disulfide" /note="BY  
 SIMILARITY."  
 Bond bond(351,364) /gene="C1QR1" /bond\_type="disulfide" /note="BY  
 SIMILARITY."  
 Bond bond(366,380) /gene="C1QR1" /bond\_type="disulfide" /note="BY  
 SIMILARITY."  
 Region 382..423 /gene="C1QR1" /region\_name="Domain" /note="EGF-LIKE 4,  
 CALCIUM-BINDING (POTENTIAL)."  
 Bond bond(386,397) /gene="C1QR1" /bond\_type="disulfide" /note="BY  
 SIMILARITY."  
 Bond bond(393,406) /gene="C1QR1" /bond\_type="disulfide" /note="BY  
 SIMILARITY."  
 Bond bond(408,422) /gene="C1QR1" /bond\_type="disulfide" /note="BY  
 SIMILARITY."  
 Region 417 /gene="C1QR1" /region\_name="Conflict" /note="E -> K (IN REF. 2)."  
 Region 424..462 /gene="C1QR1" /region\_name="Domain" /note="EGF-LIKE 5,  
 CALCIUM-BINDING (POTENTIAL)."  
 Bond bond(428,437) /gene="C1QR1" /bond\_type="disulfide" /note="BY  
 SIMILARITY."  
 Bond bond(433,446) /gene="C1QR1" /bond\_type="disulfide" /note="BY  
 SIMILARITY."  
 Bond bond(448,461) /gene="C1QR1" /bond\_type="disulfide" /note="BY  
 SIMILARITY."  
 Site 498 /gene="C1QR1" /site\_type="glycosylation" /note="N-LINKED (GLCNAC...)  
 (POTENTIAL)."  
 Region 572..592 /gene="C1QR1" /region\_name="Transmembrane region"  
 /note="POTENTIAL."  
 Region 593..643 /gene="C1QR1" /region\_name="Domain" /note="CYTOPLASMIC  
 (POTENTIAL)."  
  
 ORIGIN 1 mvtstgllll lglgqlwag aaadseavvc egtacytahw gklsaeeaqh rcnenggnla  
 61 tvkseearh vqealaqlk tkapsetkig kfwiglqrek gkctyhdipm kgfswvggge  
 121 dttywnyka skssciskrc vslldlsik phpshlpkwh espcgtpdap gnsiegflck  
 181 fnfkgmcspl algpggqlty ttpfqattss lkavpfasva nvvcgdeaes ktnyyicket  
 241 tagvfhwgss gplcvspkfg csfnnggcqq dcfeggdgsf rcgcrpgfrr lddlvtsar

301 npcssnpctg ggmchsvpls enytcpcrg yqldssqvhc vdidecedsp cdqecintpg  
 361 gfhcecwvgy qssgskeeac edvdectaay spcaqgctnt dgsfycske gymsgedst  
 421 qcedideclg npcdtlcint dgsfrcgcpa gfelapngvs ctrgsmfsej parppqkedk  
 481 gdgkestvpl tempgslns kdvsnraqtt dlsiqdsst asvpleievs seasdvwdl  
 5 541 gtylpttsgl sqpthedsvp ahsdsdtdgq klllfyilgt vvaisllal algliylkr  
 601 kakkeeikak kaqnaadsys wiperaesra penqysptpg tdc

SEQ ID NO: 11

10 NP\_006601 mannan-binding lectin serine protease 2, isoform 1 precursor; MBL-associated plasma protein of 19 kD; small MBL-associated protein [Homo sapiens] gij21264363[ref]NP\_006601.2[21264363]  
 sig\_peptide 1..15  
 mat\_peptide 16..444 /product="mannan-binding lectin serine protease 2, isoform 1, chain A"  
 15 Region 28..136 /region\_name="Domain first found in C1r, C1s, uEGF, and bone morphogenetic protein." /note="CUB" /db\_xref="CDD:smart00042"  
 Region 28..134 /region\_name="CUB domain" /note="CUB"  
 /db\_xref="CDD:pfam00431"  
 Region 138..180 /region\_name="Calcium-binding EGF-like domain"  
 20 /note="EGF\_CA" /db\_xref="CDD:smart00179"  
 variation 155 /allele="H" /allele="R" /db\_xref="dbSNP:2273343"  
 Region 184..295 /region\_name="Domain first found in C1r, C1s, uEGF, and bone morphogenetic protein." /note="CUB" /db\_xref="CDD:smart00042"  
 Region 184..293 /region\_name="CUB domain" /note="CUB"  
 25 /db\_xref="CDD:pfam00431"  
 Region 300..361 /region\_name="Domain abundant in complement control proteins" /note="CCP" /db\_xref="CDD:smart00032"  
 Region 300..361 /region\_name="Sushi domain (SCR repeat)" /note="sushi" /db\_xref="CDD:pfam00084"  
 30 Region 366..430 /region\_name="Domain abundant in complement control proteins" /note="CCP" /db\_xref="CDD:smart00032"  
 Region 366..430 /region\_name="Sushi domain (SCR repeat)" /note="sushi" /db\_xref="CDD:pfam00084"  
 variation 377 /allele="A" /allele="V" /db\_xref="dbSNP:2273346"  
 35 Region 444..679 /region\_name="Trypsin-like serine protease" /note="Tryp\_SPc" /db\_xref="CDD:smart00020" mat\_peptide 445..686 /product="mannan-binding lectin serine protease 2, isoform 1, chain B"  
 Region 445..679 /region\_name="Trypsin" /note="trypsin" /db\_xref="CDD:pfam00089"  
 40 CDS 1..686 /gene="MASP2" /coded\_by="NM\_006610.2:22..2082" /db\_xref="LocusID:10747" /db\_xref="MIM:605102"

ORIGIN 1 mrltlgl cgsvatplgp kwpepvfgrl aspgfpgeya ndqerrwtlt appgyrlrlly  
 45 61 fthfdlelsh lceydfvklis sgakvlatlc qgestdtera pgkdtfyslg sslditfrsd  
 121 ysnekpftgf eafyaaedid ecqvapgeap tcdhhchnhl ggfycscrag yvlhrnkrtc  
 181 salcsgqvft qrsgelsspe yprpypklss ctysisleeg fsvildfves fdvethpetl  
 241 cpydflikiqt dreehgpfcg ktlphrietk sntvtitfv desgdhtgwk ihtystaqpc  
 301 pypmappngh vspvqakyil kdsfsifcet gyellqghlp lksftavcqq dgswdrmpa  
 361 csivdcgppd dlpgrveyi tpggvtyka viqysceetf ytmkvndgky vceadgfwts  
 50 421 skgekslpvc epvcglart tggriyggqk akpgdfpwqv ilggtaag allydnwvlt  
 481 aahavyeqkh dasaldirmg tlkrlsphyt qawseavfi egyptdagfd ndialiklhn  
 541 kvvinsnitp iclprkeaes fmrtddigta sgwgltrgf larnlmyvdi pivdhqkcta  
 601 ayekppyprg svtanmlcag lesggkdscr gdsggalvfl dseterwfv givswgsmnc

661 geagqygvyt kvinyipwie niisdf

SEQ ID NO: 12

NP\_631947 mannan-binding lectin serine protease 2, isoform 2 precursor; MBL-associated plasma protein of 19 kD; small MBL-associated protein [Homo sapiens] gi|21264361|ref|NP\_631947.1||21264361]

sig\_peptide 1..15

mat\_peptide 16..185 /product="mannan-binding lectin serine protease 2, isoform 2"

Region 28..136 /region\_name="Domain first found in C1r, C1s, uEGF, and bone morphogenetic protein." /note="CUB" /db\_xref="CDD:smart00042"

Region 28..134 /region\_name="CUB domain" /note="CUB"

/db\_xref="CDD:pfam00431"

Region 138..180 /region\_name="Calcium-binding EGF-like domain"

/note="EGF\_CA" /db\_xref="CDD:smart00179"

variation 155 /allele="H" /allele="R" /db\_xref="dbSNP:2273343"

CDS 1..185 /gene="MASP2" /coded\_by="NM\_139208.1:22..579"

/db\_xref="LocusID:10747" /db\_xref="MIM:605102"

ORIGIN 1 mrltlgl cgsvatplgp kwpepvfgrl aspgfpgeya ndqerrwtlt appgyrlrl

61 fthfdleish lceydfvkl sgakvlatlc gqestdtera pgkdtfyslg sslditfrsd

121 ysnekpftgf eafyaaedid ecqvapgeap tcdhhchnhl ggfycscrag yvlhrnkrtc

181 seqsl

SEQ ID NO: 13

NP\_624302 mannan-binding lectin serine protease 1, isoform 2, precursor; protease, serine, 5 (mannose-binding protein-associated); manan-binding lectin serine protease-1; Ra-reactive factor serine protease p100 [Homo sapiens] gi|21264359|ref|NP\_624302.1||21264359]

sig\_peptide 1..19

mat\_peptide 20..445 /product="mannan-binding lectin serine protease 1, isoform 2, chain A"

variation 21 /allele="I" /allele="T" /db\_xref="dbSNP:1062049"

Region 23..138 /region\_name="Domain first found in C1r, C1s, uEGF, and bone morphogenetic protein." /note="CUB" /db\_xref="CDD:smart00042"

Region 23..135 /region\_name="CUB domain" /note="CUB"

/db\_xref="CDD:pfam00431"

Region 139..181 /region\_name="Calcium-binding EGF-like domain"

/note="EGF\_CA" /db\_xref="CDD:smart00179"

Region 185..294 /region\_name="CUB domain" /note="CUB"

/db\_xref="CDD:pfam00431"

Region 190..296 /region\_name="Domain first found in C1r, C1s, uEGF, and bone morphogenetic protein." /note="CUB" /db\_xref="CDD:smart00042"

variation 235 /allele="Q" /allele="E" /db\_xref="dbSNP:3203210"

variation 258 /allele="P" /allele="A" /db\_xref="dbSNP:866085"

Region 301..362 /region\_name="Domain abundant in complement control proteins" /note="CCP" /db\_xref="CDD:smart00032"

Region 301..362 /region\_name="Sushi domain (SCR repeat)" /note="sushi"

/db\_xref="CDD:pfam00084"

Region 367..432 /region\_name="Domain abundant in complement control proteins"

/note="CCP" /db\_xref="CDD:smart00032"

Region 367..432 /region\_name="Sushi domain (SCR repeat)" /note="sushi"

/db\_xref="CDD:pfam00084" mat\_peptide 446..728 /product="mannan-binding lectin serine protease 1, isoform 2, chain B"



Region 449..711 /region\_name="Trypsin-like serine protease" /note="Tryp\_SPc"  
 /db\_xref="CDD:smart00020" Region 450..711 /region\_name="Trypsin"  
 /note="trypsin" /db\_xref="CDD:pfam00089"  
 variation 616 /allele="A" /allele="V" /db\_xref="dbSNP:2461280"  
 5 Region 661..703 /region\_name="Immunoglobulin A1 protease" /note="IGA1"  
 /db\_xref="CDD:pfam02395"  
 CDS 1..728 /gene="MASP1" /coded\_by="NM\_139125.1:51..2237"  
 /db\_xref="LocusID:5648" /db\_xref="MIM:600521"

10 ORIGIN 1 mrwlllyal cflskasah tvelnnmfgq iqspgypdsy psdsevtwni tvpdgfrikl  
 61 yfmhfnless ylceydykv etedqqlatf cgrettdteq tpgqevlsp gsfmsitfrs  
 121 dfsneerftg fdahymavdv deckeredee lscdhychny iggyycscr gylhtdnrt  
 181 crvecsdnlf tqrtgvitp dfnpypkss eelytielee gfmvnlqfed ifdiedhpev  
 241 pcpdydikik vgpklvgpfc gekapepist qshsvlilfh sdnsngenrgw rlsyraagne  
 15 301 cpeiqppvhg kiepsqakyf fkdqvlvscd tgykvldnv emdtfqiecl kdgtswnkip  
 361 tckivdcrap gelehglitf strnlttyk seikyscqp yykmlnnntg iytcsaaggvw  
 421 mnkvlgslp tclpecgqps rslpslvkri iggrnaepgl fpwqalivve dtsrvpndkw  
 481 fgsgallsas wiltaahvlr sqrrdtvip vskehvtvyl glhdvrdksg avnssaarvv  
 541 lhpdfniqny nhdialvqlq epvplgphvm pvcplrepe gpaphmlglv agwgisnprv  
 20 601 tvdeiissgt rtlsdvlqyv klpvvpahac ktsyesrsgn ysvenmfca gyyeggdtkc  
 661 lgdsggafvi fddlsqrwv qglvswggpe ecgskqvygv ytkvsnyvdw vveqmglpqs  
 721 vvepqver

SEQ ID NO: 14

25 NP\_001870 mannan-binding lectin serine protease 1, isoform 1, precursor;  
 protease, serine, 5 (mannose-binding protein-associated); mannan-binding lectin  
 serine protease-1; Ra-reactive factor serine protease p100 [Homo sapiens]  
 gi|21264357|ref|NP\_001870.3||21264357]

30 sig\_peptide 1..19  
 mat\_peptide 20..448 /product="mannan-binding lectin serine protease 1, isoform 1,  
 chain A"  
 variation 21 /allele="I" /allele="T" /db\_xref="dbSNP:1062049"  
 Region 23..138 /region\_name="Domain first found in C1r, C1s, uEGF, and bone  
 35 morphogenetic protein." /note="CUB" /db\_xref="CDD:smart00042"  
 Region 23..135 /region\_name="CUB domain" /note="CUB"  
 /db\_xref="CDD:pfam00431"  
 Region 139..181 /region\_name="Calcium-binding EGF-like domain"  
 /note="EGF\_CA" /db\_xref="CDD:smart00179"  
 40 Region 185..294 /region\_name="CUB domain" /note="CUB"  
 /db\_xref="CDD:pfam00431"  
 Region 190..296 /region\_name="Domain first found in C1r, C1s, uEGF, and bone  
 morphogenetic protein." /note="CUB" /db\_xref="CDD:smart00042"  
 variation 235 /allele="Q" /allele="E" /db\_xref="dbSNP:3203210"  
 45 variation 258 /allele="P" /allele="A" /db\_xref="dbSNP:866085"  
 Region 301..362 /region\_name="Domain abundant in complement control proteins"  
 /note="CCP" /db\_xref="CDD:smart00032"  
 Region 301..362 /region\_name="Sushi domain (SCR repeat)" /note="sushi"  
 /db\_xref="CDD:pfam00084"  
 50 Region 367..432 /region\_name="Domain abundant in complement control proteins"  
 /note="CCP" /db\_xref="CDD:smart00032"  
 Region 367..432 /region\_name="Sushi domain (SCR repeat)" /note="sushi"  
 /db\_xref="CDD:pfam00084"

Region 448..691 /region\_name="Trypsin-like serine protease" /note="Tryp\_SPC"  
 /db\_xref="CDD:smart00020" mat\_peptide 449..699 /product="mannan-binding lectin  
 serine protease 1, isoform 1, chain B"

Region 449..691 /region\_name="Trypsin" /note="trypsin"

/db\_xref="CDD:pfam00089".

Region 644..675 /region\_name="Immunoglobulin A1 protease" /note="IGA1"

/db\_xref="CDD:pfam02395"

CDS 1..699 /gene="MASP1" /coded\_by="NM\_001879.3:51..2150"

/db\_xref="LocusID:5648" /db\_xref="MIM:600521"

ORIGIN 1 mrwllyyal cflskasah tvelnnmfgq iqspgypdsy psdsevtwni tvpdgrfrik  
 61 yfmhfnless ylceydykv etedqlatf cgrettdteq tpgqevvlsp gsfmsitfrs  
 121 dfsneerftg fdahymavdv deckeredee lscdhychny iggyycscr gylhtdnrt  
 181 crvecsdnlf tqrtgvitp dfnpypkss eclytielee gfmvnlqfed ifdiedhpev  
 241 pcpydyikik vgpklvgpfc gekapepist qshsvlilfh sdnsgenrgw rlsyraagne  
 301 cpelqppvhg kiepsqakyf fkdqvlvscd tgykvldnv emdtfqiecl kdgtswnkip  
 361 tckivdcrap gelehglif strnlttyk seikyscqp yykmlnnntg iytsaaggw  
 421 mnkvlgrrlp tclpvcglpk fsrkmarif ngrpaqkgtt pwiamlshln gqpfcgssll  
 481 gsswivtaah clhqsldped ptlrdsdls psdfkiilgk hwrirsdene qhlvgkhtl  
 541 hpqydpntfe ndvalvelle spvlnafvmp icipegpqge gamvivsgwg kqlqrfpet  
 601 lmeieipivd hstcqkayap lkkkvtrdmi cagekeggkd acagdsggpm vtlrnergqw  
 661 ylvgtvswgd dcgkkdrygv ysyihhndw iqrvtgvn

SEQ ID NO: 15

XP\_122683 similar to mannose binding lectin, liver (A) [Mus musculus]

gi|20872845|ref|XP\_122683.1|20872845]

source 1..239 /organism="Mus musculus" /strain="C57BL/6J"

/db\_xref="taxon:10090" /chromosome="14"

Protein 1..239 /product="similar to mannose binding lectin, liver (A)"

Region 126..236 /region\_name="C-type lectin (CTL) or carbohydrate-recognition  
 domain (CRD)" /note="CLECT" /db\_xref="CDD:smart00034"

Region 135..237 /region\_name="Lectin C-type domain" /note="lectin\_c"

/db\_xref="CDD:pfam00059"

CDS 1..239 /gene="Mbl1" /coded\_by="XM\_122683.1:10..729"

/db\_xref="LocusID:17194" /db\_xref="MGD:96923"

ORIGIN 1 mlllpplpv lcvsvsssg sqtcedtlkt csviacgrdg rdgpkgekge pgqglrglqg  
 61 ppgklgppgs vsgpgspgpk gqkgdhgdnr xxxxxxxxxx xxxxxxxxxx xxxxxxhafs  
 121 mgkksgkklf vtnhekmfks kvkslctelq gtvaipnae enkaievat giaflgitde  
 181 ategqfmyvt ggrltsnwk kdepnnhsg edcvildng lwndiscqas fkavcefp

SEQ ID NO:16

AAM21196 C-type mannose-binding lectin [Oncorhynchus mykiss]

gi|20385163|gb|AAM21196.1|AF363271\_120385163]

source 1..185 /organism="Oncorhynchus mykiss" /db\_xref="taxon:8022"

Protein 1..185 /product="C-type mannose-binding lectin"

CDS 1..185 /gene="MBL" /coded\_by="AF363271.1:25..582"

ORIGIN 1 meklaiilll sasiagdan ltqllglepl lktkveqttp eaqveavqeg ikegscpsdw  
 61 ytygshcfkf vsiqqsfvds eqnclalgg lasvhsley qfmqaltkda nghlhwlg  
 121 gfdaiegtw mwsdgsrfdy tnwdtdepnn agegedclhm naasaklwd vpcewkfasl  
 181 csrrm

## SEQ ID NO: 17

AAD45377 mannose-binding lectin [Sus scrofa]  
gi|5566370|gb|AAD45377.1|AF164576\_1[5566370]

5 source 1..240 /organism="Sus scrofa" /db\_xref="taxon:9823" /tissue\_type="liver"  
Protein 1..240 /product="mannose-binding lectin"  
CDS 1..240 /coded\_by="AF164576.1:1..723"

10 ORIGIN 1 mslfplshll livmtasht etencediqn tclviscdsp ginglpqkdg ldgakekge  
61 pgggliglgq lpgmvpgqgs pgipglpglk gqkgdsgidp gnslnlrse ldnkkwlif  
121 aqgkqvqgkkl yltngkkmsf ngvkalcaqf qasvatptns renqaiqela gteafgitd  
181 eyteggfvdI tgrvryqmw ndgepnads aehcveilkd gkwndifcsc qlsavcefp

## SEQ ID NO: 18

15 NP\_034905 mannose binding lectin, liver (A) [Mus musculus]  
gi|6754654|ref|NP\_034905.1|[6754654]

source 1..239 /organism="Mus musculus" /db\_xref="taxon:10090"  
/chromosome="14" /map="14 15.0 cM"  
20 Protein 1..239 /product="mannose binding lectin, liver (A)"  
misc\_feature 19..239 /partial /note="mature protein based on homology to rat MPB-A"  
Region 126..236 /region\_name="C-type lectin (CTL) or carbohydrate-recognition domain (CRD)" /note="CLECT" /db\_xref="CDD:smart00034"  
25 Region 135..237 /region\_name="Lectin C-type domain" /note="lectin\_c"  
/db\_xref="CDD:pfam00059"  
CDS 1..239 /gene="Mbl1" /coded\_by="NM\_010775.1:121..840"  
/db\_xref="LocusID:17194" /db\_xref="MGD:96923"  
ORIGIN 1 mlilplpvl lcvsvsssg sqtcedtlkt csviacgrdg rdgpkgekge pggglrglgq  
30 61 ppgklgppgs vgspspgpk gqkgdhgdnr aieeklanme aeirilkskl qltnklhafs  
121 mgkksqgkklf vtnhekmfks kvkslctelq gtvaiprae enkaivevat gtaflgitde  
181 ategqfmyvt ggrltsnwk kdepnnhgsg edcvildng lwndiscqas fkavcefp

## SEQ ID NO: 19

35 NP\_034906 mannose binding lectin, serum (C) [Mus musculus]  
gi|6754656|ref|NP\_034906.1|[6754656]

source 1..244 /organism="Mus musculus" /strain="BALB/c"  
/sub\_species="domesticus" /db\_xref="taxon:10090" /chromosome="19" /map="19  
40 25.0 cM" /clone="a10" /tissue\_type="liver" /clone\_lib="lambda gt10"  
Protein 1..244 /product="mannose binding lectin, serum (C)"  
sig\_peptide 1..18  
Region 120..241 /region\_name="C-type lectin (CTL) or carbohydrate-recognition domain (CRD)" /note="CLECT" /db\_xref="CDD:smart00034"  
45 Region 140..242 /region\_name="Lectin C-type domain" /note="lectin\_c"  
/db\_xref="CDD:pfam00059"  
CDS 1..244 /gene="Mbl2" /coded\_by="NM\_010776.1:177..911"  
/note="polysaccharide-binding component of RaRF; sequence similarity to mannose-binding proteins" /db\_xref="LocusID:17195" /db\_xref="MGD:96924"  
50 ORIGIN 1 msiftsflil cvvtvyaet ltegvqnsdp vvtcsspgln gfpqkdgrdg akgekgepgg  
61 glrglgpppg kvgtgppgn pglkgavgpk gdrgrdaefd tseidseiaa lrselralrn  
121 wvlfsisekv gkkyfvssvk kmsldrvkal csefgqsvat prnaeensa qkvakdiayl

181 gitdvrvegs fedltgnrvr ytnwndgepn ntgdgedcvv ilgngkwndv pcsdsflaic  
241 efsd

SEQ ID NO: 20

5 AAL14428 dendritic cell-specific ICAM-3 grabbing nonintegrin [Macaca nemestrina]  
gi|16118455|gb|AAL14428.1|AF343727\_1[16118455]

source 1..381 /organism="Macaca nemestrina" /db\_xref="taxon:9545"  
/cell\_type="peripheral blood-derived dendritic cells"

10 Protein 1..381 /product="dendritic cell-specific ICAM-3 grabbing nonintegrin"  
/name="membrane-associated mannose binding lectin"  
CDS 1..381 /coded\_by="AF343727.1:1..1146" /note="DC-SIGN"

ORIGIN 1 msdskeprlq qldlleeeql ggvgfrqtrg ykslagclgh gplvlqlsf tilagllvqv

15 61 skvpsslsqg qskqdaipyqn ltqlkvavse lsekskqqei yqeltrlkaa vgelpekskq  
121 qeiyeeltrl raavgelpek sklqeiyyel trkaavgel pekskqqeiyy qelsrikaav  
181 gdlpekskqq eiyyqkltlk aavdglpdrs kqqeiyyeli qlkaaverlc hpcpwewtff  
241 qgncyfmsns qrnwhdsita cqevgaqlvv ksaeeqnfl qlqssrsnr twmglsdlnh  
301 egtwqwvdgs plpsfkqyw nkgepnvge edcaefsgng wddkcnlak

20 fwickksaas  
361 csgdeerlls papttnppp a

SEQ ID NO: 21

AAF63470 mannose binding-like lectin precursor [Carassius auratus]  
gi|7542474|gb|AAF63470.1|AF227739\_1[7542474]

25 source 1..246 /organism="Carassius auratus" /db\_xref="taxon:7957"  
/tissue\_type="liver"

Protein <1..246 /product="mannose binding-like lectin precursor" /name="collectin"  
sig\_peptide <1..13

30 Region 14..25 /region\_name="N-terminal segment"  
Region 26..93 /region\_name="collagen-like structure"  
Region 60..63 /region\_name="break in collagen structure" Region 94..124  
/region\_name="neck region"

35 Region 125..246 /region\_name="carbohydrate recognition domain" /note="CRD"  
CDS 1..246 /gene="MBL" /coded\_by="AF227739.1:<1..742" /note="collectin with  
structural homology to mannose-binding lectin but with a predicted carbohydrate  
specificity for galactose"

ORIGIN 1 llllqfalql ldgaepqnln cpayggvpgt pghnglpgrd grdgkdgaig pkgekgesgv

40 61 svqgppgkag ppgtagekge rgpsgpqgsp gsesvleslk seiqqkaki atfekvssvc  
121 hfrkvqgkyy itdgvgnfd qglkscmefg gtmvsprtsa enqallklvv ssglgskkpy  
181 igvtdrkteg qfvdteqkql tftnwpgqp ddykglqdcg viedtglwdd ggcgdirpim  
241 ceidik

45 SEQ ID NO: 22

AAF63469 mannose binding-like lectin precursor [Danio rerio]  
gi|7542472|gb|AAF63469.1|AF227738\_1[7542472]

sig\_peptide 1..23

50 mat\_peptide 24..251 /product="mannose binding-like lectin"  
Region 24..36 /region\_name="N-terminal segment"  
Region 37..101 /region\_name="collagen-like structure"  
Region 71..74 /region\_name="break in collagen structure"  
Region 102..132 /region\_name="neck region"

Region 133..251 /region\_name="carbohydrate recognition domain" /note="CRD"  
 CDS 1..251 /gene="mbi" /coded\_by="AF227738.1:68..823" /note="collectin with  
 structural homology to mannose-binding lectin but with a predicted carbohydrate  
 specificity for galactose"

5 ORIGIN 1 mallklflga lllqlvlql magaadpqsl ncpayagvpg tpghnglpgr dgrvgrdgan  
 61 gpkgekgepg vnvqgppgka gppgpagakg ergpsglpgg dcmsdskse lqklsdkial  
 121 iekvvnfktf kkvgqkyvyt ddveetfdkg mqycssngga lvprrteen allkvfvssa  
 181 fklrflritd rekegefvdrt drkklftnw gpnqpdnykg aqdcgaiads glwddvscds  
 241 lypiceiei k

10

SEQ ID NO: 23

AAF63468 mannose binding-like lectin precursor [Cyprinus carpio]  
 gi|7542470|gb|AAF63468.1|AF227737\_1[7542470]

15

sig\_peptide 1..23

mat\_peptide 24..256 /product="mannose binding-like lectin"

Region 24..35 /region\_name="N-terminal segment"

Region 36..103 /region\_name="collagen-like structure"

Region 70..73 /region\_name="break in collagen structure"

20

Region 104..134 /region\_name="neck region"

Region 135..256 /region\_name="carbohydrate recognition domain" /note="CRD"  
 CDS 1..256 /gene="MBL" /coded\_by="AF227737.1:67..837" /note="collectin with  
 structural homology to mannose-binding lectin but with a predicted carbohydrate  
 specificity for galactose"

25

ORIGIN 1 malfklflgt lllqlfalql ldgaepqnl ncpayggvpgt pghnglpgrd grdgkdgaig  
 61 pkgekgesgv svqgppgkag ppgpagekge rgptgsqgsp gsesvleslk seiqqklkaki  
 121 atfekvasvg hfrqvgqky itdgvggtfd qglkfckdfg gtmvfprtsa enqallklvv  
 181 ssglsskkpy igvtdreteg rfvntegkql tftnwpgqp ddykglqdcg viedsglwdd  
 241 gscgdirpim ceidnk

30

SEQ ID NO: 24

AAF21018 mannose-binding lectin 2 [Sus scrofa]  
 gi|6644342|gb|AAF21018.1|AF208528\_1[6644342]

35

source 1..31 /organism="Sus scrofa" /db\_xref="taxon:9823" /chromosome="14"  
 /map="between S0007 and Sw210" Protein <1..>31 /product="mannose-binding  
 lectin 2" /name="MBL2"

CDS 1..31 /gene="MBL2"

/coded\_by="join(AF208528.1:<1..25,AF208528.1:703..>771)"

40

ORIGIN 1 tkgekgepgp gfrgsqgppg kmgppgnige t

SEQ ID NO: 25

AAK30298 mannose-binding lectin precursor protein [Gallus gallus]  
 gi|13561409|gb|AAK30298.1|[13561409]

45

sig\_peptide 1..21

mat\_peptide 22..254 /product="mannose-binding lectin protein"

Region 22..46 /region\_name="N-terminal segment"

Region 47..102 /region\_name="collagen-like"

50

Region 66 /region\_name="break in collagen-like structure"

Region 103..139 /region\_name="neck region"

Region 140..254 /region\_name="carbohydrate recognition domain; CRD"

CDS 1..254 /coded\_by="AF231714.1:242..1006"

ORIGIN 1 mtlqpfsal llclslmmt sltttdkpee kmyscpaiqc sapavnglpg rdgrdgpkge  
 61 kgdpgeglrg lqglpgkagp qglkgevpgp gekgqkgerg ivtddlhrq itdleakirv  
 121 leddlsrykk alsikdvvnv gkkmfvstgk kynfekgksl cakagsvlas prneaental  
 181 kdliidpssqa yigisdaqte grfmylsggp ltysnwkpgge pnnhknedca viedsgkwnd  
 241 ldcnsnifi icel

SEQ ID NO: 26

LNMSMC mannose-binding lectin C precursor – mouse  
 gi|7428747|pir||LNMSMC[7428747]

FEATURES Location/Qualifiers source 1..244 /organism="Mus musculus"  
 /db\_xref="taxon:10090"  
 Protein 1..244 /product="mannose-binding lectin C precursor" /note="Ra-reactive  
 factor P28a"  
 Region 1..18 /region\_name="domain" /note="signal sequence"  
 Region 19..244 /region\_name="product" /note="mannose-binding lectin C"  
 Bond bond(29) /bond\_type="disulfide" /note="interchain"  
 Bond bond(34) /bond\_type="disulfide" /note="interchain"  
 Region 38..94 /region\_name="region" /note="collagen-like"  
 Site 69 /site\_type="modified" /note="4-hydroxyproline (Pro)"  
 Region 124..240 /region\_name="domain" /note="C-type lectin homology #label  
 LCH"

ORIGIN 1 msiftsfll cvvtvyaet ltegvqnsdp vvtcsspgln gfpkgdgrdg akgekgepgg  
 61 glrglqgppg kvgtgppgn pglkgavgpk gdrgrdaefd tseidseiaa lrselralrn  
 121 wvlfslek v gkkyfvssvk kmsldrvkal csefqgsvat pmaeensa qkvakdiayl  
 181 gitdvrvegs fedltgnrvr ytnwndgepn ntgdgedcvv ilngkwndv pcsdsflaic  
 241 efsl

SEQ ID NO: 27

LNMSMA mannose-binding lectin A precursor – mouse  
 gi|625320|pir||LNMSMA[625320]

FEATURES Location/Qualifiers source 1..239 /organism="Mus musculus"  
 /db\_xref="taxon:10090"  
 Protein 1..239 /product="mannose-binding lectin A precursor" /note="Ra-reactive  
 factor P28b; serum mannan-binding protein"  
 Region 1..17 /region\_name="domain" /note="signal sequence"  
 Region 18..238 /region\_name="product" /note="mannose-binding lectin A"  
 Region 36..88 /region\_name="region" /note="collagen-like"  
 Region 119..235 /region\_name="domain" /note="C-type lectin homology #label  
 LCH"

ORIGIN 1 mlllpllpvl lcvsvsssg sqtcedtlkt csviacgrdg rdgpkgekge pgqglrglqg  
 61 ppgklgppgs vgspsgpgpk gqkgdhgdnr aieeklanme aeirilkskl qltnklhafs  
 121 mgkksqgklf vtnhekmpfs kvkslctelq gtvaipnae enkaieqvat giaflgitde  
 181 ateqqfmyvt ggrltsnwk kdepnnhsgs edcvildng lwndiscqas fkavcefpa

SEQ ID NO: 28

LNRTMA mannose-binding lectin A precursor – rat gi|71975|pir||LNRTMA[71975]

FEATURES Location/Qualifiers source 1..238 /organism="Rattus norvegicus"  
 /db\_xref="taxon:10116"

Protein 1..238 /product="mannose-binding lectin A precursor" /note="serum  
mannan-binding protein"  
Region 1..17 /region\_name="domain" /note="signal sequence"  
Region 18..238 /region\_name="product" /note="mannose-binding lectin A"  
5 Region 36..88 /region\_name="region" /note="collagen-like"  
Site 61 /site\_type="modified" /note="4-hydroxyproline (Pro)"  
Site 67 /site\_type="modified" /note="4-hydroxyproline (Pro)"  
Site 73 /site\_type="modified" /note="4-hydroxyproline (Pro)"  
Site 79 /site\_type="modified" /note="lysine derivative (Lys) (probably 5-  
10 hydroxylysine)"  
Site 82 /site\_type="modified" /note="lysine derivative (Lys) (probably 5-  
hydroxylysine)"  
Region 85..87 /region\_name="region" /note="cell attachment (R-G-D) motif"  
Region 118..234 /region\_name="domain" /note="C-type lectin homology #label  
15 LCH"

ORIGIN 1 mlllpllvll cvsvsssgs qtceetkic sviacgrdgr dgpkgekgep gqglrglqgp  
61 pgklgppgsv gapgsqgpgk qkgdrgrdsra ievklanmea eintlkskle ltnklhafsm  
121 gkksqgkffv tnhermpfsk vkalcseirg tvaipnaee nkaiqevakt saflgitdev  
20 181 tegqfmyvtg grltysnwkk depndhgsge dcvtivdngl wndiscqash tavcefp

SEQ ID NO: 29  
LNRTMC mannanose-binding lectin C precursor – rat gi|71974|pir||LNRTMC[71974]  
FEATURES Location/Qualifiers source 1..244 /organism="Rattus norvegicus"  
25 /db\_xref="taxon:10116"  
Protein 1..244 /product="mannose-binding lectin C precursor"  
Region 1..18 /region\_name="domain" /note="signal sequence"  
Region 19..244 /region\_name="product" /note="mannose-binding lectin C"  
Bond bond(29) /bond\_type="disulfide" /note="interchain"  
30 Bond bond(34) /bond\_type="disulfide" /note="interchain"  
Region 38..94 /region\_name="region" /note="collagen-like"  
Site 69 /site\_type="modified" /note="4-hydroxyproline (Pro)"  
Region 124..240 /region\_name="domain" /note="C-type lectin homology #label  
LCH"  
35 ORIGIN 1 mslftslll cvltavyaet ltegaqsscp viacsspqln gfpkgdghdg akgekgepgg  
61 glrglqgppg kvpagppgn pgskgatgpk gdrgevefd ttnidleiaa lrselramrk  
121 wllmseniv gkkyfmssvr rmlnrakal cselqgtvat prnaeenrai qnvakdvaf  
181 gitdqrtenv fedltgnrvr ytnwnegepn nvsggencvv lltngkwndv pcsdsflvvc  
241 efsd  
40

SEQ ID NO: 30  
LNHUMC mannanose-binding lectin precursor – human gi|71973|pir||LNHUMC[71973]  
FEATURES Location/Qualifiers source 1..248 /organism="Homo sapiens"  
45 /db\_xref="taxon:9606"  
Protein 1..248 /product="mannose-binding lectin precursor" /note="mannan-binding  
protein"  
Region 1..20 /region\_name="domain" /note="signal sequence"  
Region 21..248 /region\_name="product" /note="mannose-binding lectin"  
Region 42..99 /region\_name="region" /note="collagen-like"  
50 Site 47 /site\_type="modified" /note="4-hydroxyproline (Pro) (partial)"  
Site 73 /site\_type="modified" /note="4-hydroxyproline (Pro) (partial)"  
Site 79 /site\_type="modified" /note="4-hydroxyproline (Pro) (partial)"  
Site 82 /site\_type="modified" /note="4-hydroxyproline (Pro) (partial)"

Site 88 /site\_type="modified" /note="4-hydroxyproline (Pro) (partial)"  
 Region 128..244 /region\_name="domain" /note="C-type lectin homology #label  
 LCH"

ORIGIN 1 mslfplplllsmvaasys etvtcedaqk tcpaviacss pgingfpgkd grdgtkgek  
 61 epgqglrglq gppgklgppg npgpsgspg kgqkgdpgks pdgdsslaas erkalqtema  
 121 rikkwltfsl gkqvgnkffl tngeimtfek vkalcvkfqa svatprnaae ngaiqnlike  
 181 eafllgitdek tegqfvdltg nrlytnwne gepnnagsde dcvlllkngq wndvpctsh  
 241 lavcefp

10 SEQ ID NO: 31  
 BAA86864 complement C1s [Homo sapiens] gi|6407558|dbj|BAA86864.1|[6407558]

15 FEATURES Location/Qualifiers source 1..329 /organism="Homo sapiens"  
 /db\_xref="taxon:9606" /tissue\_type="peripheral leukocytes" /clone\_lib="FIXII"  
 Protein 1..329 /product="complement C1s"  
 CDS 1..329 /coded\_by="join(AB009076.1:1142..1146,  
 AB009076.1:1703..1910,AB009076.1:2118..2295,  
 AB009076.1:3495..3620,AB009076.1:4328..4527,  
 AB009076.1:5047..5200,AB009076.1:5748..>5863)" /note="This gene consists of  
 20 total 12 exons, the last 4 exons of which were reported by Toshi, M. et al. (J. Mol. Biol.  
 208:709-714, 1989)

ORIGIN 1 mwcivlfsll awvyaeptmy geilspnypq aypseveksw dievpegygi hlyfthldie  
 61 lsencaydsv qisgdtteeg rlcqgrssnn phspiveefq vpynklqvif ksdfsneerf  
 121 tgfaayvat dinectdfvd vpcshfcnnf iggyfcscpp eyflhddmkn cgvnscgdvf  
 25 181 taligeiasp nykpypens rceyqirlek gfqvvtlrr edfdveaads agncldslvf  
 241 vagdrqfgy cghgfppln ietksnaldi ifqtdltgqk kgwklryhgd pmpcpkedtp  
 301 nsvwepakak yvfrdvvqit cldgfeve

30 SEQ ID NO: 32  
 CAB56124 mannose-binding lectin [Homo sapiens]  
 gi|5911809|emb|CAB56124.1|[5911809]

35 FEATURES Location/Qualifiers source 1..248 /organism="Homo sapiens"  
 /db\_xref="taxon:9606" /chromosome="10" /map="10q11.2-q21" /note="MBL  
 haplotype HYPD"  
 Protein 1..248 /product="mannose-binding lectin"  
 sig\_peptide 1..20  
 CDS 1..248 /gene="MBL" /coded\_by="Y16582.1:892..1638"  
 ORIGIN 1 mslfplplllsmvaasys etvtcedaqk tcpaviacss pgingfpgkd gcdgtkgek  
 40 61 epgqglrglq gppgklgppg npgpsgspg kgqkgdpgks pdgdsslaas erkalqtema  
 121 rikkwltfsl gkqvgnkffl tngeimtfek vkalcvkfqa svatprnaae ngaiqnlike  
 181 eafllgitdek tegqfvdltg nrlytnwne gepnnagsde dcvlllkngq wndvpctsh  
 241 lavcefp

45 SEQ ID NO: 33  
 CAB56123 mannose-binding lectin [Homo sapiens]  
 gi|5911807|emb|CAB56123.1|[5911807]

50 FEATURES Location/Qualifiers source 1..248 /organism="Homo sapiens"  
 /db\_xref="taxon:9606" /chromosome="10" /map="10q11.2-q21" /note="MBL  
 haplotype HYPA"  
 Protein 1..248 /product="mannose-binding lectin"  
 sig\_peptide 1..20



CDS 1..248 /gene="MBL" /coded\_by="Y16581.1:892..1638"

ORIGIN 1 mslfpslpll lsmvaasys etvtcedaqk tcpaviacss pgingfpgkd grdgtkgekg  
 61 epgqglrglq gppgklgppg nppsgsgpgp kgqkgdpgks pdgdsslaas erkalqtema  
 121 rikkwltfsl gkqvgnkffl tgeimtfek vkalcvkfqa svatprnaae ngaiqnlike  
 181 eafllgitdek tegqfvdltg nrlytnwne gepnnagsde dcvlllkngq wndvpcstsh  
 241 lavcefp

SEQ ID NO: 34

CAB56122 mannose-binding lectin [Homo sapiens]

gi|5911798|emb|CAB56122.1|[5911798]

FEATURES Location/Qualifiers source 1..248 /organism="Homo sapiens"  
 /db\_xref="taxon:9606" /chromosome="10" /map="10q11.2-q21" /note="MBL  
 haplotype LXPA"

Protein 1..248 /product="mannose-binding lectin"

sig\_peptide 1..20

CDS 1..248 /gene="MBL" /coded\_by="Y16580.1:892..1638"

ORIGIN 1 mslfpslpll lsmvaasys etvtcedaqk tcpaviacss pgingfpgkd grdgtkgekg  
 61 epgqglrglq gppgklgppg nppsgsgpgp kgqkgdpgks pdgdsslaas erkalqtema  
 121 rikkwltfsl gkqvgnkffl tgeimtfek vkalcvkfqa svatprnaae ngaiqnlike  
 181 eafllgitdek tegqfvdltg nrlytnwne gepnnagsde dcvlllkngq wndvpcstsh  
 241 lavcefp

SEQ ID NO: 35

CAB56121 mannose-binding lectin [Homo sapiens]

gi|5911796|emb|CAB56121.1|[5911796]

FEATURES Location/Qualifiers source 1..248 /organism="Homo sapiens"  
 /db\_xref="taxon:9606" /chromosome="10" /map="10q11.2-q21" /note="MBL  
 haplotype LYPB"

Protein 1..248 /product="mannose-binding lectin"

sig\_peptide 1..20

CDS 1..248 /gene="MBL" /coded\_by="Y16579.1:892..1638"

ORIGIN 1 mslfpslpll lsmvaasys etvtcedaqk tcpaviacss pgingfpgkd grddtkgekg  
 61 epgqglrglq gppgklgppg nppsgsgpgp kgqkgdpgks pdgdsslaas erkalqtema  
 121 rikkwltfsl gkqvgnkffl tgeimtfek vkalcvkfqa svatprnaae ngaiqnlike  
 181 eafllgitdek tegqfvdltg nrlytnwne gepnnagsde dcvlllkngq wndvpcstsh  
 241 lavcefp

SEQ ID NO: 36

CAB56045 mannose-binding lectin [Homo sapiens]

gi|5911794|emb|CAB56045.1|[5911794]

/organism="Homo sapiens" /db\_xref="taxon:9606" /chromosome="10"

/map="10q11.2-q21" /note="MBL haplotype LYQC"

Protein 1..248 /product="mannose-binding lectin"

sig\_peptide 1..20

CDS 1..248 /gene="MBL" /coded\_by="Y16578.1:886..1632"

ORIGIN 1 mslfpslpll lsmvaasys etvtcedaqk tcpaviacss pgingfpgkd grdtkkekg  
 61 epgqglrglq gppgklgppg nppsgsgpgp kgqkgdpgks pdgdsslaas erkalqtema  
 121 rikkwltfsl gkqvgnkffl tgeimtfek vkalcvkfqa svatprnaae ngaiqnlike  
 181 eafllgitdek tegqfvdltg nrlytnwne gepnnagsde dcvlllkngq wndvpcstsh  
 241 lavcefp

SEQ ID NO: 37

CAB56120 mannanose-binding lectin [Homo sapiens]

gi|5911792|emb|CAB56120.1|[5911792]

5 FEATURES Location/Qualifiers source 1..248 /organism="Homo sapiens"  
 /db\_xref="taxon:9606" /chromosome="10" /map="10q11.2-q21" /note="MBL  
 haplotype LYPA"

Protein 1..248 /product="mannose-binding lectin"

sig\_peptide 1..20

10 CDS 1..248 /gene="MBL" /coded\_by="Y16577.1:892..1638"

ORIGIN 1 msifpslplllsmvaasys etvtcedaqq tcpaviacss pgingfpgkd grdgtkgekg  
 61 epgqglrglq gppgklgppg nppsgsgppg kgqkgdpgks pdgdsslaas erkalqtema  
 121 rikkwltfsl gkqvgnkffl tngeimtfek vkalcvkfqa svatprnaae ngaiqnlike  
 181 eafllgitdek tegqfvdltg nritytnwne gepnnagsde dcvlilkngq wndvpcstsh  
 15 241 lavcefp

SEQ ID NO: 38

CAB56044 mannanose-binding lectin [Homo sapiens]

gi|5911790|emb|CAB56044.1|[5911790]

20 FEATURES Location/Qualifiers source 1..248 /organism="Homo sapiens"  
 /db\_xref="taxon:9606" /chromosome="10" /map="10q11.2-q21" /note="MBL  
 haplotype LYQA"

Protein 1..248 /product="mannose-binding lectin"

sig\_peptide 1..20

25 CDS 1..248 /gene="MBL" /coded\_by="Y16576.1:886..1632"

ORIGIN 1 msifpslplllsmvaasys etvtcedaqq tcpaviacss pgingfpgkd grdgtkgekg  
 61 epgqglrglq gppgklgppg nppsgsgppg kgqkgdpgks pdgdsslaas erkalqtema  
 121 rikkwltfsl gkqvgnkffl tngeimtfek vkalcvkfqa svatprnaae ngaiqnlike  
 181 eafllgitdek tegqfvdltg nritytnwne gepnnagsde dcvlilkngq wndvpcstsh  
 30 241 lavcefp

SEQ ID NO: 39

AAB53110 C1qR(p) [Homo sapiens] gi|2052498|gb|AAB53110.1|[2052498]

35 FEATURES Location/Qualifiers source 1..652 /organism="Homo sapiens"  
 /db\_xref="taxon:9606" /cell\_line="U937 histiocytic cell line"  
 Protein 1..652 /product="C1qR(p)" /function="mediates enhanced phagocytosis by  
 human monocytes and macrophages in response to complement C1q, mannose  
 binding lectin (MBL) and pulmonary surfactant protein A (SPA)"

40 CDS 1..652 /coded\_by="U94333.1:149..2107" /note="C1q/MBL/SPA receptor"

ORIGIN 1 matsmgllllllltqpga gtgadteavv cvgtacytah sgklisaaeq nhcnqnggnl

61 atvkskeeaq hvqrvlaql rreaaltarm skfwiglqre kgkldpslp lkgfswvggg  
 121 edtpysnwhk elrnsciskr cvslldlsq plpnrlpkw segpcgspgs pgsniegfv  
 181 kfsfkgmcrp lalggpgqvt yttfqtss sleavpfasa arvacgegdk detqshyflc  
 45 241 kekapdvfdw gssgplcvsp kygcfnngg chqdcfeggd gsfclgcrpg frliddlvtc  
 301 asrnpccssp crggatcvlg phgknytrc pqgyldssq ldcvldvdecq dspcaqecvn  
 361 tpggfrcecw vgyepggpge gacqdvdeca lgrspcaqgc tntdgsfhcs ceegyvlage  
 421 dgtqcqdvde cvgpggplcd slcfntqgsf hcgcldpgwvl apngvsctmg pvsigppsgp  
 481 pdeedkgeke gstvpraata sprtgegtk katpttsrps lssdapitsa plkmllaps  
 50 541 sgwvrepsh hataasgpqe paggdssvat qnndgtgdk lllfyllgtv vaillllala  
 601 lgllyvrkrr akreekkekk pqnaadsysw vperaesram enqysptpgt dc

SEQ ID NO: 40

NP\_571645 mannose binding-like lectin [Danio rerio]  
gi|18858997|ref|NP\_571645.1|[18858997]

sig\_peptide 1..23

5 mat\_peptide 24..251 /product="mannose binding-like lectin"  
Region 24..36 /region\_name="N-terminal segment"  
Region 33..70 /region\_name="Collagen triple helix repeat (20 copies)"  
/note="Collagen" /db\_xref="CDD:pfam01391"  
Region 33..70 /region\_name="Collagen triple helix repeat (20 copies)"  
10 /note="Collagen" /db\_xref="CDD:pfam01391"  
Region 37..101 /region\_name="collagen-like structure"  
Region 37..70 /region\_name="Collagen triple helix repeat (20 copies)"  
/note="Collagen" /db\_xref="CDD:pfam01391"  
Region 71..74 /region\_name="break in collagen structure"  
15 Region 102..132 /region\_name="neck region"  
Region 133..251 /region\_name="carbohydrate recognition domain" /note="CRD"  
Region 134..247 /region\_name="C-type lectin (CTL) or carbohydrate-recognition  
domain (CRD)" /note="CLECT" /db\_xref="CDD:smart00034"  
Region 146..247 /region\_name="Lectin C-type domain" /note="lectin\_c"  
20 /db\_xref="CDD:pfam00059"  
CDS 1..251 /gene="mbi" /coded\_by="NM\_131570.1:68..823" /note="collectin with  
structural homology to mannose-binding lectin but with a predicted carbohydrate  
specificity for galactose;mannose binding-like lectin" /db\_xref="LocusID:58091"  
ORIGIN 1 mallklflga lllqlvlql magaadpqsI ncpayagvpg tpghnglpgr dgrvgrdgan  
25 61 gpkgekgpg vnvqgppgka gppgpagakg ergpsglpgq dcmsdskse lqlskdial  
121 iekvvnfktf kkvgqkyvyt ddveetfdkg mqycssngga lvprtlelen allkvfssa  
181 fkrfiritd rekegefvdtdrkkltftnw gpnqpdnykg aqdcgaiads glwddvscds  
241 lypiiceiei k

30 SEQ ID NO: 41

BAA90338 mannose-binding lectin-associated serine protease (MASP) related  
protein [Cyprinus carpio] gi|6807499|dbj|BAA90338.1|[6807499]  
FEATURES Location/Qualifiers source 1..118 /organism="Cyprinus carpio"  
/db\_xref="taxon:7962"  
35 Protein 1..118 /product="mannose-binding lectin-associated serine protease  
(MASP) related protein"  
CDS 1..118 /gene="MRPb"  
/coded\_by="join(AB030447.1:<1..96,AB030447.1:201..319,  
AB030447.1:436..514,AB030447.1:616..680)" /note="MASP-related protein"  
40 ORIGIN 1 kiqtgsntvs ilfhdsngsd nlgwkltyts tgsecsplaa plnghleplq snyifkdhim  
61 ltcdpgyslr qgdkefehyq iecqrdgkws sdvplckkke sqrrhrslps iltnqils

45 The second polypeptide preferably comprises at least 10, such as at least 12, for  
example at least 15, such as at least 20, for example at least 25, such as at least  
30, for example at least 35, such as at least 40, for example at least 50 consecutive  
amino acid residues of the collectin or of a variant or a homologue to said protein.  
Such a variant or homologue is preferably at least 70%, such as 80%, for example  
50 90%, such as 95% identical to the collectin.

In a preferred embodiment the second polypeptide sequence comprises the CRD domain of MBL or the neck region of MBL or the collagen-like domain of MBL. More preferably the second polypeptide comprises the neck region and the CRD domain of MBL. In a most preferred embodiment the second polypeptide sequence comprises the collagen-like domain, the neck region and the CRD domain of MBL. MBL is as defined above.

Preferably the second polypeptide sequence comprises at least amino acids 170-200 of the MBL sequence shown in Figure 2, such as at least amino acids 160-200 of the MBL sequence shown in Figure 2, such as at least amino acids 150-200 of the MBL sequence shown in Figure 2, such as at least amino acids 140-200 of the MBL sequence shown in Figure 2, such as at least amino acids 130-200 of the MBL sequence shown in Figure 2, such as at least amino acids 120-200 of the MBL sequence shown in Figure 2, such as at least amino acids 110-200 of the MBL sequence shown in Figure 2, such as at least amino acids 100-200 of the MBL sequence shown in Figure 2, such as at least amino acids 90-200 of the MBL sequence shown in Figure 2, such as at least amino acids 80-200 of the MBL sequence shown in Figure 2, such as at least amino acids 70-200 of the MBL sequence shown in Figure 2, such as at least amino acids 60-200 of the MBL sequence shown in Figure 2, such as at least amino acids 80-228 of the MBL sequence shown in Figure 2.

Preferably the second polypeptide sequence comprises amino acids 80-228 of SEQ ID. NO 2.

In a preferred embodiment the second polypeptide sequence is capable of associating with at least one MASP protein, such as a MASP protein selected from the group consisting of MASP-1, MASP-2 and MASP-3 or functional homologues or variants hereof. In particular the second polypeptide is capable of associating with said at least one MASP protein when being part of the fusion protein. Thereby the second polypeptide sequence is capable of providing the fusion protein with complement system activating activity. In a preferred embodiment the second polypeptide sequence comprises an amino acid sequence selected from: 56-228 of SEQ ID. NO 2, 55-228 of SEQ ID. NO 2, 54-228 of SEQ ID. NO 2, and 50-228 of SEQ ID.

NO 2. In a preferred embodiment the second polypeptide sequence has an amino acid sequence selected from: 56-228 of SEQ ID. NO 2, 55-228 of SEQ ID. NO 2, 54-228 of SEQ ID. NO 2, and 50-228 of SEQ ID. NO 2.

- 5 In another embodiment the second polypeptide comprises the cysteine-rich region of the collectin, such as the N-terminal region of the collectin.

#### **Fusion protein**

- 10 The fusion protein comprises the first and the second polypeptide connected to each other, optionally through a linker region. In a preferred embodiment the first polypeptide sequence is positioned N-terminally in the fusion protein and the second polypeptide sequence is positioned C-terminally.

- 15 Specific examples of the components of the fusion protein are:

- A fusion protein comprising the cysteine-rich region and the collagen-like domain of L-ficolin and the CRD domain of MBL.

- 20 - A fusion protein comprising the cysteine-rich region of L-ficolin and the collagen-like domain, the neck region and the CRD domain of MBL.

- A fusion protein comprising the cysteine-rich region and the collagen-like domain of H-ficolin and the CRD domain of MBL.

- 25 - A fusion protein comprising the cysteine-rich region of H-ficolin and the collagen-like domain, the neck region and the CRD domain of MBL.

- 30 - A fusion protein comprising the cysteine-rich region and the collagen-like domain of M-ficolin and the CRD domain of MBL.

- A fusion protein comprising the cysteine-rich region of M-ficolin and the collagen-like domain, the neck region and the CRD domain of MBL.

- A fusion protein comprising the cysteine-rich region of MBL, and the CRD domain of ficolin.
- A fusion protein comprising the cysteine-rich region of MBL and the collagen-like domain, the neck region and the CRD domain of ficolin.
- A fusion protein comprising the cysteine-rich region and the collagen-like domain of L-ficolin and the CRD domain of Pulmonary surfactant-associated protein D.
- A fusion protein comprising the cysteine-rich region of L-ficolin and the collagen-like domain, the neck region and the CRD domain of Pulmonary surfactant-associated protein D.
- A fusion protein comprising the cysteine-rich region and the collagen-like domain of a ficolin and the CRD domain of a collectin-43.
- A fusion protein comprising the cysteine-rich region of a ficolin and the collagen-like domain, the neck region and the CRD domain of a collectin-43.
- A fusion protein comprising the amino acid sequence as defined by the sequence shown in Figure 3, or a functional homologue thereof, preferably a fusion protein consisting of the amino acid sequence as shown in Figure 3. In another embodiment the fusion protein has amino acid sequence 1-50 of the amino acid shown in Figure 1 and amino acid sequence 54-228 of the amino acid sequence shown in Figure 2.
- As discussed above the fusion protein is preferably capable of forming subunit complexes as well as oligomers of subunit complexes. Preferably the fusion protein forms substantially only trimeric, tetrameric, pentameric and hexameric subunit oligomers, such as trimeric, tetrameric, and pentameric subunit oligomers, such as trimeric or tetrameric subunit oligomers, more preferably substantially only tetrameric subunit oligomers, in order to obtain a more homogenous composition of fusion proteins.

Homologues

5 In the present context the terms homologue or variant or functional homologues are used as synonyms, wherein a homologue of a protein exhibits one or more substitutions, deletions, and/or additions of one or more amino acid residues. Fragments are a subgroup of homologues being truncations of the protein.

10 A homologue of the protein may comprise one or more conservative amino acid substitutions, such as at least 2 conservative amino acid substitutions, for example at least 3 conservative amino acid substitutions, such as at least 5 conservative amino acid substitutions, for example at least 10 conservative amino acid substitutions, such as at least 20 conservative amino acid substitutions, for example at least  
15 50 conservative amino acid substitutions such as at least 75 conservative amino acid substitutions, for example at least 100 conservative amino acid substitutions. Conservative amino acid substitutions within the meaning of the present invention is substitution of one amino acid within a predetermined group of amino acids for another amino acid within the same predetermined group, exhibiting similar or substantially similar characteristics. Such predetermined groups are for example:

polar side chains (Asp, Glu, Lys, Arg, His, Asn, Gln, Ser, Thr, Tyr, and Cys,)

non-polar side chains (Gly, Ala, Val, Leu, Ile, Phe, Trp, Pro, and Met)

25 aliphatic side chains (Gly, Ala Val, Leu, Ile)

cyclic side chains (Phe, Tyr, Trp, His, Pro)

30 aromatic side chains (Phe, Tyr, Trp)

acidic side chains (Asp, Glu)

basic side chains (Lys, Arg, His)

35

amide side chains (Asn, Gln)

hydroxy side chains (Ser, Thr)

5 sulphur-containing side chains (Cys, Met), and

amino acids being monoamino-dicarboxylic acids or monoamino-monocarboxylic-monoamidocarboxylic acids (Asp, Glu, Asn, Gln).

10 Conservative substitutions may be introduced in any position of a preferred protein. It may however also be desirable to introduce non-conservative substitutions. A non-conservative substitution should lead to the formation of a homologue of a protein capable of exerting a function similar to the function of said protein. Such substitution could for example i) differ substantially in hydrophobicity, for example a hydrophobic residue (Val, Ile, Leu, Phe or Met) substituted for a hydrophilic residue such as Arg, Lys, Trp or Asn, or a hydrophilic residue such as Thr, Ser, His, Gln, Asn, Lys, Asp, Glu or Trp substituted for a hydrophobic residue; and/or ii) differ substantially in its effect on polypeptide backbone orientation such as substitution of or for Pro or Gly by another residue; and/or iii) differ substantially in electric charge, for example substitution of a negatively charged residue such as Glu or Asp for a positively charged residue such as Lys, His or Arg (and vice versa); and/or iv) differ substantially in steric bulk, for example substitution of a bulky residue such as His, Trp, Phe or Tyr for one having a minor side chain, e.g. Ala, Gly or Ser (and vice versa).

25 In a further embodiment the present invention relates to homologues of a preferred protein, wherein such homologues comprise substituted amino acids having hydrophilic or hydrophobic indices that are within  $\pm 2.5$ , for example within  $\pm 2.3$ , such as within  $\pm 2.1$ , for example within  $\pm 2.0$ , such as within  $\pm 1.8$ , for example within  $\pm 1.6$ , such as within  $\pm 1.5$ , for example within  $\pm 1.4$ , such as within  $\pm 1.3$  for example within  $\pm 1.2$ , such as within  $\pm 1.1$ , for example within  $\pm 1.0$ , such as within  $\pm 0.9$ , for example within  $\pm 0.8$ , such as within  $\pm 0.7$ , for example within  $\pm 0.6$ , such as within  $\pm 0.5$ , for example within  $\pm 0.4$ , such as within  $\pm 0.3$ , for example within  $\pm 0.25$ , such as within  $\pm 0.2$  of the value of the amino acid it has substituted.

35



The importance of the hydrophilic and hydrophobic amino acid indices in conferring interactive biologic function on a protein is well understood in the art (Kyte & Doolittle, 1982 and Hopp, U.S. Pat. No. 4,554,101, each incorporated herein by reference).

5

The amino acid hydrophobic index values as used herein are: isoleucine (+4.5); valine (+4.2); leucine (+3.8); phenylalanine (+2.8); cysteine/cystine (+2.5); methionine (+1.9); alanine (+1.8); glycine (-0.4); threonine (-0.7); serine (-0.8); tryptophan (-0.9); tyrosine (-1.3); proline (-1.6); histidine (-3.2); glutamate (-3.5); glutamine (-3.5); aspartate (-3.5); asparagine (-3.5); lysine (-3.9); and arginine (-4.5) (Kyte & Doolittle, 1982).

10

The amino acid hydrophilicity values are: arginine (+3.0); lysine (+3.0); aspartate (+3.0,+-1); glutamate (+3.0,+-1); serine (+0.3); asparagine (+0.2); glutamine (+0.2); glycine (0); threonine (-0.4); proline (-0.5,+-1); alanine (-0.5); histidine (-0.5); cysteine (-1.0); methionine (-1.3); valine (-1.5); leucine (-1.8); isoleucine (-1.8); tyrosine (-2.3); phenylalanine (-2.5); tryptophan (-3.4) (U.S. 4,554,101).

15

Substitution of amino acids can therefore in one embodiment be made based upon their hydrophobicity and hydrophilicity values and the relative similarity of the amino acid side-chain substituents, including charge, size, and the like. Exemplary amino acid substitutions which take various of the foregoing characteristics into consideration are well known to those of skill in the art and include: arginine and lysine; glutamate and aspartate; serine and threonine; glutamine and asparagine; and valine, leucine and isoleucine.

20

25

Furthermore, a homologue may comprise addition or deletion of an amino acid, for example an addition or deletion of from 2 to 100 amino acids, such as from 2 to 50 amino acids, for example from 2 to 20 amino acids, such as from 2 to 10 amino acids, for example from 2 to 5 amino acids, such as from 2 to 3 amino acids. However, additions of more than 100 amino acids, such as additions from 100 to 500 amino acids, are also comprised within the present invention.

30

35

Proteins sharing at least some homology with a preferred protein are to be considered as falling within the scope of the present invention when they are at least about

40 percent homologous, or preferably identical, with the preferred protein, such as at least about 50 percent homologous, or preferably identical, for example at least about 60 percent homologous, or preferably identical, such as at least about 70 percent homologous, or preferably identical, for example at least about 75 percent homologous, or preferably identical, such as at least about 80 percent homologous, or preferably identical, for example at least about 85 percent homologous, or preferably identical, such as at least about 90 percent homologous, or preferably identical, for example at least 92 percent homologous, or preferably identical, such as at least 94 percent homologous, or preferably identical, for example at least 95 percent homologous, or preferably identical, such as at least 96 percent homologous, or preferably identical, for example at least 97 percent homologous, or preferably identical, such as at least 98 percent homologous, or preferably identical, for example at least 99 percent homologous, or preferably identical, with the preferred protein.

Preferred proteins are complement activating proteins comprising collectins and lectins and homologues hereof.

#### Homologues of collectins

A homologue of a collectin including MBL within the scope of the present invention should be understood as any protein capable of exerting a function similar to the function of a collectin and comprising one or more of the variations described above. In particular such function is the ability to activate complement upon binding to one or more carbohydrates.

The terms functional homologues of collectin used herein relate to functional equivalents or a fragment of collectin comprising a predetermined amino acid sequence, and such homologues are defined as:

- a) A homologue comprising an amino acid sequence capable of recognising and binding to glucans, lipophosphoglycans and glycoinositol phospholipids that contain sugar with 3- and 4-hydroxyl groups in the pyranose ring (i.e. Man, Glc, Fuc or GlcNAc) either alone or when being subunit complexed as described above and/or

- b) A homologue comprising an amino acid sequence capable of forming an association with a component of the Lectin/MBL pathway such as binding to the MASP-1, MASP-2, MASP-3 and/or sMAP either alone or when being subunit complexed as described above, wherein said binding result in activation of the Lectin/MBL pathway and/or
- c) A homologue comprising an amino acid sequence capable of by the collagen-like domain forming an oligomeric structure of two or more subunits, where a subunit comprises three identical polypeptides of a cysteine-rich region, a collagen-like domain, a neck region and a carbohydrate recognition domain.

### Homologues of lectins

A homologue of a lectin including ficolins within the scope of the present invention should be understood as any protein capable of exerting a function similar to the function of a lectin and comprising one or more of the variations previously described. In particular such function is the ability to activate complement upon binding to one or more carbohydrates.

The terms functional homologues of lectin used herein relate to functional equivalents of a fragment of lectin comprising a predetermined amino acid sequence, and such homologues are defined as:

- a) A homologue comprising an amino acid sequence capable of recognising and binding to N-acetyl-glucosamine (GlcNAc), or N-acetyl-galactosamine (GalNAc), or elastin either alone or when being subunit complexed as described above and/or
- b) A homologue comprising an amino acid sequence capable of forming an association with a component of the Lectin/MBL pathway such as binding to the MASP-1, MASP-2, MASP-3 and/or sMAP either alone or when being subunit complexed as described above, wherein said binding result in activation of the Lectin/MBL pathway and/or

- c) A homologue comprising an amino acid sequence capable of by the collagen-like domain forming an oligomeric structure of two or more subunits, where a subunit comprises three identical polypeptides of a cysteine-rich region, a collagen-like domain, a neck region and a fibrinogen-like domain.

5

The activation of the lectin/MBL pathway, i.e. the activity of the fusion protein to activate the complement system may be assessed by assessing the C4 cleaving effect of the fusion protein or subunit complexes or oligomers of complexes thereof by the following method comprising the steps of

10

- applying a sample comprising a predetermined amount of fusion protein as well as a predetermined amount of MASP-1, MASP-2 or MASP-3,
- applying at least one complement factor to the sample,
- detecting the amount of cleaved complement factors,
- correlating the amount of cleaved complement factors to the amount of fusion protein, and
- determining the activity of the fusion protein.

15

20

25

The complement factor preferably used in the present method is a complement factor cleavable by the MBL/MASP-2 complex, such as C4. However, the complement factor may also be selected from C3 and C5.

30

The cleaved complement factor may be detected by a variety of means, such as by of antibodies directed to the cleaved complement factor.

The assay is carried out at conditions which minimize or eliminate interference from the classical complement activation pathway and the alternative complement activation pathway.

Preferably a homologue of a collectin and/or a lectin exhibits two of the functions defined above, more preferably three of the functions defined above.

### **Preparation of fusion protein**

5

The fusion protein may be prepared by any suitable method known to the person skilled in the art. Below are described several of the methods for preparing the fusion protein, however the invention is not limited to those methods.

10

#### **Synthetic preparation**

15

When appropriate, in particular in relation to the size of the fusion protein, the fusion protein may be produced synthetically. The methods for synthetic production of peptides are well known in art. Detailed descriptions as well as practical advice for producing synthetic peptides may be found in Synthetic Peptides: A User's Guide (Advances in Molecular Biology), Grant G. A. ed., Oxford University Press, 2002, or in: Pharmaceutical Formulation: Development of Peptides and Proteins, Frokjaer and Hovgaard eds., Taylor and Francis, 1999.

20

#### **Recombinant preparation**

25

The fusion proteins of the invention are preferably produced by use of recombinant DNA technologies. The DNA sequence encoding each part of the fusion protein may be prepared by fragmentation of the DNA sequences encoding the full-length protein, (genomic DNA or cDNA) which the fusion protein part is derived from, using DNAase I according to a standard protocol (Sambrook et al., Molecular cloning: A Laboratory manual. 2<sup>rd</sup> ed., CSHL Press, Cold Spring Harbor, NY, 1989). The obtained DNA sequences encoding the individual parts of the fusion protein may then be fused together.

30

The DNA sequence may also be prepared by polymerase chain reaction using specific primers, for instance as described in US 4,683,202 or Saiki et al., 1988, Science 239:487-491.

The DNA sequence encoding a fusion protein of the invention may be prepared synthetically by established standard methods, e.g. the phosphoamidite method described by Beaucage and Caruthers, 1981, Tetrahedron Lett. 22:1859-1869, or the method described by Matthes et al., 1984, EMBO J. 3:801-805. According to the  
5 phosphoamidite method, oligonucleotides are synthesized, e.g. in an automatic DNA synthesizer, purified, annealed, ligated and cloned in suitable vectors.

The DNA sequence is then inserted into a recombinant expression vector, which may be any vector, which may conveniently be subjected to recombinant DNA pro-  
10 cedures. The choice of vector will often depend on the host cell into which it is to be introduced. Thus, the vector may be an autonomously replicating vector, i.e. a vector that exists as an extrachromosomal entity, the replication of which is independent of chromosomal replication, e.g. a plasmid. Alternatively, the vector may be one which, when introduced into a host cell, is integrated into the host cell genome and  
15 replicated together with the chromosome(s) into which it has been integrated.

In the vector, the DNA sequence encoding a fusion protein should be operably connected to a suitable promoter sequence. The promoter may be any DNA sequence, which shows transcriptional activity in the host cell of choice and may be derived  
20 from genes encoding proteins either homologous or heterologous to the host cell. Examples of suitable promoters for directing the transcription of the coding DNA sequence in mammalian cells are the SV 40 promoter (Subramani et al., 1981, Mol. Cell Biol. 1:854-864), the MT-1 (metallothionein gene) promoter (Palmiter et al., 1983, Science 222: 809-814) or the adenovirus 2 major late promoter. A suitable  
25 promoter for use in insect cells is the polyhedrin promoter (Vasuvedan et al., 1992, FEBS Lett. 311:7-11). Suitable promoters for use in yeast host cells include promoters from yeast glycolytic genes (Hitzeman et al., 1980, J. Biol. Chem. 255:12073-12080; Alber and Kawasaki, 1982, J. Mol. Appl. Gen. 1: 419-434) or alcohol dehydrogenase genes (Young et al., 1982, in Genetic Engineering of Microorganisms for  
30 Chemicals, Hollaender et al, eds., Plenum Press, New York), or the TPI1 (US 4,599,311) or ADH2-4c (Russell et al., 1983, Nature 304:652-654) promoters. Suitable promoters for use in filamentous fungus host cells are, for instance, the ADH3 promoter (McKnight et al., 1985, EMBO J. 4:2093-2099) or the tpiA promoter.

The coding DNA sequence may also be operably connected to a suitable terminator, such as the human growth hormone terminator (Palmiter et al., op. cit.) or (for fungal hosts) the TPI1 (Alber and Kawasaki, op. cit.) or ADH3 (McKnight et al., op. cit.) promoters. The vector may further comprise elements such as polyadenylation signals (e.g. from SV 40 or the adenovirus 5' E1b region), transcriptional enhancer sequences (e.g. the SV 40 enhancer) and translational enhancer sequences (e.g. the ones encoding adenovirus VA RNAs).

The recombinant expression vector may further comprise a DNA sequence enabling the vector to replicate in the host cell in question. An example of such a sequence (when the host cell is a mammalian cell) is the SV 40 origin of replication. The vector may also comprise a selectable marker, e.g. a gene the product of which complements a defect in the host cell, such as the gene coding for dihydrofolate reductase (DHFR) or one which confers resistance to a drug, e.g. neomycin, hydromycin or methotrexate.

The procedures used to ligate the DNA sequences coding the fusion proteins, the promoter and the terminator, respectively, and to insert them into suitable vectors containing the information necessary for replication, are well known to persons skilled in the art (cf., for instance, Sambrook et al., op.cit.).

The synthesis of the recombinant fusion protein may be by use of *in vitro* or *in vivo* cultures. The host cell culture is preferably an eucaryotic host cell culture. By transformation of an eukaryotic cell culture is in this context meant introduction of recombinant DNA into the cells. The expression construct used in the process is characterised by having the encoding region selected from mammalian genes including human genes and genes with big resemblance herewith such as the genes from the chimpanzee. The expression construct used is furthermore featured by the promoter region being selected from genes of virus or eukaryotes, including mammalian cells and cells from insects.

The process for producing recombinant MBL according to the invention is characterised in that the host cell culture is preferably eukaryotic, and for example a mammalian cell culture. A preferred host cell culture is a culture of human kidney cells and in an even more preferred form the host cell culture is a culture of human em-

bryonal kidney cells (HEK cells), such as HEK 293 cell lines for production of recombinant human MBL. By "HEK 293 cell lines" is meant any cell line derived from human embryonal kidney tissue such as, but not limited to, the cell lines deposited at the American Type Culture Collection with the numbers CRL-1573 and CRL-10852.

Other cells may be chick embryo fibroblast, hamster ovary cells, baby hamster kidney cells, human cervical carcinoma cells, human melanoma cells, human kidney cells, human umbilical vascular endothelium cells, human brain endothelium cells, human oral cavity tumor cells, monkey kidney cells, mouse fibroblast, mouse kidney cells, mouse connective tissue cells, mouse oligodendritic cells, mouse macrophage, mouse fibroblast, mouse neuroblastoma cells, mouse pre-B cell, mouse B lymphoma cells, mouse plasmacytoma cells, mouse teratocarcinoma cells, rat astrocytoma cells, rat mammary epithelium cells, COS, CHO, BHK, VERO, HeLa, MDCK, WI38, and NIH 3T3 cells.

Alternatively, fungal cells (including yeast cells) may be used as host cells. Examples of suitable yeast cells include cells of *Saccharomyces* spp. or *Schizosaccharomyces* spp., in particular strains of *Saccharomyces cerevisiae*. Examples of other fungal cells are cells of filamentous fungi, e.g. *Aspergillus* spp. or *Neurospora* spp., in particular strains of *Aspergillus oryzae* or *Aspergillus niger*. The use of *Aspergillus* spp. for the expression of proteins is described in, e.g., EP 238 023.

In addition, a host cell strain may be chosen which modulates the expression of the inserted sequences, or modifies and processes the gene product in the specific fashion desired. Such modifications (for example, glycosylation) and processing (for example, cleavage) of protein products may be important for the function of the protein. Different host cells have characteristic and specific mechanisms for the post-translational processing and modification of proteins and gene products. Appropriate cell lines or host systems can be chosen to ensure the correct modification and processing of the foreign protein expressed. To this end, eukaryotic host cells which possess the cellular machinery for proper processing of the primary transcript, glycosylation, and phosphorylation of the gene product may be used. The mammalian cell types listed above are among those that could serve as suitable host cells.



Methods of transfecting mammalian cells and expressing DNA sequences introduced in the cells are described in e.g. Kaufman and Sharp, J. Mol. Biol. 159, 1982, pp. 601-621; Southern and Berg, 1982, J. Mol. Appl. Genet. 1:327-341; Loyter et al., 1982, Proc. Natl. Acad. Sci. USA 79: 422-426; Wigler et al., 1978, Cell 14:725; Corsaro and Pearson, 1981, in Somatic Cell Genetics 7, p. 603; Graham and van der Eb, 1973, Virol. 52:456; and Neumann et al., 1982, EMBO J. 1:841-845.

Other eucaryotic production systems are also envisaged by the present invention, such as the production of the fusion protein in a transgenic plant or animal.

In another aspect the present invention provides a method for producing a fusion protein by

- preparing a gene expression construct as defined above encoding a fusion protein,
- transforming a host cell culture with the construct,
- cultivating the host cell culture, thereby obtaining expression and secretion of the polypeptide into the culture medium, followed by
- obtaining a culture medium comprising recombinant fusion protein, and
- purifying the fusion protein.

The medium used to culture the cells may be any conventional medium suitable for growing mammalian cells, such as a serum-containing or serum-free medium containing appropriate supplements, or a suitable medium for growing insect, yeast or fungal cells. Suitable media are available from commercial suppliers or may be prepared according to published recipes (e.g. in catalogues of the American Type Culture Collection). Example of culture medium are RPMI-1640 or DMEM supplemented with, e.g., insulin, transferrin, selenium, and foetal bovine serum

The fusion proteins recombinantly produced by the cells may then be recovered from the culture medium by conventional procedures including separating the host

cells from the medium by centrifugation or filtration, precipitating the proteinaceous components of the supernatant or filtrate by means of a salt, e.g. ammonium sulphate, purification by a variety of chromatographic procedures, e.g. HPLC, ion exchange chromatography, affinity chromatography, or the like.

5

In a preferred embodiment the fusion protein is purified by use of carbohydrate affinity chromatography as described above. In a preferred embodiment of the invention the affinity chromatography is performed by means of matrices of mannose, hexose or N-acetyl-glucosamine derivatized matrices, which are suitable for affinity chromatography. In particular, an affinity chromatography is used, in which the matrices have been derivatized with mannose.

10

Purified recombinant fusion protein is in this context to be understood as recombinant fusion protein purified from cell culture supernatants or body fluids or tissue from transgenic animals purified by use of for example carbohydrate affinity chromatography.

15

After application of the culture media the column is washed, preferably by using non-denaturing buffers, having a composition, pH and ionic strength resulting in elimination of proteins, without eluting the fusion protein. Such a buffer may be TBS. Elution of fusion protein is performed with a selective desorbing agent, capable of efficient elution of fusion protein, such as TBS containing a desorbing agent, such as EDTA (5 mM for example) or mannose (50 mM for example), and fusion proteins are collected.

20

25

#### **Pharmaceutical composition and treatment**

30

The fusion protein obtained by the present invention may be used for the preparation of a pharmaceutical composition for the prevention and/or treatment of various diseases or conditions. In the present context the term pharmaceutical composition is used synonymously with the wording medicament.

In addition to the fusion protein, the pharmaceutical composition may comprise a pharmaceutically acceptable carrier substance and/or vehicles.

35

In particular, a stabilising agent may be added to stabilise the fusion proteins. The stabilising agent may be a sugar alcohol, saccharide, protein and/or amino-acids. An example of a stabilising agent may be albumin or maltose.

- 5 Other conventional additives may be added to the pharmaceutical composition depending on administration form for example.

In one embodiment the pharmaceutical composition is in a form suitable for injections. Conventional carrier substances, such as isotonic saline, may be used.

10

In another embodiment the pharmaceutical composition is in a form suitable for pulmonal administration, such as in the form of a powder for inhalation or creme or fluid for topical application.

- 15 A treatment in this context may comprise cure and/or prophylaxis of e.g. the immune system and reproductive system by humans and by animals having said functional units acting in this respect like those in humans. By conditions to be treated are not necessarily meant conditions presently known to be in a need of treatment, but comprise generally any condition in connection with current and/or expected need or
- 20 in connection with an improvement of a normal condition. In particular, the treatment is a treatment of a condition of deficiency of lectins, such as MBL deficiency.

- In another aspect of the present invention the manufacture is provided of a medicament consisting of said pharmaceutical compositions of fusion protein intended for
- 25 treatment of conditions comprising cure and/or prophylaxis of conditions of diseases and disorders of e.g. the immune system and reproductive system by humans and by animals having said functional units acting like those in humans.

- Said diseases, disorders and/or conditions in need of treatment with the compounds of the invention comprise eg treatment of conditions of deficiency of MBL, treatment
- 30 of cancer and of infections in connection with immunosuppressive chemotherapy including in particular those infections which are seen in connection with conditions during cancer treatment or in connection with implantation and/or transplantation of organs. The invention also comprises treatment of conditions in connection with
- 35 recurrent miscarriage.

Thus, in particular the pharmaceutical composition may be used for the treatment and/or prevention of clinical conditions selected from infections, MBL deficiency, cancer, disorders associated with chemotherapy, such as infections, diseases associated with human immunodeficiency virus (HIV), diseases related with congenital or acquired immunodeficiency. More particularly, chronic inflammatory demyelinating polyneuropathy (CIDP), Multifocal motoric neuropathy, Multiple sclerosis, Myasthenia Gravis, Eaton-Lambert's syndrome, Opticus Neuritis, Epilepsy; Primary antiphospholipid syndrome; Rheumatoid arthritis, Systemic Lupus erythematosus, Systemic scleroderma, Vasculitis, Wegner's granulomatosis, Sjögren's syndrome, Juvenile rheumatoid arthritis; Autoimmune neutropenia, Autoimmune haemolytic anaemia, Neutropenia; Crohn's disease, Colitis ulcerous, Coeliac disease; Asthma, Septic shock syndrome, Chronic fatigue syndrome, Psoriasis, Toxic shock syndrome, Diabetes, Sinuitis, Dilated cardiomyopathy, Endocarditis, Atherosclerosis, Primary hypo/agammaglobulinaemia including common variable immunodeficiency, Wiskot-Aldrich syndrome and severe combined immunodeficiency (SCID), Secondary hypo/agammaglobulinaemia in patients with chronic lymphatic leukaemia (CLL) and multiple myeloma, Acute and chronic idiopathic thrombocytopenic purpura (ITP), Allogenic bone marrow transplantation (BTM), Kawasaki's disease, and Guillan-Barre's syndrome.

The route of administration may be any suitable route, such as intravenously, intramuscularly, subcutaneously or intradermally. Also, pulmonal or topical administration is envisaged by the present invention.

In particular the fusion protein may be administered to prevent and/or treat infections in patients having clinical symptoms associated with congenital or acquired MBL deficiency or being at risk of developing such symptoms. A wide variety of conditions may lead to increased susceptibility to infections in MBL-deficient individuals, such as chemotherapy or other therapeutic cell toxic treatments, cancer, AIDS, genetic disposition, chronic infections, and neutropenia.

The pharmaceutical composition may thus be administered for a period before the onset of administration of chemotherapy or the like and during at least a part of the chemotherapy.

The fusion protein may be administered as a general "booster" before chemotherapy, or it may be administered to those only being at risk of developing MBL deficiency. The group of patients being at risk may be determined by measuring the MBL level before treatment and only subjecting those to treatment whose MBL level is below a predetermined level.

The fusion protein is administered in suitable dosage regimes, in particular it is usually administered at suitable intervals, eg. once or twice a week during chemotherapy.

Normally from 1-100 mg is administered per dosage, such as from 2-10 mg, mostly from 5-10 mg per dosage. Mostly about 0.1 mg/kg body weight is administered.

Furthermore, an aspect of the present invention is the use of a recombinant composition according to the present invention in a kit-of-parts further comprising another medicament. In particular the other medicament may be an anti-microbial medicament, such as antibiotics.

Concerning miscarriage, it has been reported that the frequency of low plasma levels of MBL is increased in patients with otherwise not explained recurrent miscarriages, which is the background for lowering of the susceptibility to miscarriage by a reconstitution of the MBL level by administration of recombinant MBL in these cases.

As to the nature of compounds of the invention, it appears, that in its broad aspect, the present invention relates to compounds which are able to act as opsonins, that is, able to enhance uptake by macrophages either through direct interaction between the compound and the macrophage or through mediating complement deposition on the target surface.

## Examples

### Example 1

**Plasmidcloning of FCNMBL-r1, -r2, -r3,-r4,-r5,-r6 and-r7.****1.1 Summary**

A series of plasmids were constructed for the expression in mammalian cells of protein fusions between recombinant human mannose-binding lectin 2 gene (rhMBL) and human ficolin 2 (FCN2). The vector is derived from a high-copy-number ColE1-based plasmid and is designed to allow protein expression in mammalian systems. The fusion protein expressions are driven by the human cytomegalovirus (CMV) immediate early promoter to promote constitutive expression. Selection is made possible in bacteria by the ampicillin-resistance gene under control of the prokaryotic  $\beta$ -lactamase promoter. The neomycin-resistance gene is driven by the SV40 early promoter, which provides stable selection with G418 in mammalian cells.

**1.2 Constructs and experimental work**

In order to express fusion proteins between Ficolin2 and MBL we have designed and constructed a series of plasmids. The new recombinant plasmids are based on the previously cloned pcDNA2001-cintMBLcDNA. This plasmid contains a synthetic intron together with the cDNA for human MBL.

The following fusions were designed (underlined font indicates FCN2 part - *italics* indicate MBL part of the fusion protein.)

**FCN2MBLr1 (SEQ ID NO:118):**

FCN2 (signalseq+ collagen+"hinge" to ficolin dom aa131) MBL (from aa129 carbohydrate bind dom.)

MELDRAVGVLGAAATLLLSFLGMAWALQAADTCPEVKMVGLEGSDKLTILRGCP-GLPGAPGDKGEAGTNGKRG

PPGPPGKAGPPGPNGAPGEPQPCLTGPRTCKDLLDRGHFLSGWHTIYLPDCR-PLTFSLGKQVGNKFFLTNGEIMT

*FEKVKALCVKFQASVATPRNAAENGAIQNLIKEEAFLGITDEKTEGQFVDLTGN-RLTYTNWNEGEPNAGSDEDC*

*VLLLKNGQWNDVPCSTSHLAVCEFPI*

**FCN2MBLr2 (SEQ ID NO: 119):**

FCN2 (signalseq+ collagen+"hinge"+part of ficolin-dom. containing pred. coil-coil to aa207) MBL (from aa129 carbohyd.bind dom.)

5 MELDRAVGVLGAATLLLSFLGMAWALQAADTCPEVKMVGLEGSDKLTILRGCP-  
GLPGAPGDKGEAGTNGKRGERG

PPGPPGKAGPPGPNGAPGEPQPCLTGPRTCKDLLDRGHFLSGWHTIYLPDCR-  
PLTVLCDMDTDGGGWTVFQRRVD

10 GSVDFYRDWATYKQGFSGSRLGEFWLGNDNIHALTAQGTSELRVDLVDFEDNY-  
QFAKLTFSLGKQVGNKFFLTNGE

*IMTFEKVKALCVKFQASVATPRNAAENGAIQNLIKEEAF LGITDEKTEGQFVDLT-  
GNRLTYTNWNEGEPNNAGSD*

15 *EDCVLLLKNGQWNDVPCSTSHLAVCEFP I*

**FCN2MBLr3 (SEQ ID NO: 120):**

20 FCN2 (signalseq+ collagen to aa92) MBL (from aa101 coil-coil + carbohyd.bind dom.)

25 MELDRAVGVLGAATLLLSFLGMAWALQAADTCPEVKMVGLEGSDKLTILRGCP-  
GLPGAPGDKGEAGTNGKRGERG

PPGPPGKAGPPGPNGAPPDGDSSLAASERKALQTEMARIKKWLTFSLG-  
KQVGNKFFLTNGEIMTFEKVKALCVKF

30 *QASVATPRNAAENGAIQNLIKEEAF LGITDEKTEGQFVDLTGNRLTYTN-  
WNEGEPNNAGSDEDCVLLLKNGQWND*

*VPCSTSHLAVCEFP I*

35 **FCN2MBLr4 (SEQ ID NO: 121):**

40 FCN2 (signalseq+ part of collagen to cons.K at aa93) MBL (from cons.K at aa77 rest of collagen+coil-coil + carbohyd.bind dom.)

MELDRAVGVLGAATLLLSFLGMAWALQAADTCPEVKMVGLEGSDKLTILRGCP-  
GLPGAPGDKGEAGTNGKRGERG

45 PPGPPGKLGPPGNPGPSGSPGPKGQKGDPGKSPDGDSSLAASERKALQTEMA-  
RIKKWLTFSLGKQVGNKFFLTNG

*EIMTFEKVKALCVKFQASVATPRNAAENGAIQNLIKEEAF LGITDEKTEGQFVDLT-  
GNRLTYTNWNEGEPNNAGS*

50 *DEDCVLLLKNGQWNDVPCSTSHLAVCEFP I*

**FCN2MBLr5 (SEQ ID NO: 122):**

FCN2 (signalseq+ part of collagen to cons.G at aa69) MBL (from cons.G at aa.64 rest of collagen(containing "kick")+coil-coil + carbohyd.bind dom.)

5 MELDRAVGVLGAATLLLSFLGMAWALQAADTCPEVKMVGLEGSDKLTILRGCP-  
GLPGAPGDKGEAGTNGQGRLRGL

QGPPGKLGPPGNPGPSGSPGPKGQKGDPGKSPDGDSSLAASERKALQTEMA-  
RIKKWLTFSLGKQVGNKFFLTNGE

10 IMTFEKVKALCVKFQASVATPRNAAENGAIQNLIKEEAFLGITDEKTEGQFVDLT-  
GNRLTYTNWNEGEPNNAGSD

EDCVLLLKNGQWNDVPCSTSHLAVCEFPI

15

**FCN2MBLr6 (SEQ ID NO: 123):**

20 MBL (replaced MBLcollagen(aa.41 to aa 99 )+coil-coil + carbohyd.bind dom.) FCN2  
(inserted collagen aa.54 to aa.92 )

MSLFPSLPLLLLSMVAASYSETVTCEDAQKTCPAVIACSSPGCPGLPGAPGDK-  
GEAGTNGKRGGERGPPGPPGKAG

25 PPGPNGAPSPDGDSSLAASERKALQTEMARIKKWLTFSLGKQVGNKFFLT-  
NGEIMTFEKVKALCVKFQASVATPR

NAAENGAIQNLIKEEAFLGITDEKTEGQFVDLTGNRLTYTNWNEGEPNNAGSDED-  
CVLLLKNGQWNDVPCSTSHL

30

AVCEFPI

**FCN2MBLr7 (SEQ ID NO: 124):**

35

MBL (signal seq. to aa.25)FCN2 (collagen to aa93) MBL (from aa100 coil-coil + car-  
bohyd.bind dom.)

40 MSLFPSLPLLLLSMVAASYSALQAADTCPEVKMVGLEGSDKLTILRGCPGLPGAP-  
GDKGEAGTNGKRGGERGPPGP

PGKAGPPGPNGAPSPDGDSSLAASERKALQTEMARIKKWLTFSLGKQVGNKF-  
FLTNGEIMTFEKVKALCVKFQAS

45 VATPRNAAENGAIQNLIKEEAFLGITDEKTEGQFVDLTGNRLTYTNWNEGEPN-  
NAGSDEDCVLLLKNGQWNDVPC

STSHLAVCEFPI



Parental plasmids used for all constructions :

- pcDNA2003-cintMBLcDNA
- Invitrogen Genestorm clone RG000632 (Cat. No. H-K1000 Invitrogen).

5      Constructions were done by recombination using the BD In-Fusion™ PCR Cloning Kit form BD (Cat. No. 631774). The BD In-Fusion Kit allows the cloning of PCR products based only on 2 x 15 bp homology between vector and end of the PCR product. Ligase, or phosphatase are unnecessary when cloning with this kit. The In-Fusion enzyme captures the DNA fragment ends and fuses the insert to the vector.

10     Primers used for the PCR reactions are shown in table 1.

PCR reactions and linearization of vector for recombination

PCR reactions were done on plasmid "Genestorm RG000632" batch N135-15C digested with Bstz17I (N135-20B). Primers pairs were used as described below. Kit for PCR reactions : PfuUltra™ Hotstart PCR Master Mix Stratagene #600630. The  
15     PCR reaction tubes were run on the BioRAD i-cycler using the temperature profile shown in table 2.

For the recombination reactions the vector pcDNA2001-cintMBLcDNA was linearized by restriction enzyme digestion with the enzymes listed below.

20

**FCN2MBLr1:**

PCR using primers : Pr1-xho-MBLFCN + Pr4-Xmn-FCNMBL-rev (product 463 bp)  
Digest of pcDNA2001-cintMBLcDNA : XhoI + XmnI (partial)

25

**FCN2MBLr2:**

PCR USING PRIMERS : Pr1-xho-MBLFCN + Pr5-Xmn-FCNMBL-rev  
Digest of pcDNA2001-cintMBLcDNA : XhoI + XmnI (partial)

**FCN2MBLr3:**

30

PCR USING PRIMERS : Pr1-xho-MBLFCN + Pr6-b-Bsp-FCNMBL-rev  
Digest of pcDNA2001-cintMBLcDNA : XhoI + BspEI

**FCN2MBLr4:**

PCR USING PRIMERS : Pr1-xho-MBLFCN + Pr2-apa-FCNMBL-rev

Digest of pcDNA2001-cintMBLcDNA : XhoI + ApaI

**FCN2MBLr5:**

PCR USING PRIMERS : Pr1-xho-MBLFCN + Pr3-apa-FCNMBL-rev

Digest of pcDNA2001-cintMBLcDNA : XhoI + ApaI

**FCN2MBLr6:**

PCR USING PRIMERS : Pr8-BstAP-MBLFCN + Pr6-b-Bsp-FCNMBL-rev

Digest of pcDNA2001-cintMBLcDNA : partial BstAPI + BspEI

**FCN2MBLr7:**

PCR USING PRIMERS : Pr7-Alw-MBLFCN + Pr6-b-Bsp-FCNMBL-rev

Digest of pcDNA2001-cintMBLcDNA : partial AlwNI + BspEI

In-Fusion PCR recombination reactions

In-Fusion PCR recombination reactions were set up using approx. 50–100 ng of Quiagen Minelute purified PCR products together with 50–100 ng of Quiagen Minelute purified linearized pcDNA2001-cintMBLcDNA .

1/10 of the recombination reactions were transformed into MAX efficiency DH5 $\alpha$  Competent Cells (Invitrogen Cat. No. 18258-012). 1/10 and 9/10 from each transformation were spread on separate LB plates containing 200 ug/ml ampicillin. Plates were incubated at 37°C overnight.

Screening for positive clones : At least 6 colonies from each experimental plate were picked for miniprep plasmid DNA isolation. To determine the presence of insert, DNA was analyzed by restriction digest analysis with the enzyme *Pst*I. Three individual positive clones from each reaction were chosen for further work.

**Restriction Analysis**

In order to verify the selected individual recombinant plasmids after the primary screen we performed an intensive restriction enzyme digestion analysis on the plasmid DNA isolated.

Plasmid DNA of the recombinants were digested with the enzyme shown in table 3. The expected fragments are also listed in the table. All recombinant clones tested exhibited the expected pattern. Digestion with *Eco*RI was not as predicted. An addi-

tional fragment was observed both in digestion of the recombinant as well of the parental plasmid. The discrepancy can be explained by an additional EcoR1 site on the parental plasmid.

## Results

5 Recombinant plasmids obtained are shown schematically in figures 4-8 for constructs r1, -r2, -r3, -r4, and -r5.

## Example 2

10 **Experiments with transient expression of recombinant fusion proteins of human MBL and human FCN2**

### 2.1 Summary

15 We report the expression of recombinant human fusion proteins FCNMBLr1, FCNMBLr4, FCNMBLr5 and MBL in HEK293 and Per.C6 cells. We found that the cell lines in the transient transfection experiment were able to produce at least the fusion proteins FCNMBLr4 and FCNMBLr5 assembled in active oligomeres with a structure primarily similar to MBL oligomer forms 3 and 4. The fusion proteins FCNMBLr4 and FCNMBLr5 behaved like MBL upon binding to a carbohydrate surface and upon activating the complement cascade.

20

### 2.2 Introduction

The aim of the studies was to elucidate the possibility of creating a hybrid protein consisting of the collagen part of human ficolin 2 and the human mannose binding lectin (MBL). Furthermore we wished to clarify if such molecules would still possess the ability to bind to complex carbohydrate structures and still are able to activate complement.

25

Two eukaryotic cell lines of human origin HEK293 and Per.C6 were used as host cell lines for transient transfections with the respective expression plasmids. Transcription was driven by the CMV-IE promoter enhancer.

30

### 2.3 Experimental

#### Material and Methods

#### Plasmids used for the transfection experiments

pME607-FCNMBL-r1, -r2, -r3, -r4, -r5, -r6 and -r7 (described in example 1)

Origin of Cells used

PerC6 cells were obtained from Crucell.

HEK 293 Freestyle cells were obtained from InVitrogen.

Culture média

- 5 PerC6 cells were cultured at 37°C in 10% (vol/vol) CO<sub>2</sub> maintained as monolayers in serum free medium.

HEK 293 Freestyle were cultured at 37°C in 8% (vol/vol) CO<sub>2</sub> maintained as suspension in an InVitrogen Freestyle medium.

Transfections and harvest of media

- 10 Per.C6 cells in serum containing medium were transfected with the DNA using the transfection reagent Lipofectamine. One day after transfection the medium was replaced with serum free medium.

HEK293 cells in serum free Freestyle medium were transfected with the DNA using the transfection reagent 293fect. The medium was collected after approximately 4

- 15 days of incubation after transfection.

Quantification of MBL

Recombinant MBL assay (TRIFMA) using Mannan coated plates or mAb-131-01 coated plates. For quantification of MBL, time-resolved immunofluorometry was carried out.

- 20 SDS-PAGE and Western blot analysis

SDS-PAGE with subsequent electrophoretic transfer of proteins to polyvinylidene difluoride membranes and detection of MBL using monoclonal anti-MBL antibody was carried out.

C4 assay

- 25 The assay is designed to measure MBL and rMBL abilities to initiate the MBL Lectin-pathway of the complement system. MBL associated serine protease (MASP 2) associated with MBL cleaves the complement factor C4 releasing C4a and C4b. The C4b deposition on the Mannan coated ELISA plates is detected with biotin labelled antibodies against C4b and Europium labelled Streptavidin.

- 30 **2.4 RESULTS**

In the experiments described herein we were able to express FCN2MBLr4, FCN2MBLr5 and MBL transiently in both HEK293 and Per.C6 cells under serum free conditions.

#### Oligomeric form of the fusion proteins

The oligomeric forms of the fusion protein were examined by non-reducing denaturing SDS PAGE followed by a western blot. The detecting antibody recognizes the CDR part of MBL (and maybe part of the coil-coil region). The results are shown in figure 10. It is evident from the figure that the most prominent form of the fusion proteins FCN2MBLr4 and FCN2MBLr5 is approximately 250 kDa corresponding to a 3- or 4-mer of subunits consisting of 3 single protein chains (24 kDa). The appearance of the oligomeric form was independent of the host cells used. MBL was produced in a wide range of oligomeric forms.

#### Binding properties

The fusion proteins were tested for functionality of the MBL carbohydrate binding domain by binding to a mannan surface and detection with an antibody that recognizes the CDR part of MBL (and maybe part of the coil-coil region). The results are shown in table 4. It can be concluded that FCN2MBLr4 and FCN2MBLr5 were expressed just as well as MBL in the host cells and that the fusion proteins bind to a mannan surface.

#### MASP-2 binding and C4 cleavage

The fusion proteins were further tested for the capacity to bind MASP-2 and for activating the serine protease of MASP-2. This was done by measuring cleavage of the MASP-2 substrate complement factor C4 upon binding of the fusion protein to a mannan surface. Results are shown in table 5. It can be concluded from these results that the fusion proteins FCN2MBLr4 and FCN2MBLr5 preserved the ability to bind and activate MASP-2.

#### **Discussion**

The results described herein clearly demonstrate that it is possible to construct fusion proteins of FCN 2 and MBL with the following properties:

1. The oligomeric structure of the fusion proteins is more simple than that of the MBL protein.
2. The fusion proteins keep the essential property of MBL activation of the complement cascade upon binding to a dense carbohydrate structure.

#### Table 1. Primers used for the PCR reactions

Sequence typed in bold shows the 15 bp homology needed for the recombination into the vector.

Primer name	DNA Sequence of Primer	Primer part of pcDNA2001-cintMBLcdna	Primer part of RG000632
<b>Pr1-xho-MBLFCN</b>	ataggctagcctgaagctcgcccttcaccatg-gagctggacag	<b>ataggctagcctcga</b>	agctcgcccttcaccatggagctggacag
<b>Pr2-apa-FCNMBL-rev</b>	Ccaactttccaggggggcccggggggccacgttctctctctttcc	g(replaced) <b>ggcccccctggaaagtgg</b>	ggaaagagagga-gaacgtggccccc
<b>Pr3-apa-FCNMBL-rev</b>	Ccaactttccaggggggcccgtgtaagcctctgagccctgtccattggtgcctctcccttggg	Caagggtca-gaggctta-cagggcccccctgga <b>aagtgg</b>	cccaaggga-gaggcaggcac-caatgga
<b>Pr4-Xmn-FCNMBL-rev</b>	Tggtcaggaagaactgttcccaactgtttgcc-cagagagaaagt-caggggcccggcagtcgggcagg	Ttctctgggcaaa-caagtgggaa- <b>caagttctcctgacca</b>	cctgccgactgccggcccctgact
<b>Pr5-Xmn-FCNMBL-rev</b>	Tggtcaggaagaactgttcccaactgtttgcc-cagagagaacttag-caaactggtagttgtcctcaaagtcc	Ttctctgggcaaa-caagtgggaa- <b>caagttctcctgacca</b>	ggacttgagga-caactac-cagttgctaag
<b>Pr6-b-Bsp-FCNMBL-rev</b>	Gactatcaccatccggaggtgctccgttgggcccaggtggtcc	<b>ccggatggtgatagt</b>	ggac-cacctgggcccacggagcacct
<b>Pr7-Alw-MBLFCN</b>	Cagcgtcttactcagctctccaggcggcagacacctgtcc	<b>cagcgtcttactcag</b>	ctctccaggcggcagacacctgtcc
<b>Pr8-BstAP-MBLFCN</b>	<b>Agacctgccctgcagtgattgcctgtagctctc-caggctgtccggggtgcctggggcccc</b>	<b>Agacctgccctgcatgattgcctgtagctctcca</b>	ggctgtccggggctgctggggcccc

Table 2:

Cycle	times	step	Temp	Time
1	1x	1	95°	21 min
2	30x	1	95°	0 min 30 sec
		2	72° (67.5° for r2)	0 min 30 sec
		3	72°	1 min
3	1x	1	72°	10 min
4	1x	1	4°	∞

5

Table 3:

pcDNA2001-cintMBLcdNA	pME607-FCN2M BLr1	pME607-FCN2M BL r2	pME607-FCN2M BL r3	pME607-FCN2M BL r4	pME607-FCN2M BL r5
<b><u>PstI</u></b> 4212	<b><u>PstI</u></b> 4212	<b><u>PstI</u></b> 4212	<b><u>PstI</u></b> 4212	<b><u>PstI</u></b> 4212	<b><u>PstI</u></b> 4212

1586 405 375	1586 788	1586 1016	1486 782	1586 800	1586 797
<u>EcoRI</u> 5810 768	<u>EcoRI</u> 6586	<u>EcoRI</u> 6814	<u>EcoRI</u> 6580	<u>EcoRI</u> 6598	<u>EcoRI</u> 6595
<u>XmaI</u> 6578	<u>XmaI</u> 6586	<u>XmaI</u> 6814	<u>XmaI</u> 6580	<u>XmaI</u> 6589	<u>XmaI</u> 6595
<u>BstXI</u> undigested	<u>BstXI</u> 6586	<u>BstXI</u> 6814	<u>BstXI</u> 6580	<u>BstXI</u> 6598	<u>BstXI</u> 6595
<u>BstAPI</u> 4622 1469 415 72	<u>BstAPI</u> 4622 1892 72	<u>BstAPI</u> 4622 2120 72	<u>BstAPI</u> 4622 1886 72	<u>BstAPI</u> 4622 1904 72	<u>BstAPI</u> 4622 1901 72
<u>NcoI</u> 3435 2408 735	<u>NcoI</u> 3435 1747 735 669	<u>NcoI</u> 3435 1975 735 669	<u>NcoI</u> 3435 1741 735 669	<u>NcoI</u> 3435 1759 735 669	<u>NcoI</u> 3435 1756 735 669

**Table 4 MBL binding to mannan measured by TRIFMA**

		µg MBL equivalents /ml
FCN2MBLr5	HEK293	0,689
FCN2MBLr5	HEK293	0,764
FCN2MBLr1	HEK293	0,874
MBL	HEK293	0,457
FCN2MBLr4	HEK293	0,851
MBL	HEK293	1,885
FCN2MBLr5	Per.C6	0,296
MBL	Per.C6	0,271
FCN2MBLr4	Per.C6	0,077
FCN2MBLr4	Per.C6	0,091
FCN2MBLr4	Per.C6	0,089
FCN2MBLr4	Per.C6	0,035
MBL	Per.C6	0,092

**5 Table 5 C4 activity of the fusion proteins**

	Cells	Aktivitet +/-
pME607-FCNMBLr5 clone 1	HEK293	+
pME607-FCNMBLr5 clone 5	HEK293	+
pME607-FCNMBLr4 clone 2	HEK293	+/+ (after purification)
pcDNA2001-cintMBLcDNA	HEK293	+
pME607-FCNMBLr5 clone 5	Per.C6	+
pME607-FCNMBLr4 clone 2 (maxi)	Per.C6	-/(+) (after purification)



**Claims**

1. A fusion protein comprising
  - i) A first polypeptide sequence derived from a lectin-complement pathway activating protein or a functional homologue thereof; and
  - ii) A second polypeptide sequence derived from a collectin or a functional homologue thereof;wherein said complement activating protein is not a collectin.
2. The fusion protein according to claim 1, wherein said first polypeptide sequence is capable of activating the lectin-complement pathway.
3. The fusion protein according to claim 1, wherein said first polypeptide sequence is capable of associating with at least one MASP protein.
4. The fusion protein according to claim 1, wherein said first polypeptide sequence is capable of associating with a MASP protein selected from the group consisting of MASP-1, MASP-2 and MASP-3 or functional homologues or variants hereof.
5. The fusion protein according to claim 1, wherein the complement activating protein is a ficolin.
6. The fusion protein according to claim 5, wherein the ficolin is selected from the group consisting of L-ficolin, H-ficolin and M-ficolin.
7. The fusion protein according to claim 5, wherein the ficolin is L-ficolin.
8. The fusion protein according to any of claims 1 to 7, wherein said first polypeptide sequence comprises at least 10, such as at least 12, for example at least 15, such as at least 20, for example at least 25, such as at least 30, for example at least 35, such as at least 40, for example at least 50 consecutive amino acids of a complement activating protein or a sequence at least 70%, such as 80%, for example 90%, such as 95% identical thereto.

9. The fusion protein according to claim 1, wherein the first polypeptide sequence comprises the collagen-like domain of a ficolin or a functional homologue or variant thereof.
- 5 10. The fusion protein according to claim 1, wherein the first polypeptide sequence comprises the collagen-like domain of L-ficolin.
11. The fusion protein according to claim 1, wherein the first polypeptide sequence comprises the cysteine-rich region of a ficolin or a functional homologue thereof.
- 10 12. The fusion protein according to claim 1, wherein first polypeptide sequence comprises the cysteine-rich region of L-ficolin
13. The fusion protein according to claim 1, wherein the first polypeptide sequence comprises the cysteine-rich region and the collagen-like domain of a ficolin or a functional homologue or variant thereof.
- 15 14. The fusion protein according to claim 1, wherein first polypeptide sequence comprises the cysteine-rich region and the collagen-like domain of L-ficolin.
- 20 15. The fusion protein according to claim 1, wherein the first polypeptide sequence comprises amino acids 1-77 SEQ ID. NO 1.
16. The fusion protein according to claim 1, wherein said second polypeptide sequence is capable of associating with one or more carbohydrates.
- 25 17. The fusion protein according to claim 1, wherein the collectin is selected from the group consisting of MBL (mannose-binding lectin), SP-A (lung surfactant protein A), SP-D (lung surfactant protein D), BK (or BC, bovine conglutinin) and CL-43 (collectin-43).
- 30 18. The fusion protein according to claim 17, wherein the collectin is MBL.
19. The fusion protein according to any of claims 1 to 18, wherein said second polypeptide sequence comprises at least 10, such as at least 12, for example at
- 35

least 15, such as at least 20, for example at least 25, such as at least 30, for example at least 35, such as at least 40, for example at least 50 consecutive amino acids of a collectin or a sequence at least 70%, such as 80%, for example 90%, such as 95% identical thereto.

5

20. The fusion protein according to claim 1, wherein the second polypeptide sequence comprises the CRD domain of a collectin or a functional homologue or variant thereof.

10

21. The fusion protein according to claim 1, wherein the second polypeptide sequence comprises the CRD domain of MBL.

22. The fusion protein according to claim 1, wherein the second polypeptide sequence comprises the neck region of MBL.

15

23. The fusion protein according to claim 1, wherein the second polypeptide sequence comprises the collagen-like domain of MBL.

20

24. The fusion protein according to claim 1, wherein the second polypeptide sequence comprises the neck region and the CRD domain of MBL.

25. The fusion protein according to claim 1, wherein the second polypeptide sequence comprises the collagen-like domain, the neck region and the CRD domain of MBL.

25

26. The fusion protein according to claim 1, wherein the second polypeptide sequence comprises amino acids 80-228 SEQ ID. NO 2.

30

27. The fusion protein according to claim 1, wherein the fusion protein comprises the cysteine-rich region and the collagen-like domain of L-ficolin and the CRD domain of MBL.

35

28. The fusion protein according to claim 1, wherein the fusion protein comprises the cysteine-rich region of L-ficolin and the collagen-like domain, the neck region and the CRD domain of MBL.

29. The fusion protein according to claim 1, wherein the fusion protein comprises the amino acid sequence as defined by SEQ ID. NO. 3, or a functional homologue thereof.
- 5
30. The fusion protein according to claim 1, wherein the fusion protein consists of the amino acid sequence as defined by SEQ ID. NO. 3.
- 10
31. An isolated nucleic acid comprising a nucleotide sequence encoding the fusion protein according to any of claims 1 to 30.
32. A vector comprising the nucleic acid sequence according to claim 31.
33. A cell comprising the vector according to claim 32.
- 15
34. The cell according to claim 33, wherein the cell is a mammalian cell.
35. The cell according to claim 33, wherein the cell is a non-mammalian cell.
- 20
36. A fusion protein according to any of claims 1 to 30 for use as a medicament.
37. A method of treatment of a clinical condition in an individual in need thereof comprising administering to said individual the fusion protein according to any of claims 1 to 30.
- 25
38. The method according to claim 37, wherein the clinical condition is an infection.
39. The method according to claim 37, wherein the individual is a human being.
- 30
40. The method according to claim 37, wherein the individual is a human being suffering from an increased risk of acquiring an infection.
41. The method according to claim 37, wherein the individual is a human being with subnormal serum MBL level.
- 35

42. The method according to claim 37, wherein the individual is a human being with normal serum MBL level.

5 43. Use of the fusion protein according to any of claims 1 to 30 for the preparation of a medicament for the treatment of a clinical condition in an individual in need thereof.

44. The use according to claim 43, wherein the clinical condition is an infection.

10 45. The use according to claim 43, wherein the individual is a human being.

46. The use according to claim 43, wherein the individual is a human being suffering from an increased risk of acquiring an infection.

15 47. The use according to claim 43, wherein the individual is a human being with sub-normal serum MBL level.

48. The use according to claim 43, wherein the individual is a human being with normal serum MBL level.

20 49. A medicament for the treatment or prevention of a clinical condition in an individual in need thereof, comprising the fusion protein according to any of claims 1 to 30.

25 50. The medicament according to claim 49, wherein the clinical condition is an infection.

51. The medicament according to claim 49, wherein the individual is a human being.


30

## Abstract of the Disclosure

The present invention relates to a fusion protein capable of activating the complement system, the fusion protein comprising a first polypeptide sequence derived from a lectin-complement pathway activating protein or a functional homologue thereof; and a second polypeptide sequence derived from a collectin or a functional homologue thereof; wherein said complement activating protein is not a collectin. A preferred fusion protein comprises amino acids of the L-ficolin sequence of figure 1 and amino acids of the MBL sequence shown in figure 2. The fusion protein is suitable for use in treatment consisting of creation, reconstitution, enhancing and/or stimulating the opsonic and/or bactericidal activity of the complement system, i.e. enhancing the ability of the immune defence to recognise and kill microbial pathogens, and accordingly, the invention relates to a medicament comprising the fusion protein, methods for producing said fusion protein and methods for treating diseases, in particular infections.

1/11

FIGURE 1: L Ficolin




FCN2 HUMAN@2  
313 aa

LQAAD TCPEVKAVGL EGSDEKLTLR  
GCPGLPGAPG DKGEACTNGK RGERGPPGPP GKAGPPGPNG APGEPPQPCLT  
GPRTCKDLLD RGHFLSGWBT IYLPDCRPLT VLCDMDTDGG GNTVFQRRVD  
GSVDFYRDWA TYKQGFGRSL GEFWLGNONI HALTAQSTSE LRVDLVDFED  
NYQFAKYRSF KVADRAEKYN LVLGAFVEGS AGDSLTFHNN QSFSTXQQDN  
DLNTGNCAVM EQGANWYKNC HVSNLNGRYL RGTGGSFANG LNWKSGKGYN  
YSYKVSEMKV RPA

Protein FCN2\_HUMAN@2:

Ficolin 2 precursor (Collagen/fibrinogen domain-containing protein 2) (Ficolin-B) (Ficolin B) (Serum lectin P35) (HBP-37) (Hucolin) (L-Ficolin).

FIGURE 2: MBL



ETVTCEDAQK TCPAVIACSS PGINGFPCKD  
 GRDGTKEGG EPGQGLRGLQ GPPGKLGPPG NPGPESGSPGP KGQKGDPGKNS  
 248 88  
 PDGDSSLAAS ERKALQTEMA RIKKWLTFSL GKQVGNKFEL TNGRIMTFEK  
 VKALCVKFQA SVATPRNAAE NGAIQNLIK EAFLGITDEK TEGQFVDLTG  
 NRLTYTNWNE GEPNNAGSDE DCVLLIKNGQ WNDVPCSTSH LAVCEFEI


Protein 'MBL-C\_HUMAN'

MANNOSE-BINDING PROTEIN C PRECURSOR (MBP-C) (MBP1) (MANNAN-BINDING  
 PROTEIN) (MANNOSE-BINDING LECTIN).



3/11

FIGURE 3: Ficolin-MBL fusion




LQAADTCPEV KMGLEGSDK LTILRGCPGL PGAPGDKGEA GTNGIGRGERG  
 PPGPPGKAGP PGPNGARSPD GDSSLAASER KALQTENARI IKWLTFFLEIK  
 QVGNKPFLETN GEINTFEKVK ALCVKFQASV ATPRNAENG AIQNLIKERA  
 FLGITDEKTE GQFVDLTGNR LTYTNWNEGE PNNAGSDSDC VILLKNGQWN  
 DVPCBTSHLA VCEFFI

Protein FCN2\_HUMAN@2':

Ficolin 2 precursor (Collagen/fibrinogen domain-containing protein 2) (Ficolin-B) (Ficolin B) (Serum lectin P35) (EBP-37) (Hucolin) (L-Ficolin).


4/11

Figure 4:




5/11

Figure 5:




6/11

Figure 6:




7/11

Figure 7:



8/11

Figure 8:



9/11

Figure 9

Signal	
MBL-C_HUMAN	MSLPSPFLILLISMWAAASYSETVTTEDAQKTCPAVIAACSSPG-----INGFPKGDGRDC
FCNMBLr5	MELDRAGVVLGAATLLLSFLGMAMALQADTCPEVKMVGLEGSDKLTLRGCPGLPGAPG
FCNMBLr4	MELDRAGVVLGAATLLLSFLGMAMALQADTCPEVKMVGLEGSDKLTLRGCPGLPGAPG
FCNMBLr3	MELDRAGVVLGAATLLLSFLGMAMALQADTCPEVKMVGLEGSDKLTLRGCPGLPGAPG
FCNMBLr1	MELDRAGVVLGAATLLLSFLGMAMALQADTCPEVKMVGLEGSDKLTLRGCPGLPGAPG
FCNMBLr2	MELDRAGVVLGAATLLLSFLGMAMALQADTCPEVKMVGLEGSDKLTLRGCPGLPGAPG
FCN2_HUMANø2	
Collagen	
MBL-C_HUMAN	TKGEKGEPPGQ-GLRGLQGPPGKLGPPGNGPSPSGSPGPKGQKGDPGKSPDGSSLAASERK
FCNMBLr5	PKGEAGTNGQ-GLRGLQGPPGKLGPPGNGPSPSGSPGPKGQKGEPPGKSPDGSSLAASERK
FCNMBLr4	PKGEAGTNGKRGERRGPPGPKLGFPGNPGSPSGSPGPKGQKGDPGKSPDGSSLAASERK
FCNMBLr3	PKGEAGTNGKRGERRGPPGPKAGPPG---PNGAR-----PDGSSLAASERK
FCNMBLr1	PKGEAGTNGKRGERRGPPGPKAGPPG---PNGAPGEPQCLTGPRCTCKDLLDRGHFTLSG
FCNMBLr2	PKGEAGTNGKRGERRGPPGPKAGPPG---PNGAPGEPQCLTGPRCTCKDLLDRGHFTLSG
FCN2_HUMANø2	DKGEAGTNGKRGERRGPPGPKAGPPG---PNGAPGEPQCLTGPRCTCKDLLDRGHFTLSG

10/11


[illegible]

Figure 9 (continued)



11/11

Figure 10: Western blot of FCN2MBLr4, FCN2MBLr5 and MBL



**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**